CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10012525,100125253,3,F,20131028,20151217,20140314,20151222,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-20448981,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151222,,OT,IN,IN,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,100125253,OT,,,100125253,1,20080331,,,,100125253,1,HIV infection
10016683,100166832,2,F,,20151209,20140317,20151209,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-20545059,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151209,,CN,US,AT,EFAVIRENZ,Drug interaction;Dyslipidaemia;Gastrointestinal toxicity;Hepatotoxicity;Hypersensitivity;Maternal exposure during pregnancy;Nephropathy toxic;Neurotoxicity;Toxicity to various agents;Treatment failure;Virologic failure,100166832,OT,,,,,,,,,100166832,1,HIV infection
10039042,100390422,2,F,20140221,20151211,20140326,20151217,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-20566469,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151217,,CN,US,IN,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy,100390422,OT,,,100390422,1,20080331,20140214,,,100390422,1,HIV infection
10073396,100733962,2,F,20140222,20151211,20140411,20151217,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-20601571,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151217,,CN,CL,CL,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,100733962,OT,,,100733962,1,20130205,,,,100733962,1,Antiretroviral therapy
10184594,101845947,7,F,20140125,20151028,20140521,20151109,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-20777256,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151109,,CN,CI,CI,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,101845947,OT,,,101845947,1,20120612,,,,101845947,1,Antiretroviral therapy
10190829,101908293,3,F,,20151209,20140523,20151214,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20810222,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.3,KG,20151214,,OT,ZA,ZA,EFAVIRENZ,Drug withdrawal syndrome neonatal;Endotracheal intubation;Exposure during breast feeding;Foetal exposure during pregnancy;Generalised tonic-clonic seizure;Off label use,101908293,LT,,,,,,,,,101908293,1,Product used for unknown indication
10190830,101908303,3,F,,20151209,20140523,20151214,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20782470,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,2.17,KG,20151214,,OT,ZA,ZA,EFAVIRENZ,Drug withdrawal syndrome neonatal;Exposure during breast feeding;Foetal exposure during pregnancy;Off label use,101908303,HO,,,,,,,,,101908303,1,Product used for unknown indication
10207462,102074622,2,F,,20151026,20140530,20151030,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-20409033,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151030,,MD,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,102074622,1,Product used for unknown indication
10208392,102083922,2,F,20140429,20151022,20140530,20151103,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20803656,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,114,KG,20151103,,CN,US,ZA,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy;Viral load increased,102083922,OT,,,102083922,1,20120905,20140327,,,102083922,1,HIV infection
10222410,102224103,3,F,20140429,20151022,20140606,20151103,EXP,,ZA-ABBVIE-14P-143-1243784-00,ABBVIE,,23,YR,,F,Y,114,KG,20151103,,MD,COUNTRY NOT SPECIFIED,ZA,EFAVIRENZ,Abortion induced;Benign hydatidiform mole;Viral load increased,102224103,HO,,,102224103,1,20120905,20140327,,,102224103,1,HIV infection
10272117,102721172,2,F,,20151030,20140702,20151113,PER,,US-009507513-1406USA009400,MERCK,,18,YR,,F,Y,,,20151113,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,102721172,1,Product used for unknown indication
10331651,103316516,6,F,20140516,20151021,20140722,20151029,EXP,,MW-ABBVIE-14P-100-1260062-00,ABBVIE,,0,DY,,M,Y,1.7,KG,20151029,,MD,COUNTRY NOT SPECIFIED,MW,EFAVIRENZ,Acrochordon;Exposure during breast feeding;Foetal exposure during pregnancy;Low birth weight baby;Premature baby,103316516,CA,,,,,,,,,103316516,1,Maternal exposure timing unspecified
10391083,103910832,2,F,2012,20151116,20140818,20151120,EXP,,US-VIIV HEALTHCARE LIMITED-A1084576A,VIIV,,,,,M,Y,,,20151120,,CN,US,US,SUSTIVA,Cataract;Glaucoma;Nephrolithiasis;Off label use;Visual acuity reduced,103910832,OT,,,103910832,2,2001,,,,103910832,1,Pneumonia
10397998,103979983,3,F,20140721,20151209,20140821,20151217,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21322235,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.9,KG,20151217,,CN,US,BW,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby;Respiratory distress,103979983,HO,,,103979983,1,20110822,20140204,,,103979983,1,Product used for unknown indication
10399711,103997113,3,F,20140710,20151209,20140821,20151217,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21316401,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151217,,CN,BW,BW,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Vaginal discharge,103997113,OT,,,103997113,1,20110822,20140204,,,103997113,1,HIV infection
10467423,104674233,3,F,,20151029,20140922,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-19958636,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,CN,US,FR,EFAVIRENZ,Ascites;Foetal exposure during pregnancy;Pulmonary hypoplasia,104674233,OT,,,,,,,,,104674233,1,Product used for unknown indication
10495696,104956964,4,F,20140902,20151209,20141003,20151217,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-21391164,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,66,KG,20151217,,OT,ZW,ZW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy;Retained products of conception,104956964,OT,,,104956964,1,20110531,20081224,,,104956964,1,HIV infection
10517572,105175723,3,F,,20150924,20141014,20151001,EXP,,CA-ABBVIE-14P-028-1294263-00,ABBVIE,"PFEFFER G, COTE H, MEZEI M, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009?73 (1):71-72.",52,YR,,M,Y,,,20151001,,MD,COUNTRY NOT SPECIFIED,CA,EFAVIRENZ,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,105175723,OT,,,105175723,2,200802,,,,105175723,1,Antiretroviral therapy
10529194,105291947,7,F,201409,20151124,20141020,20151201,EXP,FR-ANSM-PV20140326,FR-GILEAD-2014-0118805,GILEAD,,58,YR,A,M,Y,74,KG,20151201,,OT,FR,FR,EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE/EFAVIRENZ,Atrioventricular block complete;Bradycardia;Bundle branch block;Syncope,105291947,HO,,,105291947,1,20140829,201502,,,105291947,1,Hepatitis C
10540025,105400254,4,F,20140127,20151023,20141024,20151107,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-21347141,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,,,20151107,,CN,US,MW,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly;Premature baby,105400254,OT,,,105400254,1,20130522,20091118,,,105400254,1,Product used for unknown indication
10675079,106750799,9,F,20140207,20151001,20141224,20151012,EXP,,PE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-000825,BRISTOL MYERS SQUIBB,,31,YR,,M,Y,52,KG,20151012,,MD,PE,PE,EFAVIRENZ,Anaemia;Diffuse large B-cell lymphoma;Haematochezia;Leukaemia;Multi-organ failure;Non-Hodgkin's lymphoma;Proctalgia;Sepsis;Syphilis,106750799,DE,,,106750799,1,20140131,20141203,,,106750799,1,HIV infection
10702684,107026844,4,F,20140530,20151026,20150109,20151029,EXP,,HT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-006382,BRISTOL MYERS SQUIBB,,51,YR,,F,Y,64,KG,20151029,,OT,HT,HT,EFAVIRENZ,Anaemia;Atrial fibrillation;Congestive cardiomyopathy;Diarrhoea;Sepsis,107026844,OT,,,107026844,1,20140520,20141205,,,107026844,1,Tuberculosis
10782797,107827972,2,F,,20151021,20150210,20151102,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-006291,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151102,,OT,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Ultrasound antenatal screen abnormal,107827972,OT,,,107827972,1,20140916,20141031,,,107827972,1,Antiretroviral therapy
10793812,107938122,2,F,20141024,20151209,20150213,20151217,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-008111,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,,,20151217,,CN,MW,MW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,107938122,OT,,,107938122,1,20140805,20141024,,,107938122,1,HIV infection
10968228,109682282,2,F,,20151210,20150330,20151218,EXP,,BR-ABBVIE-15P-020-1366225-00,ABBVIE,,,,,,Y,,,20151218,,OT,COUNTRY NOT SPECIFIED,BR,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby,109682282,OT,,,,,,,,,109682282,1,Maternal exposure timing unspecified
10970781,109707814,4,F,20140814,20151027,20150331,20151109,EXP,,FR-PURDUE PHARMA-GBR-2015-0026584,PURDUE,,48,YR,,M,Y,,,20151109,,OT,FR,FR,SUSTIVA,Aortic bypass;Drug abuse;Intentional product misuse;Peripheral artery thrombosis,109707814,HO,,,109707814,1,20140627,20140630,,,109707814,1,Product used for unknown indication
11011237,110112375,5,F,,20150924,20150410,20151002,EXP,,CA-ABBVIE-15P-028-1372603-00,ABBVIE,,52,YR,,M,Y,,,20151002,,OT,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110112375,OT,,,,,,,,,110112375,1,HIV infection
11022257,110222572,2,F,,20150924,20150413,20151001,EXP,,CA-ABBVIE-15P-028-1373193-00,ABBVIE,,52,YR,,M,Y,,,20151001,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110222572,OT,,,,,,,,,110222572,1,Product used for unknown indication
11024072,110240723,3,F,,20150924,20150413,20151002,EXP,,CA-ABBVIE-15P-028-1372646-00,ABBVIE,,52,YR,,M,Y,,,20151002,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,110240723,OT,,,,,,,,,110240723,1,HIV infection
11024230,110242304,4,F,,20150923,20150413,20151001,EXP,,CA-ABBVIE-15P-028-1372737-00,ABBVIE,,,,,M,Y,,,20150930,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,110242304,OT,,,,,,,,,110242304,1,Product used for unknown indication
11116909,111169094,4,F,20141031,20151207,20150515,20151211,EXP,,UG-GILEAD-2014-0123355,GILEAD,,36,YR,A,M,Y,56,KG,20151211,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,111169094,OT,,,111169094,1,20140328,20141118,,,111169094,1,HIV infection
11169671,111696712,2,F,,20151130,20150605,20151207,EXP,,FR-GILEAD-2015-0157176,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GAFEY CAROLINE, YANG C, DENIS B, FONSART J, DESSEAUX K, GUIONIE M, ROZENBAUM W, DELAUGERRE C, MOLINA JM. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE BASED REGIMENS IN TREATEMENT-EXPERIENCED HIV-1 INFECTED PATIENTS, A COHORT STUDY. ANTIVIRAL THERAPY. 2015?UNK:UNK",28,YR,A,M,Y,,,20151207,,MD,FR,FR,EFAVIRENZ,Completed suicide,111696712,OT,,,111696712,1,201304,,,,111696712,1,HIV infection
11169682,111696822,2,F,,20151126,20150605,20151204,EXP,,FR-GILEAD-2015-0157177,GILEAD,"GAZAIGNES S, RESCHE-RIGON M, GAFEY CAROLINE, YANG C, DENIS B, FONSART J, DESSEAUX K, GUIONIE M, ROZENBAUM W, DELAUGERRE C, MOLINA JM. EFFICACY AND SAFETY OF A SWITCH TO RILPIVIRINE BASED REGIMENS IN TREATEMENT-EXPERIENCED HIV-1 INFECTED PATIENTS, A COHORT STUDY. ANTIVIRAL THERAPY. 2015?UNK:UNK",34,YR,A,M,Y,,,20151204,,MD,FR,FR,EFAVIRENZ,Completed suicide,111696822,DE,,,111696822,1,201301,,,,111696822,1,HIV infection
11196973,111969735,5,F,20141021,20150922,20150617,20151026,PER,,US-GILEAD-2015-0158008,GILEAD,,31,YR,A,F,Y,173.2,KG,20151026,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy,,,,,111969735,1,20120612,,,,111969735,1,HIV infection
11200116,112001168,8,F,20150526,20151207,20150618,20151215,EXP,,US-BMSGILMSD-2015-0158849,GILEAD,,0,YR,,M,Y,1.36,KG,20151215,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital hydronephrosis;Foetal megacystis;Pulmonary embolism;Pulmonary haemorrhage,112001168,CA,,,112001168,1,20141021,20150611,,,112001168,1,HIV infection
11259567,112595673,3,F,,20150803,20150710,20151023,EXP,,TN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-045269,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20151023,,OT,TN,TN,EFAVIRENZ,Acute coronary syndrome;Dyslipidaemia,112595673,OT,,,,,,,,,112595673,1,HIV infection
11271089,112710892,2,F,20130603,20151008,20150714,20151021,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-044918,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20151021,,OT,MW,MW,EFAVIRENZ,Death;Upper respiratory tract infection,112710892,DE,,,112710892,1,20130111,20130606,,,112710892,1,HIV infection
11273970,112739704,4,F,20150218,20151221,20150715,20151224,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-045344,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20151224,,OT,UG,UG,EFAVIRENZ,Acute hepatic failure;Anaemia;Cardiac failure;Hepatitis acute;Oral candidiasis;Pulmonary tuberculosis,112739704,DE,,,112739704,1,20150121,20150407,,,112739704,1,HIV infection
11274251,112742512,2,F,20120908,20150928,20150715,20151007,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17079922,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,75,KG,20151007,,OT,BR,BR,EFAVIRENZ,Anxiety;Hepatotoxicity;Pulmonary tuberculosis;Weight decreased,112742512,LT,,,112742512,1,20100125,20121022,,,112742512,1,HIV infection
11322068,113220682,2,F,,20151211,20150729,20151222,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2008-000001,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151222,,CN,GB,GB,EFAVIRENZ,Cardiac malposition;Congenital diaphragmatic anomaly;Congenital hepatobiliary anomaly;Deformity thorax;Diaphragmatic aplasia;Exomphalos;Foetal exposure during pregnancy;Microcephaly;Pneumothorax,113220682,OT,,,113220682,1,20070716,20070816,,,113220682,1,Product used for unknown indication
11325759,113257592,2,F,,20150928,20150731,20151013,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-048759,BRISTOL MYERS SQUIBB,,,,,F,Y,71,KG,20151013,,CN,DE,DE,SUSTIVA,Hepatic cirrhosis,113257592,DS,,,113257592,1,2000,2003,,,113257592,1,HIV infection
11342559,113425593,3,F,2012,20151027,20150805,20151103,EXP,,BR-ABBVIE-15P-020-1436927-00,ABBVIE,,,,,M,Y,59,KG,20151103,,CN,BR,BR,EFAVIRENZ,CD4 lymphocytes increased;Colour blindness;Nausea;Vision blurred;Vomiting;Weight decreased,113425593,OT,,,113425593,1,201111,,,,113425593,1,HIV infection
11348844,113488442,2,F,20141105,20151210,20150806,20151215,EXP,,HT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-051188,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151215,,CN,HT,HT,EFAVIRENZ;Efavirenz,Abortion spontaneous;Maternal exposure during pregnancy,113488442,OT,,,113488442,1,20140918,20140922,,,113488442,1,HIV infection
11473744,114737442,2,F,20150825,20151111,20150908,20151118,EXP,,ZW-GILEAD-2015-0170992,GILEAD,,43,YR,A,F,Y,52,KG,20151118,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abnormal loss of weight;Anaemia,114737442,OT,,,114737442,1,20150603,20150805,,,114737442,1,HIV infection
11573938,115739385,5,F,20150824,20151107,20150930,20151112,EXP,,US-ROCHE-1637050,ROCHE,,55,YR,,F,Y,72,KG,20151112,,OT,US,US,EFAVIRENZ;SUSTIVA,Depressed level of consciousness;Haemorrhagic transformation stroke;Hypotension;Product quality issue;Tachycardia,115739385,OT,,,115739385,1,20150824,20150824,,,115739385,1,Cerebrovascular accident
11576746,115767462,2,F,,20150925,20150930,20151104,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015GSK138419,VIIV,,,,,M,Y,,,20151104,,CN,GB,GB,Efavirenz,General physical health deterioration;Myocardial infarction;Speech disorder,115767462,HO,,,,,,,,,115767462,1,Product used for unknown indication
11577106,115771062,2,F,,20150925,20150930,20151104,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK138419,GLAXOSMITHKLINE,,,,,M,Y,,,20151104,,CN,GB,GB,Efavirenz,General physical health deterioration;Myocardial infarction;Speech disorder,115771062,OT,,,,,,,,,115771062,1,Product used for unknown indication
11583830,115838301,1,I,200811,20091105,20151001,20151001,PER,,US-ROCHE-667545,ROCHE,,43,YR,,F,Y,70.3,KG,20151001,,CN,US,US,SUSTIVA,Fatigue;Headache;Injection site reaction;Nausea,,,,,,,,,,,115838301,1,Hepatitis C
11583842,115838421,1,I,20051130,20091102,20151001,20151001,PER,,US-ROCHE-666443,ROCHE,,45,YR,,M,Y,,,20151001,,CN,US,US,SUSTIVA,Blood thyroid stimulating hormone abnormal;Cognitive disorder;Disease recurrence;Fatigue;Mental fatigue,115838421,OT,,,115838421,2,20031125,20040830,,,115838421,1,Hepatitis C
11585515,115855151,1,I,20150909,20150924,20151001,20151001,EXP,,GB-GILEAD-2015-0174075,GILEAD,,47,YR,A,M,Y,,,20151001,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,115855151,DE,,,,,,,,,115855151,1,Product used for unknown indication
11585604,115856044,4,F,20150922,20151029,20151001,20151103,EXP,,UG-GILEAD-2015-0174732,GILEAD,,25,YR,A,F,Y,44,KG,20151103,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,115856044,HO,,,115856044,1,20150901,20150922,,,115856044,1,Kaposi's sarcoma AIDS related
11589210,115892101,1,I,,20150813,20151002,20151002,EXP,,US-VIIV HEALTHCARE LIMITED-US2015125350,VIIV,,66,YR,,M,Y,,,20151002,,MD,US,US,Efavirenz;SUSTIVA,Drug ineffective;Drug interaction;Drug intolerance;Drug resistance;Product quality issue;Virologic failure,115892101,OT,,,115892101,1,201309,201506,,,115892101,1,Product used for unknown indication
11590835,115908354,4,F,,20151130,20151002,20151207,EXP,,ES-GILEAD-2015-0174266,GILEAD,,,,N,,Y,,,20151207,,MD,ES,ES,EFAVIRENZ,Polydactyly,115908354,CA,,,,,,,,,115908354,1,HIV infection
11593294,115932941,1,I,,20150922,20151005,20151005,EXP,,US-CIPLA LTD.-2015US07723,CIPLA,"SEEKINS D, PAVIA-RUZ N, ROSSOUW M, SAEZ-LLORENS X, BUNUPURADAH T, TAYLOR M, YANG R ET AL... EFAVIRENZ CAPSULE SPRINKLE AND LIQUID FORMULATIONS WITH DIDANOSINE AND EMTRICITABINE IN HIV-1-INFECTED INFANTS AND CHILDREN 3 MONTHS TO 6 YEARS OF AGE: STUDY AI266-922. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL",,,,,Y,,,20151005,,OT,US,US,Efavirenz,Cardiac failure;Pneumonia,115932941,DE,,,,,,,,,115932941,1,HIV infection
11593397,115933971,1,I,,20150922,20151005,20151005,EXP,,US-CIPLA LTD.-2015US07720,CIPLA,"SEEKINS D, PAVIA-RUZ N, ROSSOUW M, SAEZ-LLORENS X, BUNUPURADAH T, TAYLOR M, YANG R ET AL... EFAVIRENZ CAPSULE SPRINKLE AND LIQUID FORMULATIONS WITH DIDANOSINE AND EMTRICITABINE IN HIV-1-INFECTED INFANTS AND CHILDREN 3 MONTHS TO 6 YEARS OF AGE: STUDY AI266-922. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL",,,,,Y,,,20151005,,OT,US,US,Efavirenz,Bacterial infection,115933971,DE,,,,,,,,,115933971,1,HIV infection
11594589,115945891,1,I,201504,20150929,20151005,20151005,EXP,,US-BMSGILMSD-2015-0175040,GILEAD,,58,YR,A,M,Y,,,20151005,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hip arthroplasty,115945891,OT,,,,,,,,,115945891,1,HIV infection
11594898,115948983,3,F,20150115,20151124,20151005,20151201,EXP,,PE-GILEAD-2015-0174370,GILEAD,,,,,M,Y,,,20151201,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anencephaly;Foetal exposure during pregnancy,115948983,DE,,,115948983,1,20130612,,,,115948983,1,HIV infection
11603528,116035283,3,F,,20151020,20151007,20151030,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-065387,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151030,,MD,US,US,SUSTIVA,Paranoia;Suicidal ideation,116035283,OT,,,,,,,,,116035283,1,Product used for unknown indication
11608344,116083441,1,I,,20151001,20151007,20151007,EXP,,US-GILEAD-2015-0175342,GILEAD,,54,YR,A,M,Y,,,20151007,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness,116083441,OT,,,,,,,,,116083441,1,HIV infection
11613561,116135611,1,I,20150120,20151002,20151008,20151008,EXP,,ZA-BMSGILMSD-2015-0175575,GILEAD,,41,YR,A,F,Y,,,20151008,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,116135611,OT,,,116135611,1,20140107,,,,116135611,1,HIV infection
11613599,116135991,1,I,20150124,20151002,20151008,20151008,EXP,,ZA-BMSGILMSD-2015-0175551,GILEAD,,39,YR,A,F,Y,,,20151008,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,116135991,OT,,,116135991,1,20140703,,,,116135991,1,HIV infection
11620599,116205991,1,I,,20150929,20151012,20151012,EXP,,TW-MYLANLABS-2015M1034107,MYLAN,"LO CH, LIN TY. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME. RESPIR-CARE 2014? 59(10):E160-E162.",,,,,Y,,,20151012,,MD,TW,TW,EFAVIRENZ,Immune reconstitution inflammatory syndrome,116205991,HO,,,,,,,,,116205991,1,HIV infection
11621108,116211081,1,I,,20151008,20151012,20151012,EXP,,US-GILEAD-2015-0176313,GILEAD,,,,,F,Y,,,20151012,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Malaise;Neoplasm malignant,116211081,OT,,,,,,,,,116211081,1,HIV infection
11625951,116259511,1,I,20150414,20150417,20151013,20151013,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2015GSK054104,VIIV,,64,YR,,M,Y,67,KG,20151013,,CN,FR,FR,SUSTIVA,Arthralgia;Balance disorder;Dizziness;Fatigue;Headache;Insomnia;Malaise;Myalgia;Nausea;Paraesthesia;Poor quality sleep;Pruritus,116259511,HO,,,116259511,1,20150413,20150416,,,116259511,1,HIV infection
11626599,116265992,2,F,,20151109,20151013,20151117,EXP,,US-GILEAD-2015-0175886,GILEAD,,54,YR,A,M,Y,68.93,KG,20151117,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,116265992,OT,,,116265992,1,200706,200706,,,116265992,1,HIV infection
11627357,116273571,1,I,,20151008,20151013,20151013,EXP,,US-BMSGILMSD-2015-0176409,GILEAD,,49,YR,A,M,Y,,,20151013,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abasia;Nervous system disorder,116273571,DS,,,,,,,,,116273571,1,HIV infection
11629566,116295662,2,F,20150217,20151009,20151014,20151020,EXP,,ZA-009507513-1510ZAF006032,MERCK,,66,YR,,M,Y,60.1,KG,20151020,,CN,FR,ZA,EFAVIRENZ (+) EMTRICITABINE (+) TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Cardiac failure congestive;Hypernatraemia,116295662,DE,,,116295662,1,20150211,20150224,,,116295662,1,HIV infection
11630606,116306061,1,I,,20151006,20151014,20151014,EXP,,CA-ABBVIE-15K-028-1478419-00,ABBVIE,,54,YR,,M,Y,,,20151014,,OT,CA,CA,EFAVIRENZ,Depression;Drug interaction,116306061,OT,,,,,,,,,116306061,1,Product used for unknown indication
11633134,116331343,3,F,20150217,20151009,20151015,20151022,EXP,,ZA-GILEAD-2015-0176579,GILEAD,,66,YR,E,M,Y,60,KG,20151022,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Cardiac failure congestive;Hypernatraemia;Renal impairment,116331343,HO,,,116331343,1,20150211,20150302,,,116331343,1,HIV infection
11636385,116363852,2,F,20150411,20150820,20151016,20151020,EXP,,TH-GLAXOSMITHKLINE-TH2015123185,GLAXOSMITHKLINE,,30,YR,,F,Y,,,20151020,,OT,TH,TH,Efavirenz,Abortion spontaneous,116363852,OT,,,116363852,1,20140604,,,,116363852,1,HIV infection
11636659,116366591,1,I,,,20151015,20151015,DIR,,,,,,,,M,N,154,LBS,20151006,N,,US,,SUSTIVA,Abdominal pain upper;Dry eye;Dysuria;Eye irritation;Eye pain;Fatigue;Genital swelling;Headache;Hot flush;Influenza like illness;Joint stiffness;Joint swelling;Libido increased;Loss of consciousness;Macular degeneration;Musculoskeletal stiffness;Myalgia;Nasopharyngitis;Ocular hyperaemia;Oropharyngeal pain;Pain in extremity;Photopsia;Rash;Renal pain;Skin exfoliation;Throat irritation;Tongue disorder,116366591,DS,,,,,,,,,116366591,1,HIV infection
11636674,116366741,1,I,,20151001,20151016,20151016,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147178,VIIV,,44,YR,,M,Y,,,20151016,,CN,GB,US,SUSTIVA,Gastrointestinal disorder;Treatment failure,,,,,,,,,,,116366741,1,HIV infection
11636677,116366772,2,F,20150411,20150820,20151016,20151020,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2015123185,VIIV,,30,YR,,F,Y,,,20151020,,OT,TH,TH,Efavirenz,Abortion spontaneous,116366772,OT,,,116366772,1,20140604,,,,116366772,1,HIV infection
11638703,116387031,1,I,2015,20151014,20151016,20151016,EXP,,GB-BMSGILMSD-2015-0177156,GILEAD,,27,YR,A,F,Y,,,20151016,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depressed mood,116387031,HO,,,,,,,,,116387031,1,Product used for unknown indication
11640684,116406843,3,F,201402,20151218,20151019,20151230,EXP,,MX-GILEAD-2015-0177466,GILEAD,,37,YR,A,F,Y,,,20151230,,MD,MX,MX,EFAVIRENZ W/ZIDOVUDINE,Anaemia;Blood creatinine increased;Creatinine renal clearance decreased,116406843,OT,,,116406843,1,201309,201309,,,116406843,1,HIV infection
11641195,116411951,1,I,,20151001,20151019,20151019,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147655,VIIV,,40,YR,,M,Y,,,20151019,,CN,GB,US,SUSTIVA,Anxiety;Gastrointestinal disorder;Sleep disorder;Treatment failure,,,,,,,,,,,116411951,1,HIV infection
11641205,116412051,1,I,,20151001,20151019,20151019,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK147832,VIIV,,30,YR,,M,Y,,,20151019,,CN,GB,US,SUSTIVA,Drug effect incomplete;Gastrointestinal disorder,,,,,,,,,,,116412051,1,HIV infection
11641566,116415661,1,I,20150926,20151014,20151019,20151019,EXP,,ZA-GILEAD-2015-0177198,GILEAD,,62,YR,A,M,Y,42.6,KG,20151019,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,116415661,DE,,,116415661,1,20150612,,,,116415661,1,HIV infection
11642065,116420652,2,F,2012,20151026,20151019,20151029,EXP,,US-GILEAD-2015-0177355,GILEAD,,44,YR,A,M,Y,,,20151029,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anal cancer,116420652,OT,,,116420652,1,2012,2013,,,116420652,1,HIV infection
11644453,116444531,1,I,,20151001,20151020,20151020,EXP,,US-GLAXOSMITHKLINE-US2015GSK147655,GLAXOSMITHKLINE,,40,YR,,M,Y,,,20151020,,CN,GB,US,SUSTIVA,Anxiety;Gastrointestinal disorder;Sleep disorder;Treatment failure,,,,,,,,,,,116444531,1,HIV infection
11645010,116450101,1,I,201308,20151016,20151020,20151020,EXP,,US-GILEAD-2015-0177765,GILEAD,,,,,M,Y,,,20151020,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident,116450101,OT,,,,,,,,,116450101,1,HIV infection
11649914,116499141,1,I,,20151020,20151021,20151021,EXP,,GB-GLAXOSMITHKLINE-GB2015149218,GLAXOSMITHKLINE,,79,YR,,M,Y,,,20151021,,OT,GB,GB,Efavirenz,Malaise;Myocardial infarction;Speech disorder,116499141,OT,,,,,,,,,116499141,1,Product used for unknown indication
11651747,116517471,1,I,20080101,,20151021,20151021,DIR,,,,,30,YR,,M,N,,,20151019,N,,US,,SUSTIVA,Abnormal dreams,116517471,OT,,,116517471,1,2008,,,,,,
11652188,116521881,1,I,,20151020,20151022,20151022,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015149218,VIIV,,79,YR,,M,Y,,,20151022,,OT,GB,GB,Efavirenz,Malaise;Myocardial infarction;Speech disorder,116521881,HO,,,,,,,,,116521881,1,Product used for unknown indication
11653644,116536444,4,F,,20151014,20151022,20151106,EXP,,FR-009507513-1509FRA005380,MERCK,,51,YR,,F,Y,,,20151106,,CN,US,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis,116536444,HO,,,,,,,,,116536444,1,HIV infection
11653781,116537811,1,I,,20151009,20151022,20151022,EXP,,UG-MYLANLABS-2015M1035910,MYLAN,"MUSUBIRE AK, MEYA DB, LUKANDE R, KAMBUGU A, BOHJANEN PR, BOULWARE DR. GASTROINTESTINAL CRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MED-MYCOL-CASE-REPORTS 2015? 8:40-43.",,,,,Y,,,20151022,,OT,UG,UG,EFAVIRENZ,Cryptococcosis;Drug interaction;Ileal perforation,116537811,OT,,,,,,,,,116537811,1,Meningitis cryptococcal
11654885,116548851,1,I,20150505,20151019,20151023,20151023,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2015GSK149663,VIIV,,41,YR,,M,Y,57,KG,20151023,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Off label use;Rash erythematous,116548851,OT,,,116548851,1,20150505,,,,116548851,1,Acquired immunodeficiency syndrome
11655537,116555371,1,I,20150505,20151019,20151023,20151023,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK149663,GLAXOSMITHKLINE,,41,YR,,M,Y,57,KG,20151023,,OT,CN,CN,EFAVIRENZ,Dermatitis allergic;Off label use;Rash erythematous,116555371,OT,,,116555371,1,20150505,,,,116555371,1,Acquired immunodeficiency syndrome
11656307,116563071,1,I,,20151012,20151023,20151023,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-071521,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151023,,OT,US,US,EFAVIRENZ,Drug interaction;Treatment failure,116563071,OT,,,,,,,,,116563071,1,HIV infection
11657239,116572391,1,I,20150909,20151016,20151023,20151023,EXP,,ZA-GILEAD-2015-0177684,GILEAD,,32,YR,A,M,Y,58,KG,20151023,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intentional overdose;Suicide attempt,116572391,OT,,,116572391,1,20150909,20150909,,,116572391,1,HIV infection
11658562,116585621,1,I,20150420,20150501,20151026,20151026,EXP,,ZA-ROCHE-1648551,ROCHE,,40,YR,,F,Y,55,KG,20151026,,MD,ZA,ZA,EFAVIRENZ,Deep vein thrombosis;Gastroenteritis;Neutropenic sepsis,116585621,LT,,,116585621,1,20150414,20150414,,,116585621,1,Non-Hodgkin's lymphoma
11661955,116619553,3,F,,20151130,20151026,20151203,EXP,,LT-009507513-1510LTU007855,MERCK,,,,,,Y,,,20151203,,CN,US,LT,EFAVIRENZ,Drug resistance,116619553,OT,,,,,,,,,116619553,1,HIV infection
11662002,116620022,2,F,,20151130,20151026,20151203,EXP,,LT-009507513-1510LTU007848,MERCK,,,,,,Y,,,20151203,,CN,US,LT,EFAVIRENZ,Drug resistance,116620022,OT,,,,,,,,,116620022,1,HIV infection
11662446,116624463,3,F,,20151130,20151027,20151203,EXP,,LT-009507513-1510LTU007668,MERCK,,,,,,Y,,,20151203,,CN,US,LT,EFAVIRENZ,Drug resistance,116624463,OT,,,,,,,,,116624463,1,HIV infection
11662589,116625893,3,F,,20151130,20151027,20151203,EXP,,LT-009507513-1510LTU007670,MERCK,,,,,,Y,,,20151203,,CN,US,LT,EFAVIRENZ,Drug resistance,116625893,OT,,,,,,,,,116625893,1,HIV infection
11663996,116639961,1,I,,20151014,20151027,20151027,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-071202,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151027,,PH,US,US,SUSTIVA,Medication residue present,,,,,,,,,,,116639961,1,HIV infection
11665909,116659091,1,I,2015,20151020,20151027,20151027,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015GSK151424,VIIV,,23,YR,,F,Y,,,20151027,,MD,GB,GB,EFAVIRENZ,Chlamydial infection;Exposure during pregnancy;Hydronephrosis;Urosepsis;Viral mutation identified,116659091,OT,,,116659091,1,2015,2015,,,116659091,1,Product used for unknown indication
11668608,116686081,1,I,2015,20151020,20151027,20151027,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK151424,GLAXOSMITHKLINE,,23,YR,,F,Y,,,20151027,,MD,GB,GB,EFAVIRENZ,Chlamydial infection;Exposure during pregnancy;Hydronephrosis;Urosepsis;Viral mutation identified,116686081,OT,,,116686081,1,2015,2015,,,116686081,1,Product used for unknown indication
11678865,116788653,3,F,,20151130,20151028,20151203,EXP,,LT-009507513-1510LTU007391,MERCK,,,,,,Y,,,20151203,,CN,US,LT,EFAVIRENZ,Drug resistance,116788653,OT,,,,,,,,,116788653,1,HIV infection
11681699,116816991,1,I,,20070131,20151029,20151029,EXP,,PA-BRISTOL-MYERS SQUIBB COMPANY-13664727,BRISTOL MYERS SQUIBB,,,,,F,Y,3.1,KG,20151029,,OT,US,PA,SUSTIVA,Foetal exposure during pregnancy;Pseudarthrosis,116816991,CA,,,116816991,1,20041220,20050107,,,116816991,1,Product used for unknown indication
11682541,116825411,1,I,2009,20151019,20151029,20151029,EXP,,MX-GILEAD-2015-0178908,GILEAD,,41,YR,A,M,Y,,,20151029,,MD,MX,MX,EFAVIRENZ,Neuropathy peripheral;Pulmonary tuberculosis,116825411,OT,,,116825411,1,200903,201201,,,116825411,1,HIV infection
11684269,116842691,1,I,,20110711,20151029,20151029,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15928070,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151029,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116842691,1,HIV infection
11684270,116842701,1,I,,20110711,20151029,20151029,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15935554,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151029,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116842701,1,HIV infection
11684968,116849681,1,I,20000609,20100618,20151030,20151030,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15158538,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151030,,OT,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116849681,1,HIV infection
11685007,116850072,2,F,,20151209,20151030,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028640,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116850072,1,Antiretroviral therapy
11685757,116857571,1,I,,20151016,20151030,20151030,EXP,,UG-SUN PHARMACEUTICAL INDUSTRIES LTD-2015RR-105297,RANBAXY,"MUSUBIRE AK, MEYA DB, LUKANDE R, KAMBUGU A, BOHJANEN PR, BOULWARE DR. GASTROINTESTINAL CRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MED-MYCOL-CASE-REPORTS. 2015?840-43",,,,,Y,,,20151030,,OT,UG,UG,Efavirenz,Abdominal pain;Cryptococcosis;Drug interaction;Intestinal perforation,116857571,HO,,,116857571,3,20090611,,,,116857571,1,Meningitis cryptococcal
11685782,116857822,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028053,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116857822,1,Antiretroviral therapy
11686090,116860901,1,I,,20151016,20151030,20151030,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-071971,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151030,,CN,US,US,SUSTIVA,Abdominal discomfort;Abdominal distension;Dyspepsia;Pain,,,,,,,,,,,116860901,1,Product used for unknown indication
11686093,116860932,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028087,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860932,1,Antiretroviral therapy
11686094,116860942,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028178,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860942,1,Antiretroviral therapy
11686095,116860952,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028095,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116860952,1,Antiretroviral therapy
11686509,116865092,2,F,20150420,20151106,20151030,20151116,EXP,,ZA-PFIZER INC-2015365041,PFIZER,,40,YR,,F,Y,,,20151116,,MD,ZA,ZA,EFAVIRENZ,Deep vein thrombosis;Gastroenteritis;Neutropenic sepsis,116865092,LT,,,116865092,1,20150414,20150426,,,116865092,1,Non-Hodgkin's lymphoma
11686906,116869062,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028384,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116869062,1,Antiretroviral therapy
11687189,116871892,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028079,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116871892,1,Antiretroviral therapy
11687190,116871902,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028152,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116871902,1,Antiretroviral therapy
11687386,116873862,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028111,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116873862,1,Antiretroviral therapy
11687456,116874562,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028160,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116874562,1,Antiretroviral therapy
11688093,116880932,2,F,,20151104,20151030,20151118,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073862,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151118,,OT,BE,BE,"EFAVIRENZ;EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Neurotoxicity,116880932,OT,,,116880932,1,20090303,20111218,,,116880932,1,HIV infection
11688153,116881531,1,I,,20151020,20151030,20151030,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075673,BRISTOL MYERS SQUIBB,,13,YR,,F,Y,,,20151030,,OT,ZA,ZA,EFAVIRENZ,Ataxia;Drug level increased,116881531,OT,,,,,,,,,116881531,1,HIV infection
11688218,116882181,1,I,,20100308,20151030,20151030,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028103,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151030,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882181,1,Antiretroviral therapy
11688223,116882232,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028129,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882232,1,Antiretroviral therapy
11688225,116882252,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028145,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882252,1,Antiretroviral therapy
11688226,116882262,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028137,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882262,1,Antiretroviral therapy
11688232,116882321,1,I,,20151020,20151030,20151030,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-074364,BRISTOL MYERS SQUIBB,,6,YR,,F,Y,,,20151030,,OT,ZA,ZA,EFAVIRENZ,Ataxia;Drug level increased,116882321,OT,,,,,,,,,116882321,1,HIV infection
11688234,116882342,2,F,,20151209,20151030,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028061,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116882342,1,Antiretroviral therapy
11688467,116884671,1,I,20130412,20130425,20151101,20151101,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-18844159,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,71,KG,20151101,,OT,ZW,ZW,EFAVIRENZ,Breech delivery;Hepatotoxicity;Maternal exposure during pregnancy;Stillbirth,116884671,OT,,,116884671,1,20100429,20120806,,,116884671,1,HIV infection
11688825,116888251,1,I,20130523,20130605,20151102,20151102,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-19001783,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20151102,,OT,CI,CI,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,116888251,OT,,,116888251,1,20130107,20130517,,,116888251,1,Antiretroviral therapy
11688937,116889372,2,F,,20151209,20151102,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028624,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,116889372,1,Antiretroviral therapy
11688971,116889712,2,F,,20151209,20151102,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028632,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116889712,1,Antiretroviral therapy
11691124,116911241,1,I,20100722,20101230,20151102,20151102,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15467632,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151102,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Maternal exposure during pregnancy;Stillbirth,116911241,OT,,,,,,,,,116911241,1,Antiretroviral therapy
11691963,116919631,1,I,20130506,20130523,20151103,20151103,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-18972091,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,49.9,KG,20151103,,OT,ZW,ZW,EFAVIRENZ,Abortion threatened;Foetal death;Maternal exposure during pregnancy,116919631,OT,,,116919631,1,20110824,20121002,,,116919631,1,HIV infection
11693954,116939541,1,I,20150930,20151029,20151103,20151103,EXP,,GB-GILEAD-2015-0179845,GILEAD,,62,YR,A,M,Y,75,KG,20151103,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure acute;Myocardial infarction;Myocardial ischaemia,116939541,OT,,,116939541,1,20100120,,,,116939541,1,HIV infection
11695249,116952492,2,F,20080128,20151202,20151103,20151211,EXP,,FR-009507513-0906USA00645,MERCK,,17,YR,,F,Y,,,20151211,,CN,FR,FR,SUSTIVA,Caesarean section;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,116952492,OT,,,116952492,1,20080215,,,,116952492,1,Product used for unknown indication
11695440,116954401,1,I,20110910,20111017,20151104,20151104,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-16191124,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,,,20151104,,CN,GB,TH,EFAVIRENZ,Caesarean section;Foetal exposure during pregnancy;Jaundice neonatal;Maternal drugs affecting foetus;Premature baby;Premature rupture of membranes,116954401,HO,,,116954401,1,,20110214,,,116954401,1,Product used for unknown indication
11696973,116969734,4,F,,20151019,20151104,20151113,EXP,,AT-MERCK-1503AUT002612,MERCK,,,,,,Y,,,20151113,,OT,AT,AT,EFAVIRENZ,Virologic failure,116969734,OT,,,,,,,,,116969734,1,Product used for unknown indication
11697343,116973431,1,I,,20101230,20151104,20151104,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15467640,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151104,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Foetal exposure during pregnancy;Foetal growth restriction;Wolf-Hirschhorn syndrome,116973431,OT,,,,,,,,,116973431,1,Product used for unknown indication
11699314,116993141,1,I,20110910,20111017,20151104,20151104,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-16170078,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,55,KG,20151104,,CN,GB,TH,EFAVIRENZ,Abortion threatened;Caesarean section;Live birth;Maternal exposure during pregnancy;Pregnancy on contraceptive;Premature delivery;Premature rupture of membranes,116993141,HO,,,116993141,1,20101104,20110214,,,116993141,1,HIV infection
11699315,116993151,1,I,2008,20090902,20151104,20151104,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14764369,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,63.94,KG,20151104,,CN,US,US,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy,116993151,OT,,,116993151,1,20060509,20081116,,,116993151,1,HIV infection
11699785,116997852,2,F,,20151209,20151105,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029028,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,116997852,1,Antiretroviral therapy
11701392,117013921,1,I,20100611,20111004,20151105,20151105,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16133720,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151105,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,117013921,OT,,,117013921,1,20100422,20100611,,,117013921,1,Antiretroviral therapy
11702579,117025791,1,I,,20151022,20151105,20151105,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075612,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,,,20151105,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Sepsis;Stevens-Johnson syndrome,117025791,HO,,,,,,,,,117025791,1,HIV infection
11703721,117037211,1,I,,20100602,20151106,20151106,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-15133267,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151106,,CN,US,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117037211,OT,,,117037211,1,20100215,,,,117037211,1,HIV infection
11703722,117037221,1,I,20080920,20091218,20151106,20151106,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902597,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151106,,CN,US,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117037221,OT,,,117037221,1,20070503,20080721,,,117037221,1,Antiretroviral therapy
11703758,117037581,1,I,20040514,20100615,20151106,20151106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15152010,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151106,,CN,US,FR,EFAVIRENZ,Amniotic fluid volume increased;Live birth;Maternal exposure during pregnancy;Premature delivery,117037581,OT,,,117037581,1,20010401,20040102,,,117037581,1,Antiretroviral therapy
11703759,117037591,1,I,20120612,20130618,20151106,20151106,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-19034917,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151106,,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117037591,OT,,,117037591,1,20101007,,,,117037591,1,Antiretroviral therapy
11704123,117041231,1,I,,20151027,20151106,20151106,EXP,,GB-CIPLA LTD.-2015GB08334,CIPLA,"DYSON J. K., HUTCHINSON J., HARRISON, L., ROTIMI O., TINIAKOS D., FOSTER R G., ET AL.. LIVER TOXICITY ASSOCIATED WITH SOFOSBUVIR, AN NS5A INHIBITOR AND RIBAVIRIN USE. JOURNAL OF HEPATOLOGY. 2015?1 TO 21",,,,,Y,,,20151106,,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Jaundice;Multi-organ failure;Pneumonia klebsiella;Vomiting,117041231,DE,,,117041231,2,201407,,,,117041231,1,HIV infection
11705185,117051851,1,I,200805,20080630,20151106,20151106,EXP,,GB-009507513-0807USA00501,MERCK,,32,YR,,F,Y,57,KG,20151106,,CN,US,GB,SUSTIVA,Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,117051851,OT,,,117051851,2,2006,,,,117051851,1,HIV test
11705544,117055441,1,I,,20080911,20151106,20151106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2008-000009,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151106,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Renal dysplasia;Urinary tract obstruction,117055441,CA,,,117055441,1,20070217,20070703,,,117055441,1,Product used for unknown indication
11707547,117075472,2,F,,20151110,20151106,20151120,EXP,GB-MHRA-EYC 00129667,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-075172,BRISTOL MYERS SQUIBB,,25,YR,,M,Y,,,20151120,,CN,GB,GB,EFAVIRENZ,Abdominal pain;Chromaturia;Porphyria acute;Vomiting,117075472,HO,,,,,,,,,117075472,1,HIV infection
11707929,117079291,1,I,,20151029,20151106,20151106,EXP,,SG-CIPLA LTD.-2015SG08365,CIPLA,"PATON N.I, STOHR W, ARENAS-PINTO A, FISHER M, WILLIAMS I, JOHNSON M.ET.AL.... PROTEASE INHIBITOR MONOTHERAPY FOR LONG-TERM MANAGEMENT OF HIV INFECTION: A RANDOMISED, CONTROLLED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET HIV. 2015?2:E417-26",,,,,Y,,,20151107,,OT,SG,SG,Efavirenz,Adenocarcinoma,117079291,DE,,,,,,,,,117079291,1,HIV infection
11707935,117079351,1,I,,20151029,20151106,20151106,EXP,,SG-CIPLA LTD.-2015SG08367,CIPLA,"PATON N.I, STOHR W, ARENAS-PINTO A, FISHER M, WILLIAMS I, JOHNSON M.ET.AL.... PROTEASE INHIBITOR MONOTHERAPY FOR LONG-TERM MANAGEMENT OF HIV INFECTION: A RANDOMISED, CONTROLLED, OPEN-LABEL, NON-INFERIORITY TRIAL. LANCET HIV. 2015?2:E417-26",,,,,Y,,,20151107,,OT,SG,SG,Efavirenz,Renal failure,117079351,OT,,,,,,,,,117079351,1,HIV infection
11708246,117082461,1,I,,20151026,20151107,20151107,EXP,,UG-AUROBINDO-AUR-APL-2015-09941,AUROBINDO,,,,,,Y,,,20151107,,OT,UG,UG,Efavirenz,Abdominal pain lower;Cough;Drug interaction;Gastroenteritis cryptococcal;Ileal perforation;Immune reconstitution inflammatory syndrome;Lymphadenopathy;Pyrexia;Tachypnoea;Virologic failure;Vomiting,117082461,OT,,,,,,,,,117082461,1,Antiretroviral therapy
11708334,117083341,1,I,20120331,20130122,20151107,20151107,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17309105,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151107,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117083341,OT,,,117083341,1,20110920,,,,117083341,1,Antiretroviral therapy
11708346,117083461,1,I,20100930,20130205,20151107,20151107,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-17359787,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151107,,CN,AR,AR,EFAVIRENZ,Abortion spontaneous;Hypothyroidism;Maternal exposure during pregnancy,117083461,OT,,,117083461,3,20100920,,,,117083461,1,Antiretroviral therapy
11708376,117083761,1,I,20100222,20120814,20151107,20151107,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16902462,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,65.4,KG,20151107,,CN,US,MW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117083761,OT,,,117083761,1,20091123,20091209,,,117083761,1,HIV infection
11708458,117084581,1,I,,20100308,20151107,20151107,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028533,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151107,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084581,1,Antiretroviral therapy
11708459,117084592,2,F,,20151209,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028491,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084592,1,Antiretroviral therapy
11708461,117084612,2,F,,20151209,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028483,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084612,1,Antiretroviral therapy
11708463,117084632,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028541,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084632,1,Antiretroviral therapy
11708466,117084662,2,F,,20151209,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028525,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084662,1,Antiretroviral therapy
11708469,117084692,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028475,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084692,1,Antiretroviral therapy
11708474,117084742,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028467,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117084742,1,Antiretroviral therapy
11708618,117086182,2,F,,20151209,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028509,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086182,1,Antiretroviral therapy
11708621,117086212,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028558,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086212,1,Antiretroviral therapy
11708624,117086242,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028566,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117086242,1,Antiretroviral therapy
11708758,117087581,1,I,20100406,20101005,20151107,20151107,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15323637,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,1.69,KG,20151107,,OT,FR,FR,SUSTIVA,Cardiomegaly;Congenital pulmonary valve atresia;Congenital tricuspid valve atresia;Foetal exposure during pregnancy;Neonatal respiratory distress syndrome;Premature baby;Ventricular hypoplasia,117087581,CA,,,117087581,1,20091119,20100406,,,117087581,1,Product used for unknown indication
11708763,117087631,1,I,20100406,20101005,20151107,20151107,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15323611,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151107,,OT,FR,FR,SUSTIVA,Albuminuria;Anaemia;Blood alkaline phosphatase increased;Blood urea decreased;Live birth;Maternal exposure during pregnancy;Premature delivery;Proteinuria;Uterine disorder,117087631,OT,,,117087631,1,20091119,20091001,,,117087631,1,Antiretroviral therapy
11708765,117087652,2,F,,20151209,20151107,20151221,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028517,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151221,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087652,1,Antiretroviral therapy
11708767,117087672,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028608,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087672,1,Antiretroviral therapy
11708770,117087702,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028590,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087702,1,Antiretroviral therapy
11708773,117087732,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028582,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087732,1,Antiretroviral therapy
11708776,117087762,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028574,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087762,1,Antiretroviral therapy
11708779,117087792,2,F,,20151209,20151107,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028616,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117087792,1,Antiretroviral therapy
11709326,117093263,3,F,,20151207,20151107,20151219,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073574,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151219,,CN,ES,ES,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly,117093263,CA,,,,,,,,,117093263,1,Product used for unknown indication
11712975,117129751,1,I,20120627,20130308,20151108,20151108,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-17468729,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,3.6,KG,20151108,,OT,MW,MW,SUSTIVA,Congenital acrochordon;Foetal exposure during pregnancy;Premature baby;Sepsis neonatal,117129751,OT,,,117129751,1,20100222,20111114,,,117129751,1,Product used for unknown indication
11712989,117129891,1,I,20071118,20080702,20151108,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14251854,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151108,,CN,US,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117129891,OT,,,117129891,1,20061018,,,,117129891,1,Retroviral infection
11712990,117129901,1,I,,20010308,20151108,20151108,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0965,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151108,,OT,FR,FR,EFAVIRENZ,Abortion induced;Pregnancy,117129901,OT,,,,,,,,,117129901,1,HIV infection
11712996,117129961,1,I,20130228,20131206,20151108,20151108,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-19904374,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151108,,OT,CL,CL,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117129961,OT,,,117129961,1,20130205,,,,117129961,1,HIV infection
11713007,117130071,1,I,20001211,20010104,20151108,20151108,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0006,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151108,,MD,DE,DE,SUSTIVA,Drug administration error;Foetal death;Pregnancy,117130071,OT,,,117130071,1,199912,200011,,,117130071,1,HIV infection
11713013,117130131,1,I,20001201,20010126,20151108,20151108,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0062,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,48,KG,20151108,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Haemorrhage;Pregnancy,117130131,HO,,,117130131,1,20001201,20010110,,,117130131,1,HIV infection
11713014,117130141,1,I,20080521,20090120,20151108,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14478119,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,104,KG,20151108,,MD,GB,GB,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Normal newborn,117130141,OT,,,117130141,1,20071009,20071011,,,117130141,1,HIV infection
11713022,117130221,1,I,20080807,20091217,20151108,20151108,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-14902563,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151108,,CN,US,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117130221,OT,,,117130221,1,20041228,,,,117130221,1,Antiretroviral therapy
11713040,117130401,1,I,20000131,20001218,20151109,20151109,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0984,BRISTOL MYERS SQUIBB,,4,DY,,M,Y,3.2,KG,20151109,,OT,FR,FR,SUSTIVA,Anaemia macrocytic;Blood creatine phosphokinase increased;Blood lactic acid increased;Foetal exposure during pregnancy;Platelet count increased;Retrognathia,117130401,HO,,,117130401,1,20000127,19990630,,,117130401,1,Product used for unknown indication
11713041,117130411,1,I,20000603,20010209,20151109,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0119,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151109,,MD,US,US,EFAVIRENZ,Cervical dysplasia;Haemorrhage;Maternal exposure during pregnancy;Muscle spasms;Pregnancy;Stillbirth,117130411,OT,,,117130411,1,20000424,20000712,,,117130411,1,HIV infection
11713089,117130891,1,I,20121022,20130708,20151109,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-19102441,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20151109,,OT,US,US,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117130891,OT,,,117130891,1,20121017,20121017,,,117130891,1,Antiretroviral therapy
11713090,117130901,1,I,2012,20130711,20151109,20151109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-19118959,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20151109,,CN,UG,UG,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117130901,OT,,,117130901,1,20120427,20130108,,,117130901,1,Antiretroviral therapy
11713091,117130911,1,I,20130629,20130724,20151109,20151109,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-19159615,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,58.4,KG,20151109,,OT,ZW,ZW,EFAVIRENZ,Abortion incomplete;Maternal exposure during pregnancy;Uterine dilation and evacuation,117130911,HO,,,117130911,1,20110728,20130628,,,117130911,1,HIV infection
11713127,117131271,1,I,,20010201,20151109,20151109,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0089,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20151109,,MD,IT,IT,SUSTIVA,Abortion spontaneous;Pregnancy,117131271,OT,,,,,,,,,117131271,1,HIV infection
11713533,117135331,1,I,20120529,20121101,20151109,20151109,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17119868,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151109,,CN,US,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117135331,OT,,,117135331,1,20090525,,,,117135331,1,Antiviral treatment
11713534,117135341,1,I,20121127,20121219,20151109,20151109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17234345,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20151109,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy,117135341,OT,,,,,,,,,117135341,1,Antiretroviral therapy
11713594,117135941,1,I,20121127,20121207,20151109,20151109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17201724,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151109,,CN,US,GB,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Maternal exposure during pregnancy,117135941,OT,,,,,,,,,117135941,1,Antiretroviral therapy
11714701,117147011,1,I,,20151021,20151109,20151109,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-073544,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,50,KG,20151109,,OT,ZA,ZA,EFAVIRENZ,Hepatic cancer metastatic;Live birth;Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery;Premature labour,117147011,OT,,,,,,,,,117147011,1,HIV infection
11717175,117171751,1,I,20001024,20010601,20151109,20151109,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0512,BRISTOL MYERS SQUIBB,,,,,,Y,.19,KG,20151109,,MD,BE,BE,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Placental disorder,117171751,OT,,,,,,,,,117171751,1,Product used for unknown indication
11717763,117177631,1,I,20130815,20151028,20151110,20151110,PER,,US-009507513-1511USA000592,MERCK,,18,YR,,F,Y,,,20151110,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,117177631,1,Antiretroviral therapy
11720369,117203692,2,F,,20151030,20151110,20151112,EXP,,US-009507513-1201USA02584B1,MERCK,,,,,F,Y,3.26,KG,20151112,,CN,US,US,EFAVIRENZ,Cleft lip;Cleft palate;Foetal exposure during pregnancy,117203692,CA,,,117203692,1,20111202,20111212,,,,,
11721175,117211751,1,I,20121128,20130214,20151110,20151110,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-17392481,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.88,KG,20151110,,OT,BR,BR,EFAVIRENZ,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,117211751,OT,,,117211751,1,20120521,20120611,,,117211751,1,Product used for unknown indication
11721241,117212411,1,I,20010301,20010417,20151110,20151110,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0331,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151110,,CN,US,US,SUSTIVA,Bradycardia foetal;Foetal exposure during pregnancy,117212411,OT,,,117212411,1,20010301,,,,117212411,1,Product used for unknown indication
11723660,117236601,1,I,,20151104,20151111,20151111,EXP,,US-GLAXOSMITHKLINE-US2015158934,GLAXOSMITHKLINE,,,,,F,Y,,,20151111,,CN,US,US,SUSTIVA,Arthralgia;Blood creatine phosphokinase increased,,,,,,,,,,,117236601,1,HIV infection
11724241,117242411,1,I,20080315,20080702,20151111,20151111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14251607,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20151111,,OT,GB,UG,EFAVIRENZ,Abortion spontaneous;Arthralgia;Arthritis;Blepharitis;Conjunctivitis;Dermatitis atopic;Eczema;Excoriation;Keratitis;Maternal exposure during pregnancy;Pain;Pruritus;Seborrhoeic dermatitis;Upper respiratory tract infection,117242411,OT,,,117242411,1,20070514,20080218,,,117242411,1,HIV infection
11724432,117244321,1,I,,20151015,20151111,20151111,EXP,,BE-BMSGILMSD-2015-0178300,GILEAD,,,,,,Y,,,20151111,,MD,BE,BE,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neurotoxicity,117244321,OT,,,117244321,1,20091218,20110801,,,117244321,1,Product used for unknown indication
11725755,117257552,2,F,,20151209,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029192,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117257552,1,Antiretroviral therapy
11725766,117257662,2,F,,20151209,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029200,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117257662,1,Antiretroviral therapy
11725824,117258242,2,F,,20151209,20151111,20151230,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029218,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151230,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258242,1,Antiretroviral therapy
11725868,117258681,1,I,,20091201,20151111,20151111,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14890628,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151111,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,117258681,1,HIV infection
11725869,117258692,2,F,,20151209,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029234,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258692,1,Antiretroviral therapy
11725870,117258702,2,F,,20151209,20151111,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029226,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117258702,1,Antiretroviral therapy
11725917,117259171,1,I,20110810,20120714,20151112,20151112,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-16770240,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151112,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117259171,OT,,,117259171,1,20110411,,,,117259171,1,HIV infection
11725919,117259192,2,F,,20151209,20151112,20151229,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15029267,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151229,,OT,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117259192,1,Antiretroviral therapy
11726897,117268971,1,I,20000520,20000822,20151112,20151112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0652,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,61,KG,20151112,,CN,FR,FR,SUSTIVA,Abdominal distension;Anogenital warts;Caesarean section;Live birth;Pregnancy,117268971,HO,,,117268971,1,20000627,20000627,,,117268971,1,HIV infection
11726929,117269291,1,I,,20151029,20151112,20151112,EXP,,IN-WATSON-2015-24043,WATSON,"THAKUR BK, VERMA S, MISHRA J. LICHENOID DRUG REACTION TO ISONIAZID PRESENTING  AS EXFOLIATIVE DERMATITIS IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME. INT J STD AIDS. 2015?26(7):512-5.",31,YR,,M,Y,,,20151112,,OT,IN,IN,EFAVIRENZ,Lichenoid keratosis,117269291,OT,,,,,,,,,117269291,1,Pulmonary tuberculosis
11726952,117269521,1,I,200101,20010615,20151112,20151112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0535,BRISTOL MYERS SQUIBB,,,,,F,Y,2.9,KG,20151112,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hepatosplenomegaly;Hypertriglyceridaemia;Neutropenia,117269521,OT,,,117269521,1,20000501,20000627,,,117269521,1,Product used for unknown indication
11727074,117270741,1,I,,20081106,20151112,20151112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14398168,BRISTOL MYERS SQUIBB,,,,,F,Y,64,KG,20151112,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117270741,OT,,,117270741,1,200606,,,,117270741,1,HIV infection
11729090,117290901,1,I,,20151104,20151112,20151112,EXP,,US-VIIV HEALTHCARE LIMITED-US2015158934,VIIV,,,,,F,Y,,,20151112,,CN,US,US,SUSTIVA,Arthralgia;Blood creatine phosphokinase increased,,,,,,,,,,,117290901,1,HIV infection
11730391,117303911,1,I,,20151104,20151112,20151112,EXP,,GB-GILEAD-2015-0181138,GILEAD,,,,,M,Y,,,20151112,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,117303911,OT,,,,,,,,,117303911,1,Product used for unknown indication
11730827,117308271,1,I,201303,20151103,20151112,20151112,EXP,,ES-GILEAD-2015-0181254,GILEAD,,28,YR,A,F,Y,,,20151112,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Neuropsychiatric syndrome,117308271,OT,,,117308271,1,201102,201304,,,117308271,1,HIV infection
11731187,117311872,2,F,,20151102,20151112,20151217,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0064,BRISTOL MYERS SQUIBB,,1,DY,,,Y,2.58,KG,20151112,,OT,DE,DE,SUSTIVA,Atrial septal defect;Foetal exposure during pregnancy;Patent ductus arteriosus;Ventricular septal defect,117311872,CA,,,,,,,,,117311872,1,Product used for unknown indication
11732218,117322181,1,I,,20140616,20151113,20151113,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-21179130,BRISTOL MYERS SQUIBB,,18,YR,,F,Y,,,20151113,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,117322181,1,Product used for unknown indication
11732882,117328821,1,I,,20151111,20151113,20151113,EXP,,CA-ROCHE-1659864,ROCHE,,54,YR,,M,Y,,,20151113,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,117328821,OT,,,,,,,,,117328821,1,Product used for unknown indication
11733383,117333831,1,I,200005,20001218,20151113,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0983,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,3.91,KG,20151113,,OT,US,FR,SUSTIVA,Alanine aminotransferase increased;Anaemia;Blood creatine phosphokinase increased;Blood lactic acid increased;Foetal exposure during pregnancy;Hypertriglyceridaemia;Platelet count increased;Toe walking,117333831,HO,,,117333831,1,19991230,19990920,,,117333831,1,Product used for unknown indication
11733813,117338131,1,I,,20151029,20151113,20151113,EXP,,GB-HETERO LABS LTD-1044148,HETERO,,25,YR,,M,Y,,,20151113,,MD,GB,GB,Efavirenz,Abdominal pain;Chromaturia;Porphyria acute;Vomiting,117338131,HO,,,,,,,,,117338131,1,HIV infection
11734511,117345111,1,I,20100406,20101005,20151113,20151113,EXP,,FR-009507513-1010USA01114B1,MERCK,,1,DY,,F,Y,1.69,KG,20151113,,CN,US,FR,SUSTIVA,Cardiomegaly;Congenital pulmonary valve atresia;Congenital tricuspid valve atresia;Foetal exposure during pregnancy;Neonatal respiratory distress syndrome;Premature baby;Ventricular hypoplasia,117345111,CA,,,117345111,1,200911,20091001,,,117345111,1,Product used for unknown indication
11737686,117376861,1,I,20090821,20091012,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14815856,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151113,,OT,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117376861,OT,,,117376861,1,20030529,,,,117376861,1,Antiretroviral therapy
11738513,117385131,1,I,200604,20110420,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15690837,BRISTOL MYERS SQUIBB,,44,YR,,F,Y,,,20151113,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117385131,OT,,,117385131,1,200403,,,,117385131,1,HIV infection
11738784,117387841,1,I,,20101213,20151113,20151113,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-15443955,BRISTOL MYERS SQUIBB,,,,,F,Y,3.4,KG,20151113,,CN,ES,ES,EFAVIRENZ,Congenital anomaly;Foetal exposure during pregnancy,117387841,OT,,,117387841,1,200901,20090926,,,117387841,1,Product used for unknown indication
11739121,117391211,1,I,20090714,20110225,20151113,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15583552,BRISTOL MYERS SQUIBB,,14,YR,,F,Y,,,20151113,,CN,US,GB,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117391211,OT,,,117391211,1,20080702,20090706,,,117391211,1,Antiretroviral therapy
11739131,117391311,1,I,,20130311,20151113,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17476250,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Pachygyria,117391311,OT,,,,,,,,,117391311,1,Product used for unknown indication
11739293,117392931,1,I,2008,20090529,20151113,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14652952,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Stillbirth,117392931,OT,,,117392931,1,20060201,,,,117392931,1,HIV infection
11739295,117392951,1,I,,20130311,20151113,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707307,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,CN,US,FR,EFAVIRENZ,Congenital central nervous system anomaly;Foetal exposure during pregnancy,117392951,CA,,,,,,,,,117392951,1,Product used for unknown indication
11739296,117392961,1,I,20090609,20090610,20151113,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14663462,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117392961,OT,,,117392961,1,20081101,,,,117392961,1,HIV infection
11739603,117396031,1,I,20090315,20091217,20151113,20151113,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902605,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151113,,OT,UG,UG,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,117396031,OT,,,117396031,1,20060206,20081212,,,117396031,1,Antiretroviral therapy
11739738,117397381,1,I,20090519,20090529,20151113,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14654230,BRISTOL MYERS SQUIBB,,,,N,M,Y,1.54,KG,20151113,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neonatal asphyxia,117397381,OT,,,117397381,1,,20090519,,,117397381,1,Product used for unknown indication
11739957,117399571,1,I,20081101,20091217,20151113,20151113,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14902696,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151113,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,117399571,OT,,,117399571,1,20071008,20080904,,,117399571,1,Antiretroviral therapy
11740051,117400511,1,I,,20130212,20151113,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707323,BRISTOL MYERS SQUIBB,SUSMAN ED.. EFAVIRENZ TIED TO NEUROLOGICAL BIRTH DEFECTS.. CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 2013,,,,,Y,,,20151113,,OT,FR,FR,SUSTIVA,Congenital hydrocephalus;Foetal exposure during pregnancy,117400511,CA,,,,,,,,,117400511,1,Product used for unknown indication
11740247,117402471,1,I,,20111004,20151113,20151113,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16143976,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151113,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117402471,1,HIV infection
11741281,117412811,1,I,,20151111,20151116,20151116,EXP,,CA-ROCHE-1659874,ROCHE,,54,YR,,M,Y,,,20151116,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,117412811,OT,,,,,,,,,117412811,1,Product used for unknown indication
11741847,117418471,1,I,20150908,,20151113,20151113,DIR,,,,,53,YR,,F,N,42.3,KG,20151110,Y,OT,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF,Neutropenia;White blood cell count decreased,117418471,LT,,,117418471,1,20150728,20150908,,,117418471,1,Kaposi's sarcoma AIDS related
11744737,117447371,1,I,,20070815,20151116,20151116,EXP,,US-009507513-0708USA04038,MERCK,,,,I,M,Y,3.91,KG,20151116,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Hypospadias,117447371,OT,,,,,,,,,117447371,1,HIV infection
11744743,117447435,5,F,20150115,20151208,20151116,20151218,EXP,,PE-GILEAD-2015-0174369,GILEAD,,31,YR,A,F,Y,82,KG,20151218,,MD,PE,PE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy,117447435,HO,,,117447435,1,20130612,,,,117447435,1,HIV infection
11746781,117467811,1,I,,20111214,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16318008,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,117467811,1,Antiretroviral therapy
11746826,117468261,1,I,,20111207,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16330839,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117468261,1,HIV infection
11746837,117468371,1,I,,20111207,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16330995,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,117468371,1,HIV infection
11747180,117471801,1,I,,20111207,20151117,20151117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16331019,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151117,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117471801,1,HIV infection
11748057,117480572,2,F,,20151130,20151117,20151208,EXP,,BR-ABBVIE-15P-020-1497822-00,ABBVIE,,,,N,M,Y,,,20151208,,OT,COUNTRY NOT SPECIFIED,BR,EFAVIRENZ;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUM,Congenital skin dimples;Foetal exposure during pregnancy;Peyronie's disease,117480572,CA,,,,,,,,,117480572,1,Maternal exposure timing unspecified
11748512,117485121,1,I,,20151110,20151117,20151117,EXP,,US-BMSGILMSD-2015-0182340,GILEAD,,28,YR,A,M,Y,,,20151117,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug dose omission;Drug resistance,117485121,OT,,,117485121,1,,20151110,,,117485121,1,HIV infection
11748560,117485601,1,I,,20130311,20151117,20151117,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707349,BRISTOL MYERS SQUIBB,SUSMAN ED.. EFAVIRENZ TIED TO NEUROLOGICAL BIRTH DEFECTS.. CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. 2013,,,,,Y,,,20151117,,OT,FR,FR,SUSTIVA,Cerebral cyst;Foetal exposure during pregnancy,117485601,OT,,,,,,,,,117485601,1,Product used for unknown indication
11748738,117487381,1,I,20060614,20100308,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15025786,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117487381,1,Antiretroviral therapy
11748769,117487692,2,F,,20151209,20151118,20151224,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15026743,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151224,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117487692,1,Product used for unknown indication
11748933,117489331,1,I,,20100308,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027873,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118,,CN,US,US,SUSTIVA,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117489331,1,Antiretroviral therapy
11748953,117489532,2,F,,20151209,20151118,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028046,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117489532,1,Antiretroviral therapy
11749253,117492531,1,I,,20110214,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567381,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117492531,1,HIV infection
11749674,117496741,1,I,20080521,20151112,20151118,20151118,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015161942,VIIV,,28,YR,,F,Y,104,KG,20151118,,MD,GB,GB,Efavirenz,Caesarean section;Maternal exposure during pregnancy;Normal newborn,117496741,OT,,,117496741,1,20071012,20071022,,,117496741,1,HIV infection
11749677,117496771,1,I,,20151006,20151118,20151118,EXP,,US-VIIV HEALTHCARE LIMITED-US2015164246,VIIV,,,,,M,Y,68.93,KG,20151118,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117496771,OT,,,117496771,1,200706,200706,,,117496771,1,HIV infection
11750777,117507771,1,I,,20110214,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567456,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117507771,1,HIV infection
11750955,117509551,1,I,,20110214,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567530,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117509551,1,HIV infection
11751036,117510361,1,I,,20110214,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567548,BRISTOL MYERS SQUIBB,,20,YR,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117510361,1,HIV infection
11751173,117511733,3,F,20151008,20151208,20151118,20151217,EXP,,US-GILEAD-2015-0182212,GILEAD,,60,YR,A,F,Y,88.89,KG,20151217,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoarthritis,117511733,HO,,,117511733,1,20130222,,,,117511733,1,HIV infection
11751565,117515651,1,I,,20110214,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567605,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117515651,1,HIV infection
11752005,117520051,1,I,,20151006,20151118,20151118,EXP,,US-GLAXOSMITHKLINE-US2015164246,GLAXOSMITHKLINE,,,,,M,Y,68.93,KG,20151118,,MD,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117520051,OT,,,117520051,1,200706,200706,,,117520051,1,HIV infection
11752387,117523872,2,F,,20151209,20151118,20151224,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027980,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151224,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117523872,1,Antiretroviral therapy
11752484,117524841,1,I,,20100309,20151118,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15026032,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,117524841,1,Antiretroviral therapy
11752506,117525062,2,F,,20151209,20151119,20151224,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15027998,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151224,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117525062,1,Antiretroviral therapy
11754326,117543261,1,I,20111101,20121030,20151119,20151119,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17111626,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151119,,CN,US,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117543261,OT,,,117543261,1,20100203,,,,117543261,1,Antiretroviral therapy
11755635,117556352,2,F,201403,20151119,20151119,20151201,EXP,,FR-GILEAD-2015-0182342,GILEAD,,51,YR,A,F,Y,,,20151201,,OT,FR,FR,SUSTIVA,Asthenia;Dizziness;Vertigo,117556352,OT,,,117556352,1,20130313,20140416,,,117556352,1,HIV infection
11755763,117557631,1,I,20140622,20151113,20151119,20151119,EXP,,ZW-GILEAD-2015-0182856,GILEAD,,36,YR,A,F,Y,,,20151119,,MD,ZW,ZW,EFAVIRENZ,Acute kidney injury;Alanine aminotransferase increased;Aspartate aminotransferase increased;Pruritus;Vomiting,117557631,HO,,,117557631,1,20140612,20141001,,,117557631,1,HIV infection
11756034,117560341,1,I,,20151006,20151119,20151119,EXP,,US-009507513-1510USA006733,MERCK,,54,YR,,M,Y,68.93,KG,20151119,,CN,US,US,SUSTIVA,Blood creatinine increased;Glucose tolerance impaired;Glycosuria;Hydronephrosis;Nephrolithiasis;Proteinuria;Red blood cells urine;Renal tubular disorder,117560341,OT,,,117560341,1,200706,200706,,,117560341,1,HIV infection
11756515,117565152,2,F,,20151209,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028012,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565152,1,Antiretroviral therapy
11756516,117565162,2,F,,20151209,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028004,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565162,1,Antiretroviral therapy
11756523,117565232,2,F,,20151209,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028020,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565232,1,Antiretroviral therapy
11756525,117565252,2,F,,20151209,20151119,20151225,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15028038,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Maternal exposure during pregnancy;Normal newborn,,,,,,,,,,,117565252,1,Antiretroviral therapy
11756888,117568881,1,I,,20151107,20151120,20151120,EXP,,GB-CIPLA LTD.-2015GB08587,CIPLA,"WILKINS E, COHEN C, TROTTIER B, ESSER S, SMITH D, HAAS B, ET AL.. PATIENT-REPORTED OUTCOMES IN THE SINGLE-TABLET REGIMEN (STAR) TRIAL OF RILPIVIRINE/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE VERSUS EFAVIRENZ/EMTRICITABINE/ TENOFOVIR DISOPROXIL FUMARATE IN ANTIRETROVIRAL TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 THROUGH 48 WEEKS OF TREATMENT. AIDS CARE. 2015?1-8",,,,,Y,,,20151120,,OT,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Septic shock,117568881,DE,,,,,,,,,117568881,1,HIV infection
11758991,117589911,1,I,20080707,20151112,20151120,20151120,EXP,,GB-ABBVIE-15P-167-1501161-00,ABBVIE,,27,YR,,F,Y,,,20151120,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,117589911,OT,,,117589911,1,20080206,20080206,,,117589911,1,HIV infection
11761092,117610922,2,F,,20151117,20151120,20151130,EXP,,RO-VIIV HEALTHCARE LIMITED-RO2015GSK163541,VIIV,"TUDOR AM, MARDARESCU M, ANCA IA, PETRE C, CRISTEA C, DRAGHICENOIU CR ET AL.,. SEVERE BIRTH DEFECTS IN HIV VERTICALLY EXPOSED CHILDREN. CASE SERIES PUBLICATION: ORL. 2015?3(28):6-12",5,YR,,M,Y,,,20151130,,MD,RO,RO,Efavirenz,Gonadal dysgenesis;Hermaphroditism,117610922,OT,,,,,,,,,117610922,1,HIV infection
11761488,117614882,2,F,,20151117,20151120,20151130,EXP,,RO-GLAXOSMITHKLINE-RO2015GSK163541,GLAXOSMITHKLINE,"TUDOR AM, MARDARESCU M, ANCA IA, PETRE C, CRISTEA C, DRAGHICENOIU CR ET AL.,. SEVERE BIRTH DEFECTS IN HIV VERTICALLY EXPOSED CHILDREN. CASE SERIES PUBLICATION: ORL. 2015?3(28):6-12",5,YR,,M,Y,,,20151130,,MD,RO,RO,Efavirenz,Gonadal dysgenesis;Hermaphroditism,117614882,CA,,,,,,,,,117614882,1,HIV infection
11762108,117621081,1,I,,20151113,20151120,20151120,PER,,US-CELGENEUS-USA-2015114442,CELGENE,,,,,M,Y,,,20151120,,OT,US,US,SUSTIVA,Infection;Platelet count decreased,117621081,HO,,,117621081,1,201307,2015,,,117621081,1,Kaposi's sarcoma
11762825,117628251,1,I,,20130131,20151120,20151120,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17372277,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151120,,CN,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,117628251,OT,,,,,,,,,117628251,1,Antiretroviral therapy
11762836,117628361,1,I,20110820,20130207,20151120,20151120,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-17379041,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,71,KG,20151120,,OT,IN,IN,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117628361,OT,,,117628361,1,20110805,20110805,,,117628361,1,HIV infection
11762838,117628381,1,I,20130411,20130430,20151120,20151120,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18861518,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151120,,OT,GB,GB,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Premature delivery;Renal impairment,117628381,OT,,,117628381,1,20110102,,,,117628381,1,Antiretroviral therapy
11762840,117628401,1,I,20130411,20130430,20151120,20151120,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18861468,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,.53,KG,20151120,,OT,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Patent ductus arteriosus;Premature baby,117628401,OT,,,117628401,1,20110102,20130411,,,117628401,1,Product used for unknown indication
11762842,117628421,1,I,20120824,20130416,20151120,20151120,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-18822858,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.52,KG,20151120,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Infection;Jaundice neonatal;Premature baby,117628421,HO,,,117628421,1,20080919,20090115,,,117628421,1,Product used for unknown indication
11765868,117658681,1,I,20111212,20120113,20151122,20151122,PER,,US-009507513-1201USA02584,MERCK,,24,YR,,F,Y,,,20151121,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,117658681,1,20111202,20111212,,,117658681,1,Antiretroviral therapy
11765907,117659071,1,I,20090812,20090806,20151122,20151122,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14732424,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,68,KG,20151122,,MD,GB,GB,SUSTIVA,Abortion missed;Maternal exposure during pregnancy,117659071,OT,,,117659071,1,20030529,20090804,,,117659071,1,HIV infection
11766296,117662961,1,I,20010708,20010711,20151123,20151123,EXP,,IL-BRISTOL-MYERS SQUIBB COMPANY-10911063,BRISTOL MYERS SQUIBB,,20,YR,,F,Y,,,20151123,,OT,IL,IL,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,117662961,OT,,,117662961,1,20010529,20010624,,,117662961,1,HIV infection
11766437,117664371,1,I,,20100615,20151123,20151123,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15152028,BRISTOL MYERS SQUIBB,,,,,M,Y,2.41,KG,20151123,,CN,US,FR,EFAVIRENZ,Foetal exposure during pregnancy;Gastrointestinal disorder;Hydrocephalus;Premature baby,117664371,CA,,,117664371,1,20010405,20040523,,,117664371,1,Product used for unknown indication
11766523,117665231,1,I,20140823,20140908,20151123,20151123,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-21390984,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151123,,OT,BW,BW,EFAVIRENZ,Abortion incomplete;Pregnancy on oral contraceptive;Uterine dilation and curettage,117665231,OT,,,117665231,1,20110624,20140904,,,117665231,1,HIV infection
11767559,117675591,1,I,,20151113,20151123,20151123,EXP,GB-MHRA-ADR 23232433,GB-VIIV HEALTHCARE LIMITED-GB2015162800,VIIV,,32,YR,,F,Y,64,KG,20151123,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117675591,OT,,,117675591,1,200606,,,,117675591,1,HIV infection
11767621,117676211,1,I,,20151113,20151123,20151123,EXP,GB-MHRA-ADR 23232433,GB-GLAXOSMITHKLINE-GB2015162800,GLAXOSMITHKLINE,,32,YR,,F,Y,64,KG,20151123,,CN,GB,GB,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,117676211,OT,,,117676211,1,200606,,,,117676211,1,HIV infection
11769337,117693371,1,I,20150813,20151020,20151123,20151123,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-072853,BRISTOL MYERS SQUIBB,,78,YR,,M,Y,91,KG,20151123,,OT,US,US,SUSTIVA,Bacteraemia;Haematuria;Non-cardiac chest pain;Respiratory failure,117693371,OT,,,117693371,2,20150806,20150828,,,117693371,1,Atrial fibrillation
11769512,117695121,1,I,2015,20151116,20151123,20151123,EXP,,US-GILEAD-2015-0183012,GILEAD,,55,YR,A,F,Y,,,20151123,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Carotid artery occlusion;Cerebral thrombosis;Cerebrovascular accident;Transient ischaemic attack,117695121,HO,,,,,,,,,117695121,1,HIV infection
11772510,117725101,1,I,201510,20151022,20151124,20151124,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2015GSK151481,VIIV,,45,YR,,M,Y,,,20151124,,MD,KE,KE,EFAVIRENZ,Fatigue;Immune reconstitution inflammatory syndrome;Oral candidiasis,117725101,OT,,,117725101,1,201510,,,,117725101,1,HIV test positive
11775153,117751531,1,I,200105,20051227,20151124,20151124,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-13235460,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151124,,CN,US,JP,EFAVIRENZ,Abortion induced;Pregnancy,117751531,OT,,,117751531,1,20001003,20041018,,,117751531,1,HIV infection
11775154,117751541,1,I,20000414,20031031,20151124,20151124,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12428447,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,.46,KG,20151124,,CN,FR,FR,EFAVIRENZ,Dysmorphism;Foetal distress syndrome;Foetal exposure during pregnancy;Foetal growth restriction,117751541,CA,,,,,,,,,117751541,1,Product used for unknown indication
11775350,117753501,1,I,20100317,20100420,20151125,20151125,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15072168,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151125,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,117753501,OT,,,117753501,1,20100219,20100201,,,117753501,1,Antiretroviral therapy
11775364,117753641,1,I,,20100420,20151125,20151125,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2010-000018,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151125,,CN,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Foetal exposure during pregnancy;Sepsis,117753641,OT,,,117753641,1,20100219,20100201,,,117753641,1,Product used for unknown indication
11779613,117796131,1,I,20150123,20151120,20151125,20151125,EXP,,ZA-BMSGILMSD-2015-0184328,GILEAD,,43,YR,A,F,Y,,,20151125,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,117796131,OT,,,,,,,,,117796131,1,HIV infection
11780467,117804671,1,I,,20070815,20151126,20151126,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13884051,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,,,20151126,,OT,US,US,EFAVIRENZ,Abortion induced;Pregnancy,117804671,OT,,,,,,,,,117804671,1,HIV infection
11780712,117807121,1,I,20100701,20100520,20151126,20151126,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15116122,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151126,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Abortion spontaneous;Caesarean section;Normal newborn;Premature delivery;Twin pregnancy,117807121,OT,,,117807121,1,20100518,20100518,,,117807121,1,HIV infection
11781034,117810341,1,I,20120306,20120308,20151126,20151126,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16449464,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,72,KG,20151126,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,117810341,OT,,,117810341,1,20110915,20120202,,,117810341,1,HIV infection
11781093,117810931,1,I,,20010928,20151126,20151126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11005832,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151126,,OT,US,FR,EFAVIRENZ,Abortion induced;Haemorrhage;Pregnancy,117810931,OT,,,117810931,1,20000722,20010404,,,117810931,1,HIV infection
11781970,117819701,1,I,201403,20151119,20151126,20151126,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-081866,BRISTOL MYERS SQUIBB,,51,YR,,F,Y,,,20151126,,CN,FR,FR,SUSTIVA,Asthenia;Dizziness;Vertigo,117819701,OT,,,117819701,1,20130313,20150429,,,117819701,1,HIV infection
11783030,117830301,1,I,2007,20080617,20151127,20151127,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14255954,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151127,,CN,US,US,EFAVIRENZ,CD4 lymphocytes decreased;Maternal exposure during pregnancy;Nausea;Nervous system disorder;Normal newborn;Otitis media;Viral load increased,,,,,,,,,,,117830301,1,HIV infection
11784347,117843471,1,I,,20100716,20151129,20151129,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-15198393,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151129,,OT,IT,IT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117843471,OT,,,,,,,,,117843471,1,Antiretroviral therapy
11784460,117844601,1,I,20050912,20050921,20151129,20151129,EXP,,SN-BRISTOL-MYERS SQUIBB COMPANY-13122759,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,,,20151129,,OT,US,US,EFAVIRENZ,Malaria;Pregnancy;Pyrexia;Stillbirth,117844601,OT,,,117844601,1,20041025,20050301,,,117844601,1,HIV infection
11784777,117847771,1,I,,20151120,20151130,20151130,EXP,,CN-CIPLA LTD.-2015CN08957,CIPLA,"LI J, GUO W, HAN J, ZHUANG D, LIU S, LIU Y, ET.AL. CHARACTERIZATION OF TWO HIV-1 INFECTORS DURING INITIAL ANTIRETROVIRAL TREATMENT, AND THE EMERGENCE OF PHENOTYPIC RESISTANCE IN REVERSE TRANSCRIPTASE-ASSOCIATED MUTATION PATTERNS. GUO ET AL. VIROLOGY JOURNAL. 2015?12:1-9",,,,,Y,,,20151130,,OT,CN,CN,Efavirenz,Drug resistance;Viral load increased,117847771,OT,,,,,,,,,117847771,1,HIV infection
11784780,117847801,1,I,,20151120,20151130,20151130,EXP,,CN-CIPLA LTD.-2015CN08958,CIPLA,"LI J, GUO W, HAN J, ZHUANG D, LIU S, LIU Y, ET.AL. CHARACTERIZATION OF TWO HIV-1 INFECTORS DURING INITIAL ANTIRETROVIRAL TREATMENT, AND THE EMERGENCE OF PHENOTYPIC RESISTANCE IN REVERSE TRANSCRIPTASE-ASSOCIATED MUTATION PATTERNS. GUO ET AL. VIROLOGY JOURNAL. 2015?12:1-9",,,,,Y,,,20151130,,OT,CN,CN,Efavirenz,Drug resistance;Viral load increased,117847801,OT,,,,,,,,,117847801,1,HIV infection
11786175,117861752,2,F,20151106,20151201,20151130,20151216,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2015GSK168395,VIIV,,39,YR,,F,Y,,,20151216,,MD,CN,CN,EFAVIRENZ,Tibia fracture,117861752,HO,,,117861752,1,20151010,,,,117861752,1,HIV infection
11787162,117871622,2,F,20151106,20151201,20151130,20151216,EXP,,CN-GLAXOSMITHKLINE-CN2015GSK168395,GLAXOSMITHKLINE,,39,YR,,F,Y,,,20151216,,MD,CN,CN,EFAVIRENZ,Tibia fracture,117871622,HO,,,117871622,1,20151010,,,,117871622,1,HIV infection
11788652,117886521,1,I,200112,20010919,20151201,20151201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0841,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,60,KG,20151201,,MD,FR,FR,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Uterine hypotonus,117886521,OT,,,117886521,1,20010709,200107,,,117886521,1,HIV infection
11788693,117886931,1,I,20050627,20050801,20151201,20151201,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13059134,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151201,,MD,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,117886931,OT,,,117886931,1,20040830,20050527,,,117886931,1,HIV infection
11788761,117887611,1,I,,20010914,20151201,20151201,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0832,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151201,,PH,US,US,SUSTIVA,Abortion spontaneous;Pregnancy,117887611,OT,,,,,,,,,117887611,1,Product used for unknown indication
11788953,117889532,2,F,20121026,20151123,20151201,20151201,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17468513,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151201,,OT,CI,CI,EFAVIRENZ,Abortion spontaneous;Malaria;Maternal exposure during pregnancy,117889532,OT,,,117889532,1,20100312,20120827,,,117889532,1,Antiretroviral therapy
11789361,117893611,1,I,,20050325,20151201,20151201,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2005-000054,BRISTOL MYERS SQUIBB,,,,,F,Y,9.4,KG,20151201,,OT,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Foetal growth restriction,117893611,OT,,,,,,,,,117893611,1,Product used for unknown indication
11789987,117899871,1,I,,20060524,20151201,20151201,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2006-000015,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151201,,CN,IT,IT,SUSTIVA,Foetal exposure during pregnancy;Foetal malformation,117899871,OT,,,,,,,,,117899871,1,Product used for unknown indication
11790030,117900301,1,I,20110910,20111013,20151201,20151201,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16159766,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,55.7,KG,20151201,,CN,US,MW,EFAVIRENZ,Abortion missed;Haemoglobin decreased;Maternal exposure during pregnancy,117900301,LT,,,117900301,1,20110712,20110812,,,117900301,1,HIV infection
11792651,117926511,1,I,,20100716,20151202,20151202,EXP,,IT-009507513-1007USA02067,MERCK,,26,YR,,F,Y,,,20151202,,CN,US,IT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,117926511,OT,,,,,,,,,117926511,1,Antiretroviral therapy
11794582,117945821,1,I,20000414,20031031,20151202,20151202,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2003-000007,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151202,,CN,FR,FR,EFAVIRENZ,Abortion induced;Oligohydramnios;Placental insufficiency;Pregnancy,117945821,OT,,,,,,,,,117945821,1,Antiretroviral therapy
11796522,117965221,1,I,20141004,20151124,20151203,20151203,EXP,,MY-VIIV HEALTHCARE LIMITED-MY2015GSK171562,VIIV,,26,YR,,M,Y,,,20151203,,OT,MY,MY,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Mouth ulceration,117965221,OT,,,,,,,,,117965221,1,Antiretroviral therapy
11796667,117966671,1,I,20141004,20151124,20151203,20151203,EXP,,MY-GLAXOSMITHKLINE-MY2015GSK171562,GLAXOSMITHKLINE,,26,YR,,M,Y,,,20151203,,OT,MY,MY,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms;Mouth ulceration,117966671,OT,,,,,,,,,117966671,1,Antiretroviral therapy
11799055,117990551,1,I,,20151127,20151203,20151203,EXP,,GB-BMSGILMSD-2015-0185117,GILEAD,,33,YR,A,M,Y,,,20151203,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,117990551,DE,,,,,,,,,117990551,1,Product used for unknown indication
11799099,117990991,1,I,,20151123,20151203,20151203,EXP,,US-GILEAD-2015-0184897,GILEAD,,51,YR,A,F,Y,,,20151203,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Spinal cord injury,117990991,DS,,,,,,,,,117990991,1,HIV infection
11800288,118002881,1,I,2013,20151123,20151203,20151203,EXP,,PT-GILEAD-2015-0185123,GILEAD,,51,YR,A,M,Y,57,KG,20151203,,MD,PT,PT,EFAVIRENZ,Osteopenia;Osteoporosis,118002881,OT,,,118002881,1,200601,,,,118002881,1,HIV infection
11801300,118013001,1,I,,20151119,20151204,20151204,EXP,,"BR-SILARX PHARMACEUTICALS, INC-1045043",SILARX,ANTIRETROVIRAL PREGNANCY REGISTRY?REGISTRY ID: 083847,,,,M,Y,3.41,KG,20151204,,,BR,BR,EFAVIRENZ,Congenital anomaly;Congenital skin dimples;Peyronie's disease,118013001,CA,,,,,,,,,,,
11805673,118056731,1,I,20020222,20030108,20151207,20151207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12153615,BRISTOL MYERS SQUIBB,,21,YR,,F,Y,58,KG,20151207,,MD,FR,FR,SUSTIVA,Caesarean section;Live birth;Pregnancy;Premature rupture of membranes,118056731,OT,,,118056731,1,200104,20020407,,,118056731,1,HIV test positive
11805704,118057041,1,I,20120814,20130228,20151207,20151207,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17439225,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151207,,OT,CI,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118057041,OT,,,118057041,1,20100211,,,,118057041,1,Antiretroviral therapy
11805705,118057051,1,I,20120613,20130227,20151207,20151207,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-17433368,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20151207,,MD,CI,CI,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118057051,OT,,,118057051,1,20110516,20120521,,,118057051,1,Antiretroviral therapy
11806733,118067331,1,I,20020410,20030205,20151207,20151207,PER,,US-009507513-0306USA01112,MERCK,,1,DY,,F,Y,2.26,KG,20151207,,CN,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,,,,,118067331,8,20020312,20020410,,,118067331,1,Product used for unknown indication
11809279,118092791,1,I,,20110214,20151207,20151207,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15567621,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151207,,OT,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy,,,,,,,,,,,118092791,1,HIV infection
11809349,118093491,1,I,,20100114,20151207,20151207,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948566,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20151207,,OT,ZA,ZA,EFAVIRENZ,Induced labour;Maternal exposure during pregnancy;Stillbirth,118093491,OT,,,,,,,,,118093491,1,Antiretroviral therapy
11809351,118093511,1,I,20060116,20061207,20151207,20151207,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13604434,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151207,,CN,BW,BW,EFAVIRENZ,Caesarean section;Pregnancy;Stillbirth,118093511,OT,,,118093511,1,20041007,20050610,,,118093511,1,Product used for unknown indication
11809380,118093801,1,I,,20131202,20151207,20151207,EXP,,ET-BRISTOL-MYERS SQUIBB COMPANY-19912997,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151207,,OT,ET,ET,EFAVIRENZ,Induced labour;Maternal exposure during pregnancy;Stillbirth,118093801,OT,,,,,,,,,118093801,1,HIV infection
11809388,118093881,1,I,200212,20030227,20151208,20151208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-12198859,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,,,20151207,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Pregnancy;Uterine dilation and evacuation,118093881,OT,,,118093881,1,20020627,20030131,,,118093881,1,HIV infection
11809402,118094021,1,I,,20151130,20151208,20151208,EXP,,US-BMSGILMSD-2015-0185910,GILEAD,,50,YR,A,M,Y,,,20151207,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Viral infection,118094021,HO,,,,,,,,,118094021,1,HIV infection
11809462,118094621,1,I,200011,20030401,20151208,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12228862,BRISTOL MYERS SQUIBB,,1,YR,,M,Y,3.95,KG,20151208,,MD,FR,FR,EFAVIRENZ,Abnormal behaviour;Anaemia;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased;Brain stem auditory evoked response abnormal;Cerebral disorder;Disturbance in attention;Ear disorder;Eczema;Fat necrosis;Foetal exposure during pregnancy;Gamma-glutamyltransferase increased;Hypertonia;Learning disorder;Metabolic disorder;Molluscum contagiosum;Nasopharyngitis;Psychomotor retardation;Rhinitis;Sleep disorder,118094621,HO,,,118094621,2,20001113,20001113,,,118094621,1,Product used for unknown indication
11809885,118098851,1,I,20041129,20050325,20151208,20151208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-12911863,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151208,,OT,GB,GB,EFAVIRENZ,Amniotic cavity infection;Placental insufficiency;Pregnancy;Stillbirth,118098851,OT,,,,,,,,,118098851,1,HIV infection
11809886,118098861,1,I,20040702,20040707,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12633871,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20151208,,OT,US,US,EFAVIRENZ,Pregnancy;Premature separation of placenta;Stillbirth,118098861,OT,,,118098861,1,20030508,20031204,,,118098861,1,HIV infection
11809887,118098871,1,I,20041221,20050224,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12875852,BRISTOL MYERS SQUIBB,,17,YR,,F,Y,,,20151208,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy;Premature delivery,118098871,OT,,,118098871,1,20010126,20040610,,,118098871,1,HIV infection
11809888,118098881,1,I,20050623,20061207,20151208,20151208,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13606074,BRISTOL MYERS SQUIBB,,25,YR,,F,Y,,,20151208,,OT,BW,BW,EFAVIRENZ,Pregnancy;Stillbirth,118098881,OT,,,118098881,1,20041011,20050106,,,118098881,1,HIV infection
11809890,118098901,1,I,2002,20030424,20151208,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12254025,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151208,,CN,US,US,EFAVIRENZ,Abortion induced;Ectopic pregnancy;Thrombocytopenia;Vaginal haemorrhage,118098901,OT,,,118098901,1,20010912,20020722,,,118098901,1,HIV infection
11809891,118098911,1,I,20100705,20101029,20151208,20151208,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-15371990,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151208,,CN,US,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,118098911,OT,,,118098911,1,20100610,,,,118098911,1,Antiretroviral therapy
11809892,118098921,1,I,,20010828,20151208,20151208,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0555,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151208,,OT,DE,DE,SUSTIVA,Caesarean section;Live birth;Pregnancy;Premature rupture of membranes,118098921,OT,,,118098921,2,19980501,,,,118098921,1,HIV infection
11809926,118099261,1,I,200502,20050228,20151208,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12882957,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,57,KG,20151208,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Metrorrhagia;Pregnancy on oral contraceptive,118099261,OT,,,118099261,1,20041018,20050225,,,118099261,1,HIV infection
11811823,118118231,1,I,20090609,20090609,20151208,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14667505,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151208,,CN,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,118118231,OT,,,118118231,1,20081101,,,,118118231,1,HIV infection
11812658,118126581,1,I,,20031031,20151208,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12428397,BRISTOL MYERS SQUIBB,,,,N,,Y,2.59,KG,20151208,,OT,FR,FR,SUSTIVA,Dysmorphism;Foetal exposure during pregnancy;Haemangioma;Premature baby,118126581,OT,,,,,,,,,118126581,1,Product used for unknown indication
11812661,118126611,1,I,20060116,20061207,20151208,20151208,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2006-000016,BRISTOL MYERS SQUIBB,,,,,M,Y,2.27,KG,20151208,,CN,BW,BW,EFAVIRENZ,Breech presentation;Foetal exposure during pregnancy,118126611,OT,,,118126611,1,20041007,20050610,,,118126611,1,Product used for unknown indication
11812699,118126991,1,I,,20121121,20151208,20151208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-17196734,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151208,,OT,GB,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,118126991,OT,,,,,,,,,118126991,1,HIV infection
11812779,118127791,1,I,20020814,20020926,20151209,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12053450,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.8,KG,20151209,,OT,FR,FR,SUSTIVA,Anaemia macrocytic;Cardiac murmur;Foetal exposure during pregnancy;Hyperlactacidaemia;Hypoglycaemia;Hypotonia;Platelet count increased;Tachycardia,118127791,HO,,,118127791,4,20020814,20020814,,,118127791,1,Product used for unknown indication
11812801,118128011,1,I,,20030506,20151209,20151209,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-12268199,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,,,20151209,,OT,US,BE,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,118128011,OT,,,118128011,1,20020514,20030414,,,118128011,1,HIV infection
11812823,118128231,1,I,,20120202,20151209,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16383440,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151209,,OT,US,US,SUSTIVA,Cleft lip and palate;Foetal exposure during pregnancy,118128231,CA,,,,,,,,,118128231,1,Product used for unknown indication
11812831,118128311,1,I,20021029,20030108,20151209,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12154142,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.33,KG,20151209,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hypoglycaemia neonatal;Hypotonia neonatal;Small for dates baby,118128311,HO,,,118128311,1,,20020407,,,118128311,1,Product used for unknown indication
11812832,118128321,1,I,20120315,20120323,20151209,20151209,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-16487563,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151209,,CN,US,BW,EFAVIRENZ,Abortion spontaneous;Genital infection;Maternal exposure during pregnancy,118128321,OT,,,118128321,1,20110607,20120124,,,118128321,1,Antiretroviral therapy
11813087,118130871,1,I,,20081001,20151209,20151209,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14356554,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151209,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,118130871,1,20060717,,,,118130871,1,HIV infection
11813216,118132161,1,I,,20081112,20151209,20151209,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14405096,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,118132161,1,Antiretroviral therapy
11813260,118132601,1,I,,20151125,20151209,20151209,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2012-000028,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151209,,CN,US,AR,EFAVIRENZ,Foetal exposure during pregnancy;Foetal heart rate abnormal,118132601,OT,,,118132601,2,20110501,,,,118132601,1,Product used for unknown indication
11813277,118132771,1,I,20091001,20111004,20151209,20151209,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-16135378,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151209,,CN,AR,AR,EFAVIRENZ,Abortion spontaneous;Hepatotoxicity;Maternal exposure during pregnancy,118132771,OT,,,118132771,1,20090904,20090904,,,118132771,1,Antiretroviral therapy
11813285,118132851,1,I,,20070426,20151209,20151209,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000016,BRISTOL MYERS SQUIBB,"STARGARD, M., KEGG, S., BRITISH HIV ASSOCIATION, HIV MEDICINE (8) PAGE 32",,,,,Y,,,20151209,,OT,GB,GB,EFAVIRENZ,Congenital anomaly;Foetal exposure during pregnancy,118132851,OT,,,,,,,,,118132851,1,Product used for unknown indication
11813286,118132861,1,I,20010811,20021204,20151209,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12130142,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.66,KG,20151209,,CN,FR,FR,SUSTIVA,Apnoea;Foetal exposure during pregnancy,118132861,OT,,,118132861,1,20010726,20010811,,,118132861,1,HIV infection
11813295,118132951,1,I,20010326,20020215,20151209,20151209,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-11737376,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151209,,OT,US,CH,EFAVIRENZ,Abortion induced;Pregnancy,118132951,OT,,,,,,,,,118132951,1,HIV infection
11814242,118142421,1,I,20140806,20140811,20151209,20151209,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21301353,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,56,KG,20151209,,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,118142421,HO,,,118142421,1,20140328,20140925,,,118142421,1,Kaposi's sarcoma AIDS related
11814644,118146441,1,I,,20031204,20151209,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12454609,BRISTOL MYERS SQUIBB,,4,DY,,,Y,,,20151209,,CN,FR,SN,EFAVIRENZ,Foetal exposure during pregnancy;Foetal growth restriction;Haemorrhage,118146441,OT,,,,,,,,,118146441,1,Product used for unknown indication
11815373,118153731,1,I,20021025,20030109,20151209,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12155131,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,1.37,KG,20151209,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Patent ductus arteriosus;Premature baby,118153731,OT,,,,,,,,,118153731,1,Product used for unknown indication
11815749,118157491,1,I,20021025,20030109,20151209,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12155560,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151209,,OT,US,US,EFAVIRENZ,Live birth;Premature delivery;Twin pregnancy,118157491,OT,,,118157491,1,20020318,20020523,,,118157491,1,HIV infection
11816197,118161971,1,I,20021203,20021206,20151209,20151209,EXP,,US-009507513-0212USA01214,MERCK,,1,DY,,M,Y,2.3,KG,20151209,,CN,US,US,SUSTIVA,Congenital skin dimples;Foetal alcohol syndrome;Foetal exposure during pregnancy;Small for dates baby,118161971,CA,,,,,,,,,,,
11816446,118164461,1,I,,20030623,20151209,20151209,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-12309464,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151209,,OT,US,DE,EFAVIRENZ,Foetal exposure during pregnancy;Limb hypoplasia congenital,118164461,CA,,,,,,,,,118164461,1,Antiretroviral therapy
11822775,118227751,1,I,,20151202,20151210,20151210,EXP,,JP-GILEAD-2015-0187524,GILEAD,UNK. UNK. THE JOURNAL OF AIDS RESEARCH. 2015?17 (4):518,62,YR,A,M,Y,,,20151210,,PH,JP,JP,EFAVIRENZ,Lipodystrophy acquired;Non-alcoholic steatohepatitis,118227751,OT,,,,,,,,,118227751,1,HIV infection
11824127,118241271,1,I,200202,20020506,20151210,20151210,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11849452,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,2.53,KG,20151210,,OT,US,FR,SUSTIVA,Blood lactate dehydrogenase increased;Foetal exposure during pregnancy;Hyperlipasaemia;Hypocalcaemia;Lactic acidosis;Metabolic acidosis;Muscle twitching;Tonic clonic movements,118241271,HO,,,,,,,,,118241271,1,Product used for unknown indication
11824339,118243391,1,I,,20151130,20151210,20151210,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-083936,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20151210,,CN,IT,IT,EFAVIRENZ,Hypertrophic cardiomyopathy,118243391,OT,,,,,,,,,118243391,1,HIV infection
11824685,118246851,1,I,,20130722,20151210,20151210,EXP,,US-GILEAD-2015-0187248,GILEAD,,67,YR,E,M,Y,,,20151210,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,118246851,OT,,,,,,,,,118246851,1,HIV infection
11824871,118248711,1,I,2005,20050621,20151210,20151210,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13013008,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151210,,MD,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy;Retained products of conception;Uterine dilation and curettage,118248711,OT,,,118248711,1,2004,20050310,,,118248711,1,HIV infection
11824875,118248751,1,I,19981101,20010108,20151210,20151210,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10670578,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,2.63,KG,20151210,,OT,FR,FR,SUSTIVA,Blood creatine phosphokinase increased;Blood lactic acid increased;Foetal exposure during pregnancy;Hyperkalaemia;Hypertriglyceridaemia,118248751,HO,,,118248751,1,19981006,19990105,,,118248751,1,Product used for unknown indication
11824885,118248851,1,I,2006,20070206,20151210,20151210,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14293914,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151210,,OT,DE,DE,EFAVIRENZ,Caesarean section;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes,118248851,OT,,,118248851,1,20050101,20060925,,,118248851,1,HIV infection
11825102,118251021,1,I,19980819,19981016,20151211,20151211,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-1998SUS0283,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151211,,OT,AU,AU,EFAVIRENZ,Abortion induced;Pregnancy,118251021,OT,,,118251021,1,19980622,,,,118251021,1,HIV infection
11825103,118251031,1,I,19990224,19990318,20151211,20151211,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0275,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,46,KG,20151211,,OT,GB,GB,EFAVIRENZ,Abortion induced;Unintended pregnancy,118251031,OT,,,,,,,,,118251031,1,HIV infection
11825370,118253701,1,I,20001109,20001207,20151211,20151211,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-10636975,BRISTOL MYERS SQUIBB,,21,YR,,F,Y,,,20151211,,OT,AR,AR,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,118253701,OT,,,118253701,1,20000224,20001006,,,118253701,1,HIV infection
11825928,118259281,1,I,,20151127,20151211,20151211,EXP,,RS-SUN PHARMACEUTICAL INDUSTRIES LTD-2015R1-107725,RANBAXY,"A D, B S, D S, J R, DJ J. ISONIAZID-RESISTANT MYCOBACTERIUM KANSASII IN AN HIV-POSITIVE PATIENT, AND POSSIBLE DEVELOPMENT OF IRIS AFTER INITIATION OF HAART: CASE REPORT. INT J INFECT DIS. 2015?NOV 18",28,YR,,M,Y,,,20151211,,OT,RS,RS,Efavirenz,Condition aggravated;Drug resistance;Immune reconstitution inflammatory syndrome;Mycobacterium kansasii infection,118259281,HO,,,,,,,,,118259281,1,Tuberculosis
11827757,118277571,1,I,20141228,20150212,20151211,20151211,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-010429,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,,,20151211,,OT,UG,UG,EFAVIRENZ,Death,118277571,DE,,,118277571,1,20141128,20141212,,,118277571,1,HIV infection
11828758,118287581,1,I,2002,20020605,20151211,20151211,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-11899614,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151211,,OT,US,ZA,EFAVIRENZ,Brain malformation;Cardiac failure;Cardiac septal defect;Coarctation of the aorta;Foetal distress syndrome;Foetal exposure during pregnancy;Heterotaxia;Transposition of the great vessels,118287581,OT,,,118287581,1,19991123,20011218,,,118287581,1,Product used for unknown indication
11828984,118289841,1,I,20151126,20151207,20151211,20151211,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-085816,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151211,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Bacterial sepsis;Renal failure,118289841,DE,,,118289841,1,20150205,20150317,,,118289841,1,Antiretroviral therapy
11828987,118289871,1,I,20010401,20010627,20151211,20151211,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0573,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151211,,PH,GB,GB,SUSTIVA,Abortion induced;Foetal death;Pregnancy,118289871,OT,,,118289871,1,20010101,20010626,,,118289871,1,HIV infection
11829029,118290291,1,I,,20090206,20151211,20151211,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14499560,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151211,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,118290291,1,Antiretroviral therapy
11829226,118292261,1,I,20150217,20150218,20151211,20151211,EXP,,UG-GILEAD-2015-0175831,GILEAD,,32,YR,A,F,Y,55,KG,20151211,,MD,UG,UG,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Placenta praevia haemorrhage,118292261,HO,,,118292261,1,20140611,20150830,,,118292261,1,HIV infection
11830073,118300731,1,I,,20060926,20151213,20151213,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-13522941,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151213,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,,,,,,,118300731,1,HIV infection
11830078,118300781,1,I,2001,20020522,20151213,20151213,EXP,,SN-BRISTOL-MYERS SQUIBB COMPANY-11885282,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,2.01,KG,20151213,,OT,US,SN,EFAVIRENZ,Death;Foetal exposure during pregnancy;Foetal growth restriction;Haemorrhage;Small for dates baby,118300781,OT,,,118300781,1,20000118,20010507,,,118300781,1,Product used for unknown indication
11830700,118307001,1,I,20080916,20080917,20151214,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14354096,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151214,,OT,US,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Pneumonia bacterial,118307001,OT,,,118307001,2,,20080206,,,118307001,1,Antiretroviral therapy
11830764,118307641,1,I,20060218,20070202,20151214,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13675079,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,,,20151214,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy;Premature delivery,118307641,OT,,,118307641,1,20060217,20050727,,,118307641,1,HIV infection
11830876,118308762,2,F,20000501,20151216,20151214,20151216,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0597,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151216,,MD,AT,AT,SUSTIVA,Abortion induced;Pregnancy,118308762,OT,,,118308762,1,19990908,20000509,,,118308762,1,HIV infection
11832932,118329321,1,I,20151021,20151204,20151214,20151214,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-085994,BRISTOL MYERS SQUIBB,,56,YR,,M,Y,65,KG,20151214,,CN,FR,FR,SUSTIVA,Lipodystrophy acquired,118329321,OT,,,118329321,1,20061109,20151021,,,118329321,1,Product used for unknown indication
11833039,118330392,2,F,2009,20151210,20151214,20151214,EXP,,"UG-ROXANE LABORATORIES, INC.-2015-RO-02075RO",ROXANE,"MUSUBIRE A,MEYA D,LUKANDE R,KAMBUGU A,ET AL. GASTROINTESTINAL CRYPTOCOCCOMA - IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME OR CRYPTOCOCCAL RELAPSE IN A PATIENT WITH AIDS?. MEDICAL MYCOLOGY CASE REPORTS 2015 JUN?8:40-43.",37,YR,,M,Y,,,20151214,,OT,COUNTRY NOT SPECIFIED,UG,EFAVIRENZ,Cryptococcosis;Intestinal perforation,118330392,HO,,,118330392,1,20090611,,,,118330392,1,HIV test positive
11833040,118330401,1,I,19991209,19990610,20151214,20151214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0578,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151214,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,,,,,,,118330401,1,HIV infection
11835079,118350791,1,I,20001215,20001213,20151215,20151215,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0964,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151215,,CN,CH,CH,SUSTIVA,Abortion induced;Pregnancy,118350791,OT,,,118350791,1,19980101,,,,118350791,1,HIV infection
11835685,118356851,1,I,,20000629,20151215,20151215,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0534,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151215,,CN,US,US,SUSTIVA,Pregnancy,,,,,,,,,,,118356851,1,HIV infection
11836076,118360761,1,I,,20151207,20151215,20151215,EXP,,US-VIIV HEALTHCARE LIMITED-US2015GSK176876,VIIV,,47,YR,,M,Y,,,20151215,,CN,US,US,SUSTIVA,Seizure,118360761,OT,,,,,,,,,118360761,1,HIV infection
11837969,118379691,1,I,,20151207,20151215,20151215,EXP,,US-GLAXOSMITHKLINE-US2015GSK176876,GLAXOSMITHKLINE,,47,YR,,M,Y,,,20151215,,CN,US,US,SUSTIVA,Seizure,118379691,OT,,,,,,,,,118379691,1,HIV infection
11838750,118387501,1,I,20150925,20151207,20151215,20151215,EXP,,US-GILEAD-2015-0187288,GILEAD,,35,YR,A,F,Y,93.88,KG,20151215,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Exposure via body fluid;Maternal exposure during pregnancy,118387501,OT,,,,,,,,,118387501,1,Product used for unknown indication
11838887,118388871,1,I,,20100723,20151215,20151215,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-15212301,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151215,,OT,AR,AR,SUSTIVA,Foetal exposure during pregnancy;Pulmonary artery stenosis congenital,118388871,CA,,,118388871,1,20051012,20060323,,,118388871,1,Product used for unknown indication
11838907,118389071,1,I,19990908,20000626,20151216,20151216,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10652667,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,3.2,KG,20151216,,CN,GB,FR,SUSTIVA,Abdominal distension;Abdominal pain;Anaemia;Blood creatine phosphokinase increased;Flatulence;Foetal exposure during pregnancy;Hepatomegaly;Hypercholesterolaemia;Hyperlactacidaemia;Hypertriglyceridaemia;Hypotonia;Malaise;Mucous stools;Neutropenia;Obesity;Oxygen saturation decreased;Platelet count increased;Ventricular tachycardia,118389071,OT,,,,,,,,,118389071,1,Product used for unknown indication
11840219,118402191,1,I,20020808,20020730,20151216,20151216,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11971330,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151216,,OT,FR,FR,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118402191,OT,,,118402191,1,20010108,20020726,,,118402191,1,HIV infection
11841004,118410043,3,F,20150104,20151228,20151216,20151231,EXP,,UG-GILEAD-2015-0132067,GILEAD,,36,YR,A,M,Y,56,KG,20151231,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypotension;Pneumonia;Pyrexia,118410043,HO,,,118410043,1,20140319,20150103,,,118410043,1,Kaposi's sarcoma AIDS related
11841288,118412881,1,I,20151204,20151206,20151216,20151216,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-085990,BRISTOL MYERS SQUIBB,,67,YR,,M,Y,170,KG,20151216,,PH,US,US,SUSTIVA,Gastrostomy;Pneumonia,118412881,HO,,,,,,,,,118412881,1,HIV infection
11841621,118416211,1,I,19991203,19990713,20151216,20151216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0794,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,73,KG,20151216,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,118416211,1,19990309,19990413,,,118416211,1,HIV infection
11843123,118431231,1,I,,20100723,20151216,20151216,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-15212673,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151216,,OT,BR,BR,EFAVIRENZ,Congenital hydronephrosis;Foetal exposure during pregnancy;Vesicoureteric reflux,118431231,OT,,,118431231,1,20041219,20040701,,,118431231,1,Product used for unknown indication
11843180,118431801,1,I,2001,20020712,20151216,20151216,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-11956372,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,,,20151216,,OT,BR,BR,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118431801,OT,,,118431801,1,20010412,,,,118431801,1,HIV infection
11843221,118432211,1,I,,20000317,20151216,20151216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0309,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151216,,MD,US,US,SUSTIVA,Pregnancy,,,,,118432211,1,19990201,,,,118432211,1,HIV infection
11843222,118432221,1,I,19991204,20001205,20151216,20151216,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10631778,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151216,,MD,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118432221,OT,,,118432221,1,19990806,19991007,,,118432221,1,HIV infection
11843675,118436751,1,I,200301,20030206,20151217,20151217,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2003-000008,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151217,,CN,ES,ES,SUSTIVA,Cystic lymphangioma;Foetal exposure during pregnancy;Pterygium colli,118436751,OT,,,118436751,1,,20021211,,,118436751,1,Product used for unknown indication
11844251,118442511,1,I,,20070927,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13923537,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.92,KG,20151217,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby,118442511,OT,,,118442511,1,,20070301,,,118442511,1,Product used for unknown indication
11844507,118445071,1,I,19990501,20010402,20151217,20151217,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0300,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151217,,OT,US,US,SUSTIVA,Pregnancy,,,,,118445071,1,19990201,19990801,,,118445071,1,HIV infection
11844732,118447321,1,I,200112,20020118,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12160255,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151217,,OT,US,US,EFAVIRENZ,Live birth;Pre-eclampsia;Pregnancy,118447321,OT,,,118447321,1,20020105,20020124,,,118447321,1,HIV infection
11844875,118448751,1,I,20000101,20010402,20151217,20151217,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0304,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151217,,OT,US,US,SUSTIVA,Caesarean section;Normal newborn;Pregnancy,,,,,118448751,1,20000630,20000801,,,118448751,1,HIV infection
11845497,118454971,1,I,199909,20020318,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11776523,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151217,,MD,US,US,EFAVIRENZ,Activated partial thromboplastin time prolonged;Blood bilirubin increased;Jaundice;Live birth;Nausea;Pregnancy;Premature labour;Prothrombin time prolonged;Transaminases increased;Vomiting,118454971,HO,,,118454971,1,199908,200001,,,118454971,1,HIV infection
11845498,118454981,1,I,2007,20080423,20151217,20151217,EXP,,EC-BRISTOL-MYERS SQUIBB COMPANY-14163802,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217,,CN,EC,EC,EFAVIRENZ,Caesarean section;Dysplasia;Normal newborn;Pregnancy on contraceptive,118454981,OT,,,118454981,1,200309,20070629,,,118454981,1,Antiretroviral therapy
11848255,118482551,1,I,2000,20030225,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12194932,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151217,,OT,US,US,SUSTIVA,Abortion induced;Anaemia;Pregnancy,118482551,OT,,,118482551,1,200006,20001020,,,118482551,1,HIV infection
11848277,118482771,1,I,20000301,20000807,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0616,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151217,,MD,US,US,SUSTIVA,Abortion induced;Pregnancy,118482771,OT,,,118482771,1,199911,20000329,,,118482771,1,HIV infection
11848286,118482861,1,I,20071212,20080604,20151217,20151217,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14223465,BRISTOL MYERS SQUIBB,,40,YR,,F,Y,,,20151217,,CN,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Premature labour;Respiratory distress;Stillbirth,118482861,HO,,,118482861,1,20071212,,,,118482861,1,HIV infection
11848343,118483431,1,I,19990415,19990416,20151217,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0391,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,65,KG,20151217,,MD,US,US,SUSTIVA,Abortion spontaneous;Pregnancy,118483431,OT,,,118483431,1,19990414,19990416,,,118483431,1,HIV infection
11848730,118487301,1,I,20001006,20001010,20151218,20151218,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0855,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,3.45,KG,20151218,,MD,IT,IT,SUSTIVA,Foetal exposure during pregnancy;Meningomyelocele,118487301,CA,,,118487301,1,20000112,20000217,,,118487301,1,Product used for unknown indication
11848781,118487811,1,I,,20070223,20151218,20151218,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000013,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151218,,CN,DE,DE,SUSTIVA,Foetal exposure during pregnancy;Talipes,118487811,OT,,,,,,,,,118487811,1,Product used for unknown indication
11848810,118488101,1,I,19990712,19990809,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-1999SUS0973,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,63,KG,20151218,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Ectopic pregnancy;Pregnancy,118488101,OT,,,118488101,1,19990428,19990804,,,118488101,1,HIV infection
11849030,118490301,1,I,20021202,20021202,20151218,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12124038,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,,,20151218,,OT,ZA,ZA,EFAVIRENZ,Abortion induced;Pregnancy,118490301,OT,,,118490301,1,20020228,20021112,,,118490301,1,HIV infection
11849620,118496201,1,I,,20010301,20151218,20151218,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0162,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218,,CN,US,US,SUSTIVA,Pregnancy,,,,,118496201,1,200007,,,,118496201,1,HIV infection
11851736,118517361,1,I,2005,20061206,20151218,20151218,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13644026,BRISTOL MYERS SQUIBB,,21,YR,,F,Y,,,20151218,,OT,BW,BW,EFAVIRENZ,Abortion spontaneous;Pregnancy,118517361,OT,,,118517361,1,20040526,20050210,,,118517361,1,HIV infection
11851941,118519411,1,I,19990902,20001003,20151218,20151218,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0763,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20151218,,OT,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,118519411,1,19990528,19990528,,,118519411,1,HIV infection
11852213,118522131,1,I,20080407,20090831,20151218,20151218,EXP,,SE-009507513-0909SWE00004,MERCK,,33,YR,,F,Y,,,20151218,,CN,SE,SE,EFAVIRENZ,Drug interaction;Pregnancy on contraceptive,118522131,OT,,,118522131,2,20060124,20080422,,,118522131,1,Antiviral treatment
11852734,118527341,1,I,200009,20001214,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10647170,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,2.2,KG,20151218,,CN,US,FR,SUSTIVA,Bronchitis;Developmental delay;Eczema;Foetal exposure during pregnancy;Gastrooesophageal reflux disease;Growth retardation;Hypertriglyceridaemia;Low birth weight baby;Lymphopenia;Neutropenia;Platelet count increased;Sleep disorder;Strabismus;Vascular malformation,118527341,CA,,,,,,,,,118527341,1,Product used for unknown indication
11853156,118531561,1,I,20030127,20030129,20151218,20151218,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-12177291,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,,,20151218,,CN,US,BR,EFAVIRENZ,Abortion incomplete;Pregnancy;Uterine dilation and curettage,118531561,OT,,,118531561,1,20010412,20030106,,,118531561,1,HIV infection
11853159,118531591,1,I,2004,20041019,20151218,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12736013,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151218,,OT,ZA,ZA,EFAVIRENZ,Ectopic pregnancy;Pregnancy on contraceptive;Salpingectomy,118531591,OT,,,118531591,1,20020911,20041001,,,118531591,1,HIV infection
11853166,118531661,1,I,201107,20120329,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16497539,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,2.27,KG,20151218,,CN,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Limb malformation;Premature baby,118531661,OT,,,118531661,1,20110321,20110321,,,118531661,1,Product used for unknown indication
11853167,118531671,1,I,20120228,20120430,20151218,20151218,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16567547,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151218,,CN,US,MW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,118531671,OT,,,118531671,1,20110902,20120122,,,118531671,1,HIV infection
11853192,118531921,1,I,20110728,20120329,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16491946,BRISTOL MYERS SQUIBB,,18,YR,,F,Y,,,20151218,,CN,US,US,EFAVIRENZ,Live birth;Maternal exposure during pregnancy;Polyhydramnios;Premature delivery,118531921,OT,,,118531921,1,20081001,20110321,,,118531921,1,Antiretroviral therapy
11853400,118534001,1,I,19990920,20000301,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0218,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.36,KG,20151218,,CN,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Laryngomalacia;Low birth weight baby;Maternal drugs affecting foetus,118534001,CA,,,,,,,,,118534001,1,Product used for unknown indication
11853427,118534271,1,I,20010322,20010523,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10850311,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,3.24,KG,20151218,,OT,US,US,EFAVIRENZ,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118534271,OT,,,118534271,1,,20000810,,,118534271,1,Product used for unknown indication
11853428,118534281,1,I,20020730,20020315,20151218,20151218,EXP,,NZ-BRISTOL-MYERS SQUIBB COMPANY-11788080,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151218,,CN,US,NZ,EFAVIRENZ,Gestational hypertension;Pregnancy;Premature delivery,118534281,OT,,,118534281,1,20020124,20020314,,,118534281,1,Antiretroviral therapy
11853446,118534461,1,I,20011216,20020121,20151218,20151218,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-11676939,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,76.8,KG,20151218,,OT,US,BE,EFAVIRENZ,Abortion induced;Pregnancy on contraceptive,118534461,OT,,,118534461,1,20010621,,,,118534461,1,HIV infection
11853466,118534662,2,F,,20111004,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-16156010,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,118534662,OT,,,,,,,,,118534662,1,HIV infection
11853478,118534782,2,F,20141104,20150202,20151218,20151218,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-005274,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,49,KG,20151218,,CN,MW,MW,EFAVIRENZ,Abortion incomplete;Maternal exposure during pregnancy;Uterine dilation and curettage,118534782,HO,,,118534782,1,20110801,,,,118534782,1,HIV infection
11853497,118534971,1,I,20000822,20000928,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0733,BRISTOL MYERS SQUIBB,,,,,M,Y,1.72,KG,20151218,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Jaundice;Premature baby;Respiratory distress,118534971,OT,,,118534971,1,20010314,20000914,,,118534971,1,Product used for unknown indication
11853499,118534991,1,I,19991025,20000626,20151218,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0519,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,90,KG,20151218,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Pregnancy,118534991,OT,,,118534991,1,19990818,200004,,,118534991,1,HIV infection
11853500,118535001,1,I,19981117,20000524,20151218,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0434,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,61,KG,20151218,,MD,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118535001,OT,,,118535001,1,19980724,19980916,,,118535001,1,HIV infection
11853562,118535621,1,I,19991027,20000317,20151219,20151219,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0310,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151219,,MD,US,US,SUSTIVA,No adverse event;Normal newborn;Pregnancy,,,,,118535621,1,19980914,199903,,,118535621,1,HIV infection
11853583,118535831,1,I,20000201,20010402,20151219,20151219,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0310,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,,,20151219,,OT,US,US,SUSTIVA,No adverse event;Normal newborn;Pregnancy,,,,,118535831,1,20000309,20000601,,,118535831,1,HIV infection
11853584,118535841,1,I,20010621,20010604,20151219,20151219,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10864775,BRISTOL MYERS SQUIBB,,22,YR,,F,Y,,,20151219,,OT,US,US,SUSTIVA,Abortion induced;Pregnancy on contraceptive,118535841,OT,,,118535841,1,20001116,20010516,,,118535841,1,HIV infection
11853586,118535861,1,I,20010612,20010821,20151219,20151219,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10960482,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151219,,OT,US,US,EFAVIRENZ,Cardiac disorder;Foetal exposure during pregnancy,118535861,OT,,,,,,,,,118535861,1,Product used for unknown indication
11853736,118537361,1,I,20080521,20080605,20151219,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14217178,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151219,,CN,US,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Vanishing twin syndrome,118537361,OT,,,,,,,,,118537361,1,HIV infection
11853741,118537411,1,I,,20080513,20151219,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14200083,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151219,,CN,ZA,ZA,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,118537411,OT,,,,,,,,,118537411,1,HIV infection
11853783,118537831,1,I,,20151205,20151219,20151219,EXP,,ES-HETERO LABS LTD-1045685,HETERO,,1,WK,,,Y,,,20151219,,MD,ES,ES,Efavirenz,Foetal exposure during pregnancy;Polydactyly,118537831,CA,,,,,,,,,118537831,1,Maternal exposure timing unspecified
11853906,118539061,1,I,20010601,20011109,20151219,20151219,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-11539285,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.03,KG,20151219,,MD,DE,DE,EFAVIRENZ,Anaemia;Foetal exposure during pregnancy;Premature baby,118539061,OT,,,118539061,1,20001121,20001120,,,118539061,1,Product used for unknown indication
11853926,118539261,1,I,20010323,20010417,20151219,20151219,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10804029,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,3.32,KG,20151219,,MD,US,US,SUSTIVA,Cardiac murmur;Foetal exposure during pregnancy;Pulmonary arterial pressure increased,118539261,OT,,,118539261,1,20010301,20010323,,,118539261,1,Product used for unknown indication
11853946,118539461,1,I,19991110,20010416,20151219,20151219,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10813491,BRISTOL MYERS SQUIBB,,0,DY,,,Y,.73,KG,20151219,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Foetal heart rate decreased;Premature baby,118539461,HO,,,118539461,1,19970915,19990503,,,118539461,1,Product used for unknown indication
11854127,118541271,1,I,200010,20010216,20151220,20151220,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10721025,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,59,KG,20151220,,CN,FR,FR,SUSTIVA,Abdominal pain;Abscess;Caesarean section;Hepatic steatosis;Infection;Influenza like illness;Lactic acidosis;Pancreatitis acute;Pregnancy;Premature delivery;Uterine contractions abnormal,118541271,HO,,,118541271,1,200005,200102,,,118541271,1,HIV test positive
11854400,118544001,1,I,,20151210,20151221,20151221,EXP,,UG-CIPLA LTD.-2015UG09491,CIPLA,"CASTELNUOVO B., KIRAGGA A., MUSAAZI J., SEMPA J., MUBIRU F., WANYAMA J., WANDERA B., ET AL.. OUTCOMES IN A COHORT OF PATIENTS STARTED ON ANTIRETROVIRAL TREATMENT AND FOLLOWED UP FOR A DECADE IN AN URBAN CLINIC IN UGANDA. PLOS ONE. 2015?1 TO 11",,,,,Y,,,20151221,,OT,UG,UG,Efavirenz,Accidental death,118544001,DE,,,,,,,,,118544001,1,HIV test positive
11854637,118546371,1,I,20000101,20010219,20151221,20151221,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0137,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,,,20151221,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Pericarditis,118546371,OT,,,118546371,1,20000511,,,,118546371,1,Product used for unknown indication
11854899,118548991,1,I,20120408,20130810,20151221,20151221,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-19223064,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,1.72,KG,20151221,,CN,US,NG,EFAVIRENZ,Congenital hepatomegaly;Dysmorphism;Finger deformity;Foetal exposure during pregnancy;Premature baby;Respiratory distress;Splenomegaly;Talipes;Trisomy 21,118548991,CA,,,118548991,1,20081205,20111207,,,118548991,1,Product used for unknown indication
11854912,118549121,1,I,20110428,20110907,20151221,20151221,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-16041576,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,3.42,KG,20151221,,CN,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly,118549121,CA,,,118549121,2,201007,,,,118549121,1,Product used for unknown indication
11855538,118555381,1,I,20080207,20080507,20151221,20151221,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14183164,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.19,KG,20151221,,CN,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly;Premature baby;Trisomy 21,118555381,CA,,,118555381,1,200710,200710,,,118555381,1,Product used for unknown indication
11855568,118555681,1,I,2015,20151214,20151221,20151221,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK177987,VIIV,,,,,M,Y,,,20151221,,CN,RU,RU,STOCRIN (EFAVIRENZ),Rash;Toxic skin eruption,118555681,HO,,,118555681,1,2015,,,,118555681,1,HIV infection
11855652,118556521,1,I,20151216,,20151218,20151218,DIR,,,,,49,YR,,F,N,,,20151216,N,,US,,SUSTIVA,Decreased appetite;Neuropathy peripheral,118556521,OT,,,,,,,,,,,
11855793,118557931,1,I,2015,20151214,20151221,20151221,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK177987,GLAXOSMITHKLINE,,,,,M,Y,,,20151221,,CN,RU,RU,STOCRIN (EFAVIRENZ),Rash;Toxic skin eruption,118557931,OT,,,118557931,1,2015,,,,118557931,1,HIV infection
11856216,118562161,1,I,2003,20030523,20151221,20151221,EXP,,SG-BRISTOL-MYERS SQUIBB COMPANY-12284030,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.85,KG,20151221,,CN,SG,SG,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,118562161,OT,,,118562161,1,20010226,20030518,,,118562161,1,Product used for unknown indication
11856472,118564721,1,I,2001,20010911,20151221,20151221,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-10983674,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151221,,OT,US,GB,SUSTIVA,Congenital central nervous system anomaly;Foetal exposure during pregnancy;Trisomy 21;Vascular malformation,118564721,CA,,,,,,,,,118564721,1,Product used for unknown indication
11856802,118568021,1,I,20010323,20010417,20151221,20151221,EXP,,US-009507513-01041906,MERCK,,1,DY,,F,Y,3.32,KG,20151221,,CN,US,US,SUSTIVA,Cardiac murmur;Foetal exposure during pregnancy;Pulmonary arterial pressure increased,118568021,OT,,,118568021,1,20000418,20000912,,,118568021,1,Product used for unknown indication
11856980,118569801,1,I,19990115,19990208,20151221,20151221,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-M093171,BRISTOL MYERS SQUIBB,,23,YR,,F,Y,,,20151221,,CN,US,US,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,118569801,OT,,,118569801,1,19981111,19981218,,,118569801,1,HIV infection
11856981,118569811,1,I,20010811,20020129,20151221,20151221,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11699261,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.66,KG,20151221,,CN,FR,FR,SUSTIVA,Apnoea;Cardiac murmur;Foetal exposure during pregnancy,118569811,HO,,,118569811,1,200007,,,,118569811,1,Product used for unknown indication
11857070,118570701,1,I,201204,20151120,20151221,20151221,EXP,,NG-009507513-1512NGA010372,MERCK,,1,DY,,F,Y,,,20151221,,CN,US,NG,EFAVIRENZ,Arachnodactyly;Congenital eye disorder;Foetal exposure during pregnancy;Hepatomegaly;Respiratory distress;Splenomegaly;Talipes;Trisomy 21,118570701,DE,,,118570701,1,20081205,20111207,,,,,
11858331,118583311,1,I,2000,20001124,20151222,20151222,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10619344,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,3.47,KG,20151222,,OT,US,FR,SUSTIVA,Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased;Electroencephalogram abnormal;Foetal exposure during pregnancy;Gastrointestinal disorder;Hypertriglyceridaemia;Livedo reticularis;Microcytosis;Neutropenia;Pyelonephritis,118583311,OT,,,118583311,5,2000,2000,,,118583311,1,Product used for unknown indication
11858628,118586281,1,I,20060218,20060803,20151222,20151222,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13466040,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.62,KG,20151222,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Hospitalisation;Premature baby,118586281,OT,,,118586281,1,20060217,20050727,,,118586281,1,Product used for unknown indication
11858629,118586291,1,I,,20081105,20151222,20151222,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000002,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151222,,CN,GB,FR,SUSTIVA,Foetal exposure during pregnancy;Heart disease congenital,118586291,OT,,,118586291,1,20051201,20071211,,,118586291,1,Product used for unknown indication
11858664,118586641,1,I,20010322,20010507,20151222,20151222,EXP,,US-009507513-01050823,MERCK,,1,DY,,M,Y,3.24,KG,20151222,,CN,US,US,SUSTIVA,Cystic fibrosis;Foetal exposure during pregnancy;Meconium ileus,118586641,CA,,,118586641,1,20001109,20000810,,,118586641,1,Product used for unknown indication
11860634,118606341,1,I,201411,20151215,20151222,20151222,EXP,,US-GILEAD-2015-0188884,GILEAD,,37,YR,A,F,Y,,,20151222,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous,118606341,OT,,,118606341,1,20140625,20141210,,,118606341,1,HIV infection
11861222,118612221,1,I,,20151214,20151222,20151222,EXP,,US-GILEAD-2015-0188659,GILEAD,,57,YR,A,M,Y,,,20151222,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Osteoporosis,118612221,OT,,,,,,,,,118612221,1,HIV infection
11861450,118614501,1,I,,20151215,20151222,20151222,EXP,,US-GILEAD-2015-0188859,GILEAD,"KAHLON A, GNANABAKTHAN N, SYED W, DHILLON A, SHARMA A. DEVLOPMENT OF FANCONI SYNDROME AFTER ADDITION OF LEDIPASVIR/SOFOSBUVIR IN A PATIENT ON TENOFOVIR. CRITICAL CARE MEDICINE. 2015?43 (12 SUPPL 1):318",63,YR,A,M,Y,,,20151222,,OT,US,US,EFAVIRENZ,Drug interaction;Fanconi syndrome acquired,118614501,OT,,,118614501,1,2005,,,,118614501,1,HIV infection
11861994,118619941,1,I,,20151216,20151222,20151222,EXP,,US-BMSGILMSD-2015-0189055,GILEAD,,48,YR,A,M,Y,,,20151222,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Non-Hodgkin's lymphoma,118619941,OT,,,,,,,,,118619941,1,HIV infection
11862024,118620241,1,I,,20151215,20151222,20151222,EXP,,PT-GILEAD-2015-0188780,GILEAD,,39,YR,A,M,Y,,,20151222,,MD,PT,PT,EFAVIRENZ,Alcohol poisoning;Drug ineffective;Hepatitis C,118620241,HO,,,118620241,1,20150604,20150730,,,118620241,1,Hepatitis C
11862089,118620891,1,I,20151209,,20151222,20151222,DIR,,,,,66,YR,,M,N,,,20151221,N,PH,US,,EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Hyperkalaemia;Hypoaldosteronism,118620891,HO,118620891,HP,118620891,1,20100707,20151209,,,118620891,1,HIV infection
11862309,118623091,1,I,20000713,20001101,20151222,20151222,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0849,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151222,,MD,DE,DE,SUSTIVA,Abortion missed;Pregnancy;Uterine dilation and curettage,118623091,OT,,,118623091,1,19980501,20000816,,,118623091,1,HIV infection
11862500,118625001,1,I,20151013,20151217,20151223,20151223,EXP,,ZW-GILEAD-2015-0189327,GILEAD,,39,YR,A,F,Y,,,20151222,,MD,ZW,ZW,EFAVIRENZ,Acute kidney injury;Pyelonephritis,118625001,OT,,,118625001,1,20150407,20151023,,,118625001,1,HIV infection
11862974,118629741,1,I,20010615,20010827,20151223,20151223,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0779,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,,,20151223,,MD,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Foetal heart rate deceleration abnormality,118629741,OT,,,118629741,1,20001013,20001102,,,118629741,1,Product used for unknown indication
11863472,118634721,1,I,,20151215,20151223,20151223,EXP,,GB-CIPLA LTD.-2015GB09526,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151223,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug interaction,118634721,OT,,,,,,,,,118634721,1,HIV infection
11863641,118636411,1,I,19991209,19990610,20151223,20151223,PER,,US-009507513-99061896,MERCK,,28,YR,,F,Y,,,20151223,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,,,,,,,118636411,1,HIV infection
11863799,118637991,1,I,19990226,20001003,20151223,20151223,PER,,US-009507513-00121657,MERCK,,22,YR,,F,Y,,,20151223,,CN,US,US,SUSTIVA,Pregnancy;Premature delivery,,,,,118637991,1,19990528,19990528,,,118637991,1,HIV infection
11863851,118638511,1,I,,19991008,20151223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-1999SUS1187,BRISTOL MYERS SQUIBB,,30,YR,,F,Y,,,20151223,,OT,US,US,SUSTIVA,Gestational diabetes;Pregnancy,118638511,OT,,,118638511,1,19990824,,,,118638511,1,HIV infection
11864883,118648831,1,I,19981218,19990118,20151223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-M092047,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151223,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy;Pyelonephritis,118648831,HO,,,118648831,1,199810,19981217,,,118648831,1,HIV infection
11864989,118649891,1,I,,20000905,20151223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0690,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151223,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Prenatal screening test abnormal;Umbilical malformation,118649891,OT,,,118649891,1,20000530,20000606,,,118649891,1,Product used for unknown indication
11864990,118649901,1,I,200105,20011129,20151223,20151223,EXP,,SE-BRISTOL-MYERS SQUIBB COMPANY-11612629,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151223,,OT,US,SE,EFAVIRENZ,Abortion induced;Foetal death;Pregnancy,118649901,OT,,,118649901,1,200007,20010417,,,118649901,1,HIV infection
11865093,118650931,1,I,20010807,20001219,20151223,20151223,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10664837,BRISTOL MYERS SQUIBB,,,,N,M,Y,3.41,KG,20151223,,CN,US,FR,EFAVIRENZ,Foetal exposure during pregnancy;Neonatal disorder;Polydactyly,118650931,CA,,,118650931,1,20000127,20001218,,,118650931,1,Product used for unknown indication
11865813,118658131,1,I,,20151214,20151223,20151223,EXP,,US-BAXTER-2015BAX069219,BAXTER,"VISHNU P, DORER R, ABOULAFIA D. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME-ASSOCIATED BURKITT LYMPHOMA AFTER COMBINATION ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2015 JAN 01?15 (1):E23-E29.",45,YR,,M,Y,,,20151223,,MD,US,US,EFAVIRENZ,Death,118658131,DE,,,,,,,,,118658131,1,Immune reconstitution inflammatory syndrome
11865821,118658211,1,I,,20151214,20151223,20151223,EXP,,US-BAXTER-2015BAX069220,BAXTER,"VISHNU P, DORER R, ABOULAFIA D. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME-ASSOCIATED BURKITT LYMPHOMA AFTER COMBINATION ANTIRETROVIRAL THERAPY IN HIV-INFECTED PATIENTS. CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA. 2015 JAN 01?15 (1):E23-E29.",45,YR,,M,Y,,,20151223,,MD,US,US,EFAVIRENZ,Disease progression;Refractory cancer,118658211,DE,,,,,,,,,118658211,1,Immune reconstitution inflammatory syndrome
11866308,118663081,1,I,20151116,20151218,20151223,20151223,EXP,,US-GILEAD-2015-0189536,GILEAD,,,,,M,Y,,,20151223,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Myocardial infarction,118663081,HO,,,,,,,,,118663081,1,HIV infection
11866624,118666241,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09523,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Drug resistance;Neurotoxicity,118666241,OT,,,,,,,,,118666241,1,HIV infection
11866634,118666341,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09525,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Gastrointestinal toxicity,118666341,OT,,,,,,,,,118666341,1,HIV infection
11866635,118666351,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09524,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND ET AL. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Intentional overdose;Neurotoxicity;Suicide attempt,118666351,OT,,,,,,,,,118666351,1,HIV infection
11866666,118666661,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09527,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118666661,OT,,,,,,,,,118666661,1,HIV infection
11866703,118667031,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09541,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118667031,OT,,,,,,,,,118667031,1,HIV infection
11866729,118667291,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09544,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity,118667291,OT,,,,,,,,,118667291,1,HIV infection
11866733,118667331,1,I,,20151215,20151224,20151224,EXP,,GB-CIPLA LTD.-2015GB09547,CIPLA,"SCOURFIELD A, ZHENG J, CHINTHAPALLI S, WATERS L, MARTIN T, MANDALIA S AND NELSON M. DISCONTINUATION OF ATRIPLA AS FIRST-LINE THERAPY IN HIV-1 INFECTED INDIVIDUALS. AIDS. 2012?26:1399-1401",,,,,Y,,,20151224,,MD,GB,GB,Tenofovir/Emtricitabine/Efavirenz,Neurotoxicity;Pneumocystis jirovecii pneumonia,118667331,OT,,,,,,,,,118667331,1,HIV infection
11866743,118667431,1,I,,20151215,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09633,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224,,OT,IN,IN,Efavirenz,Virologic failure,118667431,OT,,,,,,,,,118667431,1,HIV infection
11866747,118667471,1,I,,20151215,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09582,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151224,,OT,IN,IN,Efavirenz,Cerebral malaria;Treatment failure,118667471,DE,,,,,,,,,118667471,1,HIV infection
11866759,118667591,1,I,,20151215,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09671,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224,,OT,IN,IN,Efavirenz,Cervix carcinoma;Treatment failure,118667591,DE,,,,,,,,,118667591,1,HIV infection
11866763,118667631,1,I,,20151215,20151224,20151224,EXP,,IN-CIPLA LTD.-2015IN09669,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151224,,OT,IN,IN,Efavirenz,Virologic failure,118667631,OT,,,,,,,,,118667631,1,HIV infection
11866881,118668811,1,I,2007,20100817,20151224,20151224,EXP,,TH-BRISTOL-MYERS SQUIBB COMPANY-15262066,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151224,,OT,TH,TH,EFAVIRENZ,Abortion incomplete;Female sterilisation;Maternal exposure during pregnancy;Uterine dilation and curettage;Uterine haemorrhage,118668811,OT,,,118668811,1,20051013,,,,118668811,1,HIV infection
11867010,118670101,1,I,20050215,20050407,20151224,20151224,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-12966636,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.36,KG,20151224,,MD,GB,GB,EFAVIRENZ,Foetal exposure during pregnancy;Hydronephrosis;Premature baby,118670101,CA,,,118670101,1,20050417,20050417,,,118670101,1,Product used for unknown indication
11867300,118673001,1,I,2012,20151216,20151224,20151224,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2015GSK180022,VIIV,,,,,M,Y,,,20151224,,CN,GB,GB,Efavirenz,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,118673001,OT,,,,,,,,,,,
11867399,118673991,1,I,200003,20001023,20151224,20151224,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10583250,BRISTOL MYERS SQUIBB,,4,YR,,M,Y,3.47,KG,20151224,,OT,US,FR,SUSTIVA,Abnormal behaviour;Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased;Cardiovascular disorder;Depression;Electroencephalogram abnormal;Foetal exposure during pregnancy;Gastrointestinal disorder;Gastrointestinal haemorrhage;Haematochezia;Hepatic enzyme increased;Hypertriglyceridaemia;Lipase increased;Microcytosis;Neutropenia;Pyelonephritis;Segmented hyalinising vasculitis;Speech disorder,118673991,HO,,,118673991,5,199906,,,,118673991,1,Product used for unknown indication
11867488,118674881,1,I,2012,20151216,20151224,20151224,EXP,,GB-GLAXOSMITHKLINE-GB2015GSK180022,GLAXOSMITHKLINE,,,,,M,Y,,,20151224,,CN,GB,GB,Efavirenz,Cerebrovascular accident;Cognitive disorder;Depression;Fatigue;Hypokinesia;Intentional self-injury,118674881,OT,,,,,,,,,,,
11868349,118683491,1,I,19990722,20000510,20151224,20151224,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10380954,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,1.08,KG,20151224,,MD,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby,118683491,OT,,,118683491,1,19990605,19990201,,,118683491,1,Product used for unknown indication
11868354,118683541,1,I,20001221,20011107,20151224,20151224,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-11527520,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151224,,OT,US,FR,EFAVIRENZ,Gestational diabetes;Normal newborn;Pregnancy,118683541,OT,,,118683541,1,19970902,,,,118683541,1,Antiretroviral therapy
11868390,118683901,1,I,20010503,20011115,20151224,20151224,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11544715,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151224,,OT,US,US,EFAVIRENZ,Abortion induced;Pregnancy,118683901,OT,,,118683901,1,20000310,20010312,,,118683901,1,HIV infection
11868474,118684741,1,I,19991110,20010417,20151225,20151225,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10799815,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151225,,OT,US,US,EFAVIRENZ,Caesarean section;Pregnancy;Premature separation of placenta,118684741,HO,,,118684741,1,19970915,19990503,,,118684741,1,HIV infection
11868611,118686111,1,I,,20030124,20151225,20151225,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12167631,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151225,,OT,FR,FR,EFAVIRENZ,Abdominal pain upper;Caesarean section;Cellulitis gangrenous;Hepatic steatosis;Lactic acidosis;Pancreatitis necrotising;Pregnancy;Premature delivery;Uterine hypertonus,118686111,HO,,,,,,,,,118686111,1,HIV infection
11868755,118687551,1,I,20010803,20010827,20151225,20151225,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-10970085,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151225,,OT,US,US,SUSTIVA,Abortion induced;Pregnancy,118687551,OT,,,,,,,,,118687551,1,Antiretroviral therapy
11868899,118688991,1,I,20150610,20151215,20151225,20151225,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090131,BRISTOL MYERS SQUIBB,,23,YR,,M,Y,54,KG,20151225,,CN,CN,CN,EFAVIRENZ,Pruritus;Pyrexia;Rash papular,118688991,HO,,,118688991,1,20150605,20150610,,,118688991,1,HIV infection
11869072,118690721,1,I,20051212,20061126,20151225,20151225,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-13589700,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151225,,CN,BW,BW,EFAVIRENZ,Abortion spontaneous;Pregnancy,118690721,OT,,,118690721,1,20030504,20040715,,,118690721,1,HIV infection
11869539,118695391,1,I,,20151215,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09673,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151228,,OT,IN,IN,Efavirenz,Pneumonia bacterial;Treatment failure,118695391,OT,,,,,,,,,118695391,1,HIV infection
11869540,118695401,1,I,,20151215,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09674,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151228,,OT,IN,IN,Efavirenz,Myocardial infarction,118695401,DE,,,,,,,,,118695401,1,HIV infection
11869655,118696551,1,I,20000229,20000210,20151228,20151228,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-10277309,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,73,KG,20151228,,OT,FR,FR,EFAVIRENZ,Abortion spontaneous;Pregnancy,118696551,OT,,,118696551,1,19991110,20000124,,,118696551,1,HIV infection
11869805,118698051,1,I,,20020702,20151228,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2002-000020,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151228,,OT,US,US,SUSTIVA,Cystic lymphangioma;Dandy-Walker syndrome;Face oedema;Foetal exposure during pregnancy;Localised oedema;Mineral metabolism disorder,118698051,OT,,,,,,,,,118698051,1,Product used for unknown indication
11869844,118698441,1,I,200106,20010723,20151228,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2001SUS0689,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,3.29,KG,20151228,,MD,US,US,EFAVIRENZ,Apnoea;Cerebral atrophy;Foetal exposure during pregnancy;Pneumonia parainfluenzae viral;Premature baby;Seizure,118698441,LT,,,118698441,1,20010611,200105,,,118698441,1,Product used for unknown indication
11870144,118701441,1,I,,20151215,20151228,20151228,EXP,,IN-CIPLA LTD.-2015IN09585,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151228,,OT,IN,IN,Efavirenz,Blood bilirubin abnormal,118701441,OT,,,,,,,,,118701441,1,HIV infection
11870680,118706801,1,I,20040704,20070706,20151228,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2007-000019,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151228,,CN,US,US,EFAVIRENZ,Caesarean section;Oligohydramnios;Pregnancy;Stillbirth;Umbilical cord abnormality,118706801,OT,,,118706801,1,20070201,20070201,,,118706801,1,Antiretroviral therapy
11871337,118713371,1,I,20010601,20001102,20151228,20151228,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-2000SUS0851,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,55,KG,20151228,,MD,FR,FR,SUSTIVA,Caesarean section;Escherichia pyelonephritis;Live birth;Pregnancy;Pyrexia,118713371,HO,,,118713371,3,20001102,20001102,,,118713371,1,HIV infection
11873848,118738481,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09595,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738481,OT,,,,,,,,,118738481,1,HIV infection
11873856,118738561,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09596,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO H.J., WALLIS C.L., KATZENSTEIN D.A., STEVENS W.S., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60:1552 TO 1558",,,,,Y,,,20151229,,MD,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738561,OT,,,,,,,,,118738561,1,HIV infection
11873872,118738721,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09600,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Drug resistance;Treatment failure,118738721,OT,,,,,,,,,118738721,1,HIV infection
11873873,118738731,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09621,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Aspartate aminotransferase;Treatment failure,118738731,OT,,,,,,,,,118738731,1,HIV infection
11873887,118738871,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09623,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Alanine aminotransferase;Treatment failure,118738871,OT,,,,,,,,,118738871,1,HIV infection
11874007,118740071,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09587,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Diarrhoea;Treatment failure,118740071,OT,,,,,,,,,118740071,1,HIV infection
11874027,118740271,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09618,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,OT,IN,IN,Efavirenz,Discomfort;Treatment failure,118740271,OT,,,,,,,,,118740271,1,HIV infection
11874332,118743321,1,I,,20151215,20151229,20151229,EXP,,IN-CIPLA LTD.-2015IN09584,CIPLA,"KUMARASAMY N., AGA E., RIBAUDO HJ., WALLIS CL., KATZENSTEIN DA., STEVENS WS., ET AL.. LOPINAVIR/RITONAVIR MONOTHERAPY AS SECOND-LINE ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: WEEK 104 ANALYSIS OF AIDS CLINICAL TRIALS GROUP (ACTG) A5230. CLINICAL INFECTIOUS DISEASES. 2015?60 (10):1552-1558",,,,,Y,,,20151229,,MD,IN,IN,Efavirenz,Hypophosphataemia;Treatment failure,118743321,OT,,,,,,,,,118743321,1,HIV infection
11877838,118778381,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09744,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118778381,OT,,,,,,,,,118778381,1,HIV infection
11877843,118778431,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09732,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118778431,DE,,,,,,,,,118778431,1,HIV infection
11877848,118778481,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09728,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,COUNTRY NOT SPECIFIED,VN,Efavirenz,Drug resistance;Virologic failure,118778481,OT,,,,,,,,,118778481,1,HIV infection
11877922,118779221,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09758,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Virologic failure,118779221,OT,,,,,,,,,118779221,1,HIV infection
11877928,118779281,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09733,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118779281,OT,,,,,,,,,118779281,1,HIV infection
11877958,118779581,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09739,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118779581,OT,,,,,,,,,118779581,1,HIV infection
11878000,118780001,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09740,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Virologic failure,118780001,OT,,,,,,,,,118780001,1,HIV infection
11878112,118781121,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09751,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118781121,OT,,,,,,,,,118781121,1,HIV infection
11878135,118781351,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09762,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118781351,OT,,,,,,,,,118781351,1,HIV infection
11878475,118784751,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09745,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118784751,OT,,,,,,,,,118784751,1,HIV infection
11878522,118785221,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09729,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118785221,OT,,,,,,,,,118785221,1,HIV infection
11878534,118785341,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09730,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118785341,OT,,,,,,,,,118785341,1,HIV infection
11878535,118785351,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09750,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151230,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118785351,DE,,,,,,,,,118785351,1,HIV infection
11879892,118798921,1,I,200003,20061127,20151230,20151230,EXP,,FR-009507513-1309FRA012607,MERCK,,4,YR,,M,Y,3.47,KG,20151230,,CN,US,FR,SUSTIVA,Abnormal behaviour;Aspartate aminotransferase increased;Blood creatine phosphokinase increased;Blood lactate dehydrogenase increased;Cardiovascular disorder;Depression;Electroencephalogram abnormal;Foetal exposure during pregnancy;Gastrointestinal disorder;Gastrointestinal haemorrhage;Haematochezia;Hepatic enzyme increased;Hypertriglyceridaemia;Lipase increased;Microcytosis;Neutropenia;Pyelonephritis;Segmented hyalinising vasculitis;Speech disorder,118798921,OT,,,118798921,1,199906,2000,,,118798921,1,Product used for unknown indication
11879900,118799001,1,I,,20030722,20151230,20151230,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2003-000013,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,3.46,KG,20151230,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby;Respiratory distress,118799001,OT,,,118799001,1,20001218,20030619,,,118799001,1,Product used for unknown indication
11881127,118811271,1,I,,20151216,20151230,20151230,EXP,,VN-CIPLA LTD.-2015VN09731,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811271,OT,,,,,,,,,118811271,1,HIV infection
11881177,118811771,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09734,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811771,OT,,,,,,,,,118811771,1,HIV infection
11881185,118811851,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09735,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118811851,DE,,,,,,,,,118811851,1,HIV infection
11881196,118811961,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09736,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118811961,OT,,,,,,,,,118811961,1,HIV infection
11881215,118812151,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09737,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118812151,OT,,,,,,,,,118812151,1,HIV infection
11881235,118812351,1,I,20140220,20151210,20151231,20151231,PER,,US-009507513-1512USA007300,MERCK,,29,YR,,F,Y,,,20151231,,CN,US,US,EFAVIRENZ,Maternal exposure during pregnancy;No adverse event;Normal newborn,,,,,,,,,,,118812351,1,Antiretroviral therapy
11881338,118813381,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09743,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118813381,OT,,,,,,,,,118813381,1,HIV infection
11881344,118813441,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09741,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Death;Drug resistance;Virologic failure,118813441,DE,,,,,,,,,118813441,1,HIV infection
11881345,118813451,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09742,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118813451,OT,,,,,,,,,118813451,1,HIV infection
11881486,118814861,1,I,,20151216,20151231,20151231,EXP,,VN-CIPLA LTD.-2015VN09738,CIPLA,"LE T, DUNSTAN SJ, THWAITES GE, CHAU NVV, FARRAR J, SHIKUMA CM ET AL.. HIGH PREVALENCE OF PI RESISTANCE IN PATIENTS FAILING SECOND-LINE ART IN VIETNAM. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2015?1 TO 13",,,,,Y,,,20151231,,OT,VN,VN,Efavirenz,Drug resistance;Virologic failure,118814861,OT,,,,,,,,,118814861,1,HIV infection
11881804,118818041,1,I,,20151225,20151231,20151231,EXP,GB-MHRA-ADR 23291462,GB-VIIV HEALTHCARE LIMITED-GB2015182052,VIIV,,1,DY,,M,Y,1.92,KG,20151231,,CN,GB,GB,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction,118818041,OT,,,118818041,1,20070301,20070625,,,118818041,1,Product used for unknown indication
11883015,118830151,1,I,20151020,20151223,20151231,20151231,EXP,,UG-GILEAD-2015-0190043,GILEAD,,47,YR,A,F,Y,74,KG,20151231,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Sepsis,118830151,HO,,,118830151,1,20150907,20150921,,,118830151,1,HIV infection
11883063,118830631,1,I,,20151216,20151231,20151231,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090408,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151231,,OT,PT,PT,EFAVIRENZ,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy,118830631,OT,,,118830631,1,2007,,,,118830631,1,HIV infection
11883169,118831691,1,I,20151026,20151222,20151231,20151231,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-091273,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,62.5,KG,20151231,,MD,CL,CL,EFAVIRENZ,Appendicectomy;Peritonitis,118831691,HO,,,118831691,1,20130401,,,,118831691,1,HIV infection
3790999,37909993,3,F,20020504,20151210,20020516,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11854981,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151217,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy,37909993,OT,,,37909993,1,,20020401,,,37909993,1,HIV infection
3812755,38127553,3,F,20020212,20151224,20020711,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-11936044,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151228,,OT,US,US,SUSTIVA,Abortion spontaneous;Placental disorder;Pregnancy,38127553,OT,,,,,,,,,38127553,1,Antiretroviral therapy
3839792,38397924,4,F,20020710,20151126,20020918,20151211,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12035572,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.5,KG,20151211,,OT,US,US,EFAVIRENZ,Cleft palate;Foetal exposure during pregnancy,38397924,OT,,,38397924,1,20020218,20020114,,,38397924,1,Product used for unknown indication
3865372,38653722,2,F,2001,20151112,20021125,20151126,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-11647732,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151126,,CN,US,US,SUSTIVA,Pregnancy,,,,,38653722,1,20011208,20011226,,,38653722,1,HIV infection
3871948,38719483,3,F,20021203,20151216,20021212,20151231,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12130175,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.3,KG,20151231,,CN,US,US,SUSTIVA,Congenital skin dimples;Foetal alcohol syndrome;Foetal exposure during pregnancy;Small for dates baby,38719483,OT,,,,,,,,,38719483,1,Product used for unknown indication
3887123,38871232,2,F,20020913,20151121,20030115,20151201,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12060018,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,,,20151201,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Urinary tract obstruction,38871232,OT,,,38871232,1,20010215,20020903,,,38871232,1,Product used for unknown indication
3927305,39273052,2,F,20030109,20151211,20030410,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12231734,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151214,,OT,US,US,SUSTIVA,Death;Pregnancy;Stillbirth,39273052,OT,,,39273052,1,20021007,20021007,,,39273052,1,HIV infection
3962911,39629114,4,F,20030416,20151210,20030630,20151221,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12302055,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151221,,CN,US,FR,SUSTIVA,Pregnancy;Stillbirth;Umbilical cord compression,39629114,OT,,,39629114,1,20000303,200108,,,39629114,1,HIV infection
3971583,39715832,2,F,2002,20030710,20030722,20151207,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-12327581,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151207,,MD,ZA,ZA,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Premature rupture of membranes,39715832,OT,,,39715832,1,20020828,,,,39715832,1,HIV infection
3994361,39943612,2,F,19980909,20151124,20030905,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12370672,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20151208,,PH,FR,FR,EFAVIRENZ,Abortion spontaneous;Pregnancy on oral contraceptive;Thrombocytopenia,39943612,OT,,,39943612,1,19980906,20030320,,,39943612,1,HIV infection
3994870,39948702,2,F,20030328,20151124,20030908,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12369583,BRISTOL MYERS SQUIBB,,29,DY,,M,Y,,,20151208,,OT,FR,FR,SUSTIVA,Anaemia;Foetal exposure during pregnancy;Neutropenia,39948702,HO,,,39948702,1,,20030227,,,39948702,1,Product used for unknown indication
3998234,39982342,2,F,20010114,20151211,20030915,20151218,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12201240,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151218,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Neural tube defect;Talipes,39982342,OT,,,39982342,1,200006,20001020,,,39982342,1,Product used for unknown indication
4008254,40082544,4,F,20030520,20151125,20031006,20151208,EXP,,DK-BRISTOL-MYERS SQUIBB COMPANY-12399515,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151208,,CN,DK,DK,EFAVIRENZ,Abortion missed;Exposure during pregnancy,40082544,HO,,,40082544,1,200109,200304,,,40082544,1,HIV infection
4092890,40928902,2,F,2003,20040217,20040223,20151223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12509352,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151223,,CN,US,US,SUSTIVA,Abnormal behaviour;Caesarean section;Live birth;Pregnancy;Premature delivery;Premature rupture of membranes;Suicidal ideation,40928902,OT,,,40928902,1,20031108,20031110,,,40928902,1,HIV infection
4159551,41595512,2,F,20040125,20151203,20040625,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12618450,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,,,20151208,,OT,FR,FR,SUSTIVA,Abortion induced;Drug interaction;Pregnancy on contraceptive;Therapeutic response decreased,41595512,OT,,,41595512,1,20031215,,,,41595512,1,HIV infection
4175225,41752259,9,F,,20121116,20040723,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12645404,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,4.15,KG,20151208,,OT,CH,US,EFAVIRENZ,Arnold-Chiari malformation;Foetal exposure during pregnancy;Large for dates baby;Meningomyelocele;Premature baby,41752259,OT,,,41752259,2,20030310,20040219,,,41752259,1,Product used for unknown indication
4201530,42015303,3,F,20040523,20151127,20040901,20151207,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12499257,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,56,KG,20151207,,OT,FR,FR,SUSTIVA,Polyhydramnios;Pregnancy;Premature delivery;Premature rupture of membranes,42015303,OT,,,42015303,1,20010401,,,,42015303,1,HIV test positive
4209582,42095823,3,F,20040815,20151118,20040915,20151124,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12700944,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,66.66,KG,20151124,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,42095823,OT,,,,,,,,,42095823,1,HIV infection
5684101,56841013,3,F,2004,20151128,20041129,20151214,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-12571378,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,73.01,KG,20151214,,MD,US,US,SUSTIVA,Normal newborn;Pain;Pregnancy;Rash,,,,,56841013,1,20010313,20040217,,,56841013,1,HIV infection
5768520,57685202,2,F,20040106,20151211,20050331,20151222,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-12330361,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151222,,CN,US,CH,EFAVIRENZ,Pregnancy;Stillbirth,57685202,OT,,,57685202,2,20030701,20030701,,,57685202,1,HIV infection
5858118,58581185,5,F,,20121116,20050811,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13067566,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151208,,OT,CH,US,EFAVIRENZ,Caesarean section;Gestational diabetes;Live birth;Pregnancy;Premature delivery,58581185,OT,,,,,,,,,58581185,1,Acquired immunodeficiency syndrome
5861676,58616762,2,F,,20151201,20050816,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13032883,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151209,,MD,US,US,SUSTIVA,Congenital anomaly;Foetal exposure during pregnancy,58616762,OT,,,,,,,,,58616762,1,Product used for unknown indication
6013552,60135522,2,F,200206,20151123,20060328,20151208,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-13322532,BRISTOL MYERS SQUIBB,,,,,M,Y,2.6,KG,20151208,,MD,DE,DE,SUSTIVA,Dyspnoea;Foetal exposure during pregnancy;Group B streptococcus neonatal sepsis;Rotavirus infection,60135522,HO,,,60135522,1,200110,200110,,,60135522,1,Product used for unknown indication
6013572,60135722,2,F,1994,20040901,20060328,20151208,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-13309745,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,56,KG,20151208,,MD,DE,DE,SUSTIVA,Abdominal pain upper;Asthenia;Caesarean section;Diabetes mellitus;Diarrhoea;Drug ineffective;Flatulence;Herpes zoster;Lipodystrophy acquired;Live birth;Myalgia;Oedema peripheral;Pancreatitis acute;Pneumocystis jirovecii pneumonia;Pregnancy;Premature delivery;Pruritus;Urticaria papular,60135722,OT,,,60135722,1,1999,200110,,,60135722,1,HIV infection
6050433,60504335,5,F,20060428,20151120,20060523,20151124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-13379078,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,77.8,KG,20151124,,OT,CA,CA,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,60504335,OT,,,60504335,1,20050422,20060324,,,60504335,1,HIV test positive
6054951,60549512,2,F,,20151120,20060530,20151203,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-13390802,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151203,,CN,IT,IT,SUSTIVA,Abortion induced;Pregnancy,60549512,OT,,,,,,,,,60549512,1,Product used for unknown indication
6073969,60739694,4,F,20050926,20151116,20060628,20151124,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13421672,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,2.76,KG,20151124,,MD,US,US,EFAVIRENZ,Eyelid ptosis;Foetal exposure during pregnancy;Hemiparesis;Hydrocele;Ultrasound scan abnormal,60739694,OT,,,60739694,2,20050916,20060122,,,60739694,1,Product used for unknown indication
6150572,61505722,2,F,20060425,20151111,20061020,20151124,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13542238,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,2.33,KG,20151124,,CN,FR,FR,SUSTIVA,Atrial septal defect;Foetal exposure during pregnancy;Premature baby,61505722,CA,,,,,,,,,61505722,1,Product used for unknown indication
6158911,61589112,2,F,20060112,20151120,20061031,20151124,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13242870,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151124,,CN,US,ZA,EFAVIRENZ,Abortion induced;Exposure during pregnancy,61589112,OT,,,61589112,1,200503,20060103,,,61589112,1,HIV infection
6161318,61613187,7,F,2006,20151214,20061103,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13559935,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,,,20151218,,OT,US,ZA,EFAVIRENZ,Congenital nose malformation;Foetal exposure during pregnancy;Limb deformity;Premature baby;Talipes,61613187,OT,,,61613187,1,20050223,20051229,,,61613187,1,HIV infection
6203174,62031742,2,F,2006,20151121,20061227,20151201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13329677,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20151201,,MD,FR,FR,SUSTIVA,Abortion spontaneous;Metrorrhagia;Pregnancy,62031742,OT,,,62031742,1,200512,200602,,,62031742,1,HIV infection
6221705,62217052,2,F,20060621,20151126,20070124,20151211,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13627872,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.23,KG,20151211,,MD,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,62217052,OT,,,,,,,,,62217052,1,Product used for unknown indication
6260112,62601124,4,F,,20151215,20070313,20151222,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-13709290,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151222,,OT,IT,IT,EFAVIRENZ,Foetal exposure during pregnancy;Talipes,62601124,OT,,,,,,,,,62601124,1,HIV infection
6264473,62644733,3,F,20061129,20151215,20070319,20151219,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13714431,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,,,20151219,,OT,FR,FR,EFAVIRENZ,Exomphalos;Foetal exposure during pregnancy,62644733,CA,,,62644733,1,,20061019,,,62644733,1,Product used for unknown indication
6302681,63026812,2,F,,20151125,20070502,20151209,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-13765631,BRISTOL MYERS SQUIBB,"STARGARD, M., KEGG, S., BRITISH HIV ASSOCIATION, HIV MEDICINE (8) PAGE 32",,,,F,Y,,,20151209,,OT,GB,GB,EFAVIRENZ,Abortion induced;Pregnancy,63026812,OT,,,,,,,,,63026812,1,HIV infection
6356516,63565169,9,F,20070702,20151221,20070713,20151228,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13837919,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,1.11,KG,20151228,,CN,US,US,EFAVIRENZ,Breech presentation;Dandy-Walker syndrome;Foetal exposure during pregnancy;Foetal growth restriction;Foetal malformation;Umbilical cord around neck,63565169,DE,,,63565169,1,20070201,20070201,,,63565169,1,Product used for unknown indication
6362915,63629152,2,F,,20151119,20070720,20151203,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-13692827,BRISTOL MYERS SQUIBB,,,,,F,Y,55,KG,20151203,,CN,US,DE,SUSTIVA,Medication error;Pregnancy,,,,,63629152,1,200609,200701,,,63629152,1,HIV infection
6388912,63889126,6,F,,20070910,20070822,20151224,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13884226,BRISTOL MYERS SQUIBB,,,,N,F,Y,3.2,KG,20151224,,CN,US,US,EFAVIRENZ,Aplasia cutis congenita;Foetal exposure during pregnancy;Premature baby,63889126,OT,,,,,,,,,63889126,1,Product used for unknown indication
6392304,63923043,3,F,,20151222,20070828,20151223,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-13607288,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,1.92,KG,20151223,,CN,GB,GB,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction,63923043,OT,,,63923043,1,20040716,20070625,,,63923043,1,Product used for unknown indication
6411936,64119362,2,F,,20151029,20070912,20151113,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13884366,BRISTOL MYERS SQUIBB,,,,,M,Y,3.91,KG,20151113,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Hypospadias,64119362,CA,,,,,,,,,64119362,1,HIV infection
6431218,643121810,10,F,20080108,20080221,20071001,20151208,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13921481,BRISTOL MYERS SQUIBB,,,,N,F,Y,2.95,KG,20151208,,OT,ZA,US,EFAVIRENZ,Amniotic band syndrome;Anophthalmos;Cleft lip and palate;Foetal exposure during pregnancy;Neural tube defect;Premature baby,643121810,OT,,,643121810,1,20070627,20070627,,,643121810,1,Product used for unknown indication
6464471,64644712,2,F,,20151118,20071112,20151216,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-13626064,BRISTOL MYERS SQUIBB,,,,,F,Y,69,KG,20151216,,MD,US,US,SUSTIVA,Artificial insemination by donor;Pregnancy,,,,,,,,,,,64644712,1,Product used for unknown indication
6464491,64644913,3,F,,20151116,20071112,20151120,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-13814561,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151120,,CN,US,US,SUSTIVA,Pregnancy,,,,,64644913,1,200703,,,,64644913,1,Product used for unknown indication
6481176,64811762,2,F,,20071203,20071205,20151218,EXP,,NL-BRISTOL-MYERS SQUIBB COMPANY-14002315,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151218,,OT,NL,NL,EFAVIRENZ,In vitro fertilisation;Premature delivery;Premature rupture of membranes;Twin pregnancy;Virologic failure,64811762,OT,,,,,,,,,64811762,1,HIV infection
6481177,64811773,3,F,,20151211,20071205,20151217,EXP,,NL-BRISTOL-MYERS SQUIBB COMPANY-14003263,BRISTOL MYERS SQUIBB,,,,I,M,Y,1.08,KG,20151217,,OT,NL,NL,EFAVIRENZ,Atrioventricular block complete;Blood lactic acid increased;Congestive cardiomyopathy;Foetal exposure during pregnancy,64811773,OT,,,,,,,,,64811773,1,Product used for unknown indication
6481178,64811783,3,F,,20151211,20071205,20151217,EXP,,NL-BRISTOL-MYERS SQUIBB COMPANY-14003255,BRISTOL MYERS SQUIBB,,,,I,F,Y,.99,KG,20151217,,OT,NL,NL,EFAVIRENZ,Atrioventricular block complete;Cardiomyopathy;Foetal exposure during pregnancy,64811783,OT,,,,,,,,,64811783,1,Product used for unknown indication
6532793,65327933,3,F,200712,20080619,20080123,20151223,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14044457,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,1.26,KG,20151223,,CN,US,FR,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby;Respiratory distress;Talipes,65327933,CA,,,65327933,1,20070328,20070808,,,65327933,1,Product used for unknown indication
6532800,65328003,3,F,2007,20151113,20080123,20151127,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14046536,BRISTOL MYERS SQUIBB,,0,YR,,M,Y,1.75,KG,20151127,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Premature baby;Respiratory distress,65328003,OT,,,65328003,1,20070328,20070808,,,65328003,1,Product used for unknown indication
6532801,65328012,2,F,2007,20080116,20080123,20151223,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14046544,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151223,,OT,FR,FR,SUSTIVA,Caesarean section;HELLP syndrome;Mania;Maternal exposure during pregnancy;Pre-eclampsia;Premature delivery;Twin pregnancy,65328012,OT,,,65328012,1,20070328,20070808,,,65328012,1,Antiretroviral therapy
6554213,65542134,4,F,20070907,20151123,20080215,20151208,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-13874722,BRISTOL MYERS SQUIBB,,,,N,M,Y,1.9,KG,20151208,,CN,US,CH,EFAVIRENZ,Developmental hip dysplasia;Foetal exposure during pregnancy;Low birth weight baby;Pulmonary valve stenosis,65542134,OT,,,65542134,1,,20070202,,,65542134,1,Product used for unknown indication
6568941,65689414,4,F,,20151126,20080304,20151209,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099899,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151209,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689414,OT,,,,,,,,,65689414,1,Product used for unknown indication
6568942,65689424,4,F,,20151029,20080304,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099493,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689424,OT,,,,,,,,,65689424,1,Product used for unknown indication
6568943,65689434,4,F,,20151029,20080304,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099675,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689434,OT,,,,,,,,,65689434,1,Product used for unknown indication
6568944,65689444,4,F,,20151029,20080304,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099766,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689444,OT,,,,,,,,,65689444,1,Product used for unknown indication
6568946,65689464,4,F,,20151029,20080304,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099550,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151113,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689464,OT,,,,,,,,,65689464,1,Product used for unknown indication
6568949,65689494,4,F,,20151126,20080304,20151209,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099881,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151209,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689494,OT,,,,,,,,,65689494,1,Product used for unknown indication
6568950,65689504,4,F,,20151130,20080304,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14099915,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151208,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Neurodevelopmental disorder,65689504,OT,,,,,,,,,65689504,1,Product used for unknown indication
6612453,66124532,2,F,20080129,20151127,20080411,20151211,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-13854682,BRISTOL MYERS SQUIBB,,17,YR,,F,Y,,,20151211,,CN,US,ZA,EFAVIRENZ,Caesarean section;Normal newborn;Pregnancy;Vulvovaginal warts,66124532,OT,,,66124532,1,20070322,20070618,,,66124532,1,HIV infection
6615249,66152492,2,F,,20151127,20080415,20151209,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14148324,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151209,,CN,US,ZA,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy,66152492,OT,,,66152492,1,20051122,20071126,,,66152492,1,HIV infection
6619574,66195742,2,F,,20151210,20080421,20151217,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14156657,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217,,CN,IE,IE,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,66195742,OT,,,,,,,,,66195742,1,HIV infection
6621933,66219332,2,F,,20151210,20080423,20151217,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14158273,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217,,CN,IE,IE,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,66219332,OT,,,,,,,,,66219332,1,HIV infection
6621936,66219362,2,F,,20151210,20080423,20151215,EXP,,IE-BRISTOL-MYERS SQUIBB COMPANY-14158299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151215,,CN,IE,IE,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,66219362,OT,,,,,,,,,66219362,1,HIV infection
6625913,66259133,3,F,,20151211,20080428,20151222,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14162846,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151222,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Multiple congenital abnormalities,66259133,OT,,,66259133,1,20060101,,,,66259133,1,Product used for unknown indication
6635741,66357412,2,F,20080411,20151030,20080508,20151113,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14182448,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151113,,MD,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Selective abortion,66357412,OT,,,,,,,,,66357412,1,HIV infection
6649623,66496232,2,F,,20151030,20080527,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14202303,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,55,KG,20151113,,OT,GB,GB,EFAVIRENZ,Inhibitory drug interaction;Pregnancy on oral contraceptive,66496232,OT,,,66496232,1,20000801,200804,,,66496232,1,Product used for unknown indication
6656066,66560662,2,F,,20151208,20080603,20151209,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14170856,BRISTOL MYERS SQUIBB,,,,,F,Y,83,KG,20151209,,CN,GB,GB,SUSTIVA,Ectopic pregnancy;Pregnancy with contraceptive device,66560662,OT,,,66560662,1,200311,20061025,,,66560662,1,HIV infection
6660466,66604662,2,F,20080526,20151026,20080609,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14209035,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20151109,,OT,US,US,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66604662,OT,,,66604662,1,20080512,20080512,,,66604662,1,HIV infection
6668479,66684793,3,F,2007,20080701,20080616,20151218,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14152987,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151218,,CN,US,ZA,EFAVIRENZ,Caesarean section;Cephalo-pelvic disproportion;Maternal exposure during pregnancy;Normal newborn,66684793,OT,,,66684793,1,20060330,20071113,,,66684793,1,HIV infection
6668497,66684972,2,F,20080107,20151204,20080616,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13881982,BRISTOL MYERS SQUIBB,,,,,M,Y,3.12,KG,20151209,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Haemangioma,66684972,OT,,,66684972,1,,20070521,,,66684972,1,Product used for unknown indication
6688989,66889893,3,F,200805,20151026,20080702,20151106,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14245021,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,57,KG,20151106,,CN,GB,GB,SUSTIVA,Drug interaction;Maternal exposure during pregnancy;Pregnancy with implant contraceptive,66889893,OT,,,66889893,2,2006,,,,66889893,1,HIV test
6694162,66941623,3,F,20070621,20151027,20080709,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14251904,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151108,,CN,US,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66941623,OT,,,66941623,1,20060309,20070501,,,66941623,1,HIV infection
6695638,66956382,2,F,20080320,20151027,20080710,20151108,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-14255277,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151108,,CN,CH,CH,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,66956382,OT,,,66956382,1,2007,20080305,,,66956382,1,HIV infection
6698357,66983572,2,F,20071122,20151027,20080714,20151108,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-14258685,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151108,,OT,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,66983572,OT,,,66983572,1,20060914,20070514,,,66983572,1,HIV infection
6711435,67114352,2,F,20080315,20151027,20080728,20151108,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14277164,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20151108,,CN,GB,GB,SUSTIVA,Abortion spontaneous;Maternal exposure during pregnancy,67114352,OT,,,67114352,1,20070514,20080218,,,67114352,1,HIV infection
6718498,67184983,3,F,20080221,20151027,20080805,20151108,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14288252,BRISTOL MYERS SQUIBB,,1,MON,,M,Y,,,20151108,,MD,ZA,ZA,EFAVIRENZ,Cardiac failure;Foetal exposure during pregnancy;Pneumonia;Truncus arteriosus persistent,67184983,DE,,,,,,,,,67184983,1,Product used for unknown indication
6723333,67233335,5,F,20080805,20151209,20080811,20151219,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14292569,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,3.81,KG,20151219,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Tooth development disorder,67233335,CA,,,67233335,1,,20080805,,,67233335,1,Antiretroviral therapy
6724374,67243745,5,F,20070201,20151030,20080812,20151113,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14290209,BRISTOL MYERS SQUIBB,,0,DY,,,Y,1.25,KG,20151113,,MD,DE,DE,EFAVIRENZ,Anal atresia;Anal stenosis;Bacterial sepsis;Congenital anomaly;Congenital central nervous system anomaly;Congenital foot malformation;Congenital musculoskeletal anomaly;Dextrocardia;Foetal exposure during pregnancy;Premature baby;Single functional kidney;Spine malformation;Systemic inflammatory response syndrome,67243745,OT,,,67243745,1,20050101,20060925,,,67243745,1,Product used for unknown indication
6793373,67933732,2,F,,20151028,20081022,20151108,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14378285,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151108,,MD,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,67933732,OT,,,,,,,,,67933732,1,HIV infection
6797602,67976026,6,F,20070611,20151022,20081028,20151106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14332951,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,92,KG,20151106,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy;Oligohydramnios;Pregnancy on contraceptive,67976026,OT,,,67976026,1,20070217,20070703,,,67976026,1,HIV infection
6805758,68057582,2,F,,20151028,20081107,20151107,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14394183,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,,,20151107,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,68057582,OT,,,,,,,,,68057582,1,Product used for unknown indication
6806942,68069429,9,F,20080422,20151211,20081110,20151217,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14017800,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,68,KG,20151217,,CN,GB,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,68069429,OT,,,68069429,1,20051201,20071211,,,68069429,1,Antiretroviral therapy
6826111,68261112,2,F,,20151112,20081201,20151127,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14083364,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151127,,MD,GB,GB,EFAVIRENZ,Ectopic pregnancy;Maternal exposure during pregnancy,68261112,OT,,,,,,,,,68261112,1,Antiretroviral therapy
6831328,68313283,3,F,,20151029,20081203,20151113,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14427819,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151113,,MD,DE,DE,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,68313283,OT,,,68313283,1,20060810,20070320,,,68313283,1,HIV infection
6866921,68669214,4,F,20081005,20151029,20081226,20151113,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14410146,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,52,KG,20151113,,MD,FR,FR,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,68669214,OT,,,68669214,1,2001,20081031,,,68669214,1,HIV infection
6950172,69501723,3,F,,20090325,20090324,20151210,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14554364,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151210,,CN,GB,GB,EFAVIRENZ,Anaemia;Blood triglycerides increased;Caesarean section;Hepatic function abnormal;Injection site reaction;Premature delivery;Premature rupture of membranes;Twin pregnancy;Virologic failure,69501723,OT,,,,,,,,,69501723,1,HIV infection
6975594,69755944,4,F,20081001,20151026,20090422,20151106,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14243208,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,67,KG,20151106,,MD,DE,DE,SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Premature delivery,69755944,OT,,,69755944,1,20060501,20080626,,,69755944,1,HIV infection
7021228,70212282,2,F,20090506,20090609,20090612,20151217,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14655690,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,72.56,KG,20151217,,CN,US,US,BLINDED EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and curettage,70212282,OT,,,70212282,1,20051208,20090329,,,70212282,1,HIV infection
7033376,70333764,4,F,20090525,20151102,20090625,20151113,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-14671929,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20151113,,MD,BE,BE,EFAVIRENZ,Abortion spontaneous;Pregnancy on contraceptive,70333764,OT,,,70333764,1,20070924,20090515,,,70333764,1,HIV infection
7053825,70538252,2,F,,20151111,20090717,20151122,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14701890,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151122,,OT,GB,GB,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,70538252,OT,,,70538252,1,20071023,,,,70538252,1,Product used for unknown indication
7091132,70911323,3,F,,20151209,20090824,20151215,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14743918,BRISTOL MYERS SQUIBB,BERA E.. MATERNAL OUTCOMES FOLLOWING INTRODUCTION OF ANTIRETROVIRAL THERAPY IN THE PUBLIC SECTOR: A PROSPECTIVE STUDY AT A TERTIARY HOSPITAL IN THE EASTERN CAPE.. SOUTH AFRICAN JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2009?1?15(1)::26-33.,32,YR,,F,Y,,,20151215,,OT,ZA,ZA,EFAVIRENZ,Hepatic failure;Lactic acidosis;Live birth;Maternal exposure during pregnancy,70911323,HO,,,,,,,,,70911323,1,Antiretroviral therapy
7105391,71053912,2,F,,20151112,20090904,20151118,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14763908,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151118,,MD,US,US,SUSTIVA,Foetal exposure during pregnancy;Hearing impaired,71053912,CA,,,,,,,,,71053912,1,Product used for unknown indication
7106047,710604711,11,F,20090711,20151104,20090904,20151104,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-14767123,BRISTOL MYERS SQUIBB,,0,DY,,F,Y,2.69,KG,20151104,,CN,US,US,EFAVIRENZ,Breech presentation;Foetal exposure during pregnancy;Ventricular septal defect,710604711,CA,,,710604711,1,20060509,20081116,,,710604711,1,Product used for unknown indication
7111460,71114603,3,F,20090930,20151023,20090911,20151102,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14642565,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,,,20151102,,CN,FR,FR,SUSTIVA,Caesarean section;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,71114603,OT,,,71114603,1,20080724,,,,71114603,1,HIV infection
7123445,71234453,3,F,,20151111,20090921,20151122,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14785612,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151122,,MD,ZA,ZA,EFAVIRENZ,Death;Maternal exposure during pregnancy,71234453,OT,,,71234453,1,20051025,,,,71234453,1,Antiretroviral therapy
7123446,71234463,3,F,200603,20151209,20090921,20151215,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14785638,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20151215,,MD,ZA,ZA,EFAVIRENZ,Death;Maternal exposure during pregnancy,71234463,DE,,,,,,,,,71234463,1,Product used for unknown indication
7123915,71239152,2,F,,20151029,20090921,20151113,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-14786123,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,CN,AR,AR,EFAVIRENZ,Foetal exposure during pregnancy;Neonatal aspiration;Premature baby;Small for dates baby;Thrombosis,71239152,OT,,,71239152,1,20090303,20090303,,,71239152,1,Product used for unknown indication
7124632,71246323,3,F,200512,20151120,20090922,20151201,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14785646,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151201,,MD,ZA,ZA,EFAVIRENZ,Death;Maternal exposure during pregnancy,71246323,DE,,,71246323,1,20051122,,,,71246323,1,Antiretroviral therapy
7140532,71405322,2,F,20081230,20151026,20091006,20151106,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14559363,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,92,KG,20151106,,MD,FR,FR,SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Normal newborn,71405322,OT,,,71405322,1,200807,20090317,,,71405322,1,HIV infection
7238125,723812510,10,F,20080103,20151209,20100106,20151215,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-14918437,BRISTOL MYERS SQUIBB,,12,MON,,F,Y,3.18,KG,20151215,,CN,AU,AU,EFAVIRENZ,Congenital tricuspid valve stenosis;Foetal exposure during pregnancy;Hepatitis C;Hypoplastic right heart syndrome,723812510,LT,,,723812510,1,,20080512,,,723812510,1,Product used for unknown indication
7240788,72407882,2,F,2008,20151030,20100108,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14922280,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151113,,CN,GB,GB,EFAVIRENZ,Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,72407882,OT,,,72407882,2,20040811,20080624,,,72407882,1,HIV infection
7258000,72580002,2,F,,20151112,20100127,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14940548,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Congenital anomaly;Foetal exposure during pregnancy,72580002,CA,,,,,,,,,72580002,1,Antiretroviral therapy
7258011,72580112,2,F,,20151112,20100127,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948517,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Arachnoid cyst;Foetal exposure during pregnancy,72580112,CA,,,,,,,,,72580112,1,Product used for unknown indication
7259094,72590942,2,F,,20151117,20100128,20151129,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948533,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151129,,OT,ZA,ZA,EFAVIRENZ,Asphyxia;Cardiac failure congestive;Death;Foetal exposure during pregnancy;Pulmonary valve stenosis congenital,72590942,DE,,,,,,,,,72590942,1,Product used for unknown indication
7259098,72590982,2,F,,20151112,20100128,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948558,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Trisomy 18,72590982,CA,,,,,,,,,72590982,1,Product used for unknown indication
7259099,72590992,2,F,,20151116,20100128,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948574,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Congenital multiplex arthrogryposis;Death neonatal;Foetal exposure during pregnancy,72590992,OT,,,,,,,,,72590992,1,Product used for unknown indication
7259102,72591022,2,F,,20151113,20100128,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948590,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Oesophageal atresia;Tracheo-oesophageal fistula,72591022,CA,,,,,,,,,72591022,1,Product used for unknown indication
7259103,72591032,2,F,,20151113,20100128,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948616,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Syndactyly,72591032,OT,,,,,,,,,72591032,1,Product used for unknown indication
7259105,72591053,3,F,,20151121,20100128,20151201,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-14948632,BRISTOL MYERS SQUIBB,,,,,M,Y,2.77,KG,20151201,,OT,ZA,ZA,EFAVIRENZ,Foetal exposure during pregnancy;Polydactyly,72591053,CA,,,72591053,1,,20080518,,,72591053,1,Product used for unknown indication
7319685,73196852,2,F,,20151029,20100315,20151113,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-14626725,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151113,,PH,DE,DE,SUSTIVA,Abortion;Maternal exposure during pregnancy,73196852,OT,,,,,,,,,73196852,1,Antiretroviral therapy
7326580,73265807,7,F,,20151117,20100321,20151129,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15024789,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151129,,CN,US,US,SUSTIVA,Atrial septal defect;Foetal exposure during pregnancy,73265807,CA,,,,,,,,,73265807,1,Product used for unknown indication
7326581,73265814,4,F,,20151112,20100321,20151123,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15024797,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151123,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Gastroschisis,73265814,CA,,,,,,,,,73265814,1,Product used for unknown indication
7326582,73265824,4,F,,20151029,20100321,20151113,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15024805,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Polydactyly,73265824,CA,,,,,,,,,73265824,1,Product used for unknown indication
7326584,73265847,7,F,,20151029,20100321,20151113,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15024854,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151113,,OT,US,US,SUSTIVA,Foetal exposure during pregnancy;Hypertonia;Talipes,73265847,CA,,,,,,,,,73265847,1,Product used for unknown indication
7328578,73285783,3,F,,20151209,20100323,20151214,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15029879,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151214,,CN,US,US,SUSTIVA,Foetal exposure during pregnancy;Plagiocephaly,73285783,CA,,,73285783,1,,20051226,,,73285783,1,Product used for unknown indication
7398818,73988183,3,F,20080829,20151029,20100525,20151113,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-14478093,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20151113,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Normal newborn;Pregnancy on contraceptive,73988183,OT,,,73988183,1,20070808,20080206,,,73988183,1,HIV infection
7400044,74000444,4,F,20080521,20151112,20100526,20151118,EXP,,GB-GILEAD-2010-0029316,GILEAD,,28,YR,A,F,Y,104,KG,20151118,,MD,GB,GB,SUSTIVA,Caesarean section;Maternal exposure during pregnancy,74000444,OT,,,74000444,1,20071024,20071011,,,74000444,1,HIV infection
7407379,74073793,3,F,20080707,20151117,20100602,20151123,EXP,,GB-GILEAD-2010-0029482,GILEAD,,26,YR,A,F,Y,,,20151123,,MD,GB,GB,SUSTIVA,Anaemia;Caesarean section;Normal newborn;Pregnancy on contraceptive,74073793,OT,,,74073793,1,20070808,20080206,,,74073793,1,HIV infection
7408389,74083892,2,F,201004,20151214,20100603,20151223,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15120728,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151223,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Hydrocephalus,74083892,OT,,,74083892,1,20070817,20091202,,,74083892,1,Product used for unknown indication
7408392,74083924,4,F,20100421,20151216,20100603,20151218,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15126741,BRISTOL MYERS SQUIBB,,31,YR,,F,Y,,,20151218,,CN,FR,FR,SUSTIVA,Abortion induced;Bartholinitis;Maternal exposure during pregnancy;Pyelonephritis,74083924,HO,,,74083924,1,20070817,20091202,,,74083924,1,HIV infection
7412939,74129392,2,F,,20151123,20100608,20151207,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14668420,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151207,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,74129392,1,Antiretroviral therapy
7412942,74129422,2,F,,20151113,20100608,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-14714265,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118,,CN,US,US,SUSTIVA,Maternal exposure during pregnancy,,,,,,,,,,,74129422,1,HIV infection
7412958,74129584,4,F,,20151027,20100608,20151028,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15066335,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151028,,CN,US,US,SUSTIVA,Exposure during pregnancy;No adverse event,,,,,,,,,,,74129584,1,Product used for unknown indication
7440856,74408564,4,F,,20151117,20100629,20151128,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15156771,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151128,,OT,US,US,EFAVIRENZ,Foetal exposure during pregnancy;Hypospadias,74408564,CA,,,,,,,,,74408564,1,Product used for unknown indication
7451576,74515765,5,F,20100602,20151023,20100701,20151105,EXP,,US-GILEAD-2010-0030045,GILEAD,,0,DY,,F,Y,2.95,KG,20151105,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acrochordon;Foetal exposure during pregnancy,74515765,CA,,,74515765,1,20090903,20090924,,,74515765,1,HIV infection
7494744,74947442,2,F,201007,20151119,20100722,20151129,EXP,,TW-BRISTOL-MYERS SQUIBB COMPANY-15203383,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151129,,MD,TW,TW,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,74947442,OT,,,74947442,1,20100402,,,,74947442,1,HIV infection
7512166,75121663,3,F,,20151209,20100730,20151214,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-15212632,BRISTOL MYERS SQUIBB,,,,,F,Y,2.7,KG,20151214,,OT,BR,BR,EFAVIRENZ,Foetal exposure during pregnancy;Maternal drugs affecting foetus;Melanocytic naevus;Patent ductus arteriosus,75121663,OT,,,75121663,1,20021107,20021106,,,75121663,1,Product used for unknown indication
7512167,75121672,2,F,,20151210,20100730,20151215,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-15212707,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20151215,,OT,AR,AR,EFAVIRENZ,Foetal exposure during pregnancy;Horner's syndrome,75121672,CA,,,75121672,1,20021205,20050111,,,75121672,1,Product used for unknown indication
7570976,75709767,7,F,2006,20151023,20100902,20151107,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-15256381,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,54,KG,20151107,,CN,US,DE,SUSTIVA,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Twin pregnancy;Urinary tract infection;Virologic failure,75709767,HO,,,75709767,1,20071016,200610,,,75709767,1,HIV infection
7570980,75709805,5,F,20090613,20110119,20100902,20151123,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-15256464,BRISTOL MYERS SQUIBB,,0,DY,,M,Y,.86,KG,20151123,,CN,US,DE,SUSTIVA,Bronchopulmonary dysplasia;Developmental delay;Foetal exposure during pregnancy;Patent ductus arteriosus;Premature baby,75709805,OT,,,,,,,,,75709805,1,Product used for unknown indication
7570982,75709827,7,F,2009,20120404,20100902,20151124,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-15256449,BRISTOL MYERS SQUIBB,,0,YR,,F,Y,6.76,KG,20151124,,CN,US,DE,SUSTIVA,Cerebral palsy;Congenital hydrocephalus;Foetal exposure during pregnancy;Intestinal perforation;Intraventricular haemorrhage;Microcephaly;Neonatal respiratory distress syndrome;Patent ductus arteriosus;Peritonitis;Premature baby;Retinopathy of prematurity;Strabismus,75709827,CA,,,75709827,4,,20090613,,,75709827,1,Product used for unknown indication
7587496,75874962,2,F,20091212,20100909,20100915,20151208,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15281645,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20151208,,CN,FR,FR,SUSTIVA,Abortion spontaneous;Maternal exposure during pregnancy;Uterine dilation and evacuation,75874962,OT,,,,,,,,,75874962,1,HIV infection
7591099,75910992,2,F,,20151028,20100917,20151112,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-15286461,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151112,,CN,GB,GB,SUSTIVA,Maternal exposure during pregnancy;Muscle rupture;Rhabdomyolysis,75910992,OT,,,,,,,,,75910992,1,HIV infection
7640015,76400152,2,F,200901,20151028,20101026,20151112,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-15345911,BRISTOL MYERS SQUIBB,,44,YR,,F,Y,,,20151112,,CN,IT,IT,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI;SUSTIVA,Caesarean section;Maternal exposure during pregnancy;Normal newborn,76400152,OT,,,76400152,1,2007,200904,,,76400152,1,HIV infection
7671815,76718152,2,F,2009,20151028,20101116,20151113,EXP,,IT-GILEAD-2010-0032936,GILEAD,,44,YR,A,F,Y,,,20151113,,MD,IT,IT,SUSTIVA,Caesarean section;Dyslipidaemia;Lactic acidosis;Maternal exposure during pregnancy;Normal newborn;Pregnancy,76718152,OT,,,76718152,1,200904,200907,,,76718152,1,HIV infection
7752886,77528866,6,F,20100722,20151026,20110107,20151216,EXP,,US-GILEAD-2011-0034854,GILEAD,,30,YR,A,F,Y,,,20151216,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,77528866,OT,,,,,,,,,77528866,1,HIV infection
7752911,77529116,6,F,,20151026,20110107,20151112,EXP,,US-GILEAD-2011-0034856,GILEAD,,25,WK,I,F,Y,.3,KG,20151112,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction;Wolf-Hirschhorn syndrome,77529116,CA,,,,,,,,,77529116,1,HIV infection
7830902,78309022,2,F,,20151028,20110227,20151109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15570807,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20151109,,CN,US,US,EFAVIRENZ,Foetal exposure during pregnancy;HIV infection,78309022,OT,,,,,,,,,78309022,1,Product used for unknown indication
7830904,78309042,2,F,,20151125,20110227,20151209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15570898,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151209,,OT,US,US,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,78309042,OT,,,,,,,,,78309042,1,HIV infection
7920187,79201873,3,F,200604,20151117,20110429,20151123,EXP,,GB-GILEAD-E2B_00001248,GILEAD,,44,YR,A,F,Y,,,20151123,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,79201873,OT,,,79201873,1,200509,,,,79201873,1,HIV infection
8143762,81437622,2,F,20110821,20151123,20110920,20151208,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-16072910,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,70.1,KG,20151208,,CN,US,ZW,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy,81437622,OT,,,81437622,1,20090603,,,,81437622,1,HIV infection
8163168,81631683,3,F,20110914,20151126,20110930,20151209,EXP,,MW-BRISTOL-MYERS SQUIBB COMPANY-16102360,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,53.5,KG,20151209,,CN,US,MW,EFAVIRENZ,Ectopic pregnancy;Neutrophil count decreased;Pregnancy on contraceptive;Upper respiratory tract infection,81631683,OT,,,81631683,1,20110624,20110624,,,81631683,1,HIV infection
8260766,82607662,2,F,2006,20151204,20111123,20151209,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,1.19,KG,20151209,,CN,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal malformation;Spina bifida,82607662,DE,,,82607662,1,,20050908,,,82607662,1,Product used for unknown indication
8310422,83104222,2,F,,20151127,20111223,20151209,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16313751,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure timing unspecified,83104222,OT,,,,,,,,,83104222,1,HIV infection
8310423,83104232,2,F,,20151127,20111223,20151209,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-16307837,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209,,CN,US,BR,EFAVIRENZ,Abortion spontaneous;Maternal exposure timing unspecified,83104232,OT,,,,,,,,,83104232,1,HIV infection
8457821,84578212,2,F,20120224,20151130,20120314,20151207,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-16436339,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,47.8,KG,20151207,,CN,US,ZW,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy;Neutropenia,84578212,OT,,,84578212,1,20100210,20120130,,,84578212,1,HIV infection
8603267,86032672,2,F,,20151121,20120607,20151209,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-15705668,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151209,,CN,GB,US,EFAVIRENZ,Maternal exposure during pregnancy,,,,,,,,,,,86032672,1,Product used for unknown indication
8603296,86032963,3,F,,20151030,20120607,20151118,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-16347718,BRISTOL MYERS SQUIBB,,,,,F,Y,93,KG,20151118,,CN,US,US,SUSTIVA,Decreased appetite;Malaise;Maternal exposure during pregnancy;Migraine;Weight decreased,,,,,,,,,,,86032963,1,HIV test
8728787,87287872,2,F,,20151130,20120817,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-16858938,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151208,,CN,US,ZA,EFAVIRENZ,Abortion induced;Abortion spontaneous;Maternal exposure during pregnancy,87287872,OT,,,,,,,,,87287872,1,HIV infection
8745670,87456705,5,F,,20151106,20120826,20151118,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-16898553,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151118,,CN,GB,GB,SUSTIVA,Foetal exposure during pregnancy;Turner's syndrome,87456705,OT,,,87456705,1,2011,,,,87456705,1,Product used for unknown indication
8764293,87642933,3,F,20120227,20151215,20120831,20151221,EXP,,GB-GILEAD-2012-0060486,GILEAD,,27,YR,A,F,Y,47,KG,20151221,,CN,US,GB,SUSTIVA,Abortion induced;Maternal exposure during pregnancy,87642933,OT,,,87642933,1,2011,,,,87642933,1,HIV infection
8777092,87770922,2,F,20120721,20151120,20120911,20151125,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-16923286,BRISTOL MYERS SQUIBB,,0,DY,,,Y,2.26,KG,20151125,,MD,AR,AR,EFAVIRENZ,Deafness;Foetal exposure during pregnancy;Low birth weight baby,87770922,OT,,,87770922,1,201105,20120721,,,87770922,1,Product used for unknown indication
8784344,87843443,3,F,,20151119,20120913,20151124,EXP,,GB-GILEAD-2012-0060487,GILEAD,,,,,F,Y,,,20151124,,CN,GB,GB,SUSTIVA,Foetal exposure during pregnancy;Turner's syndrome,87843443,CA,,,87843443,1,2011,,,,87843443,1,Product used for unknown indication
8858448,88584484,4,F,20110921,20151118,20121025,20151130,EXP,,AR-BRISTOL-MYERS SQUIBB COMPANY-17061169,BRISTOL MYERS SQUIBB,,33,YR,,F,Y,,,20151130,,CN,US,AR,EFAVIRENZ,Abortion induced;Herpes zoster;Maternal exposure during pregnancy,88584484,OT,,,88584484,2,20110501,,,,88584484,1,HIV infection
8949679,89496792,2,F,,20121121,20121206,20151211,EXP,,GB-009507513-1109GBR00053,MERCK,,32,YR,,F,Y,,,20151211,,CN,GB,GB,EFAVIRENZ,Caesarean section;Live birth;Maternal exposure during pregnancy;Premature delivery;Premature rupture of membranes;Uterine leiomyoma,89496792,OT,,,,,,,,,89496792,1,HIV infection
9029398,90293982,2,F,201110,20151118,20130125,20151129,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17295288,BRISTOL MYERS SQUIBB,,3,YR,,,Y,,,20151129,,CN,GB,FR,SUSTIVA,Abnormal behaviour;Agitation;Developmental delay;Foetal exposure during pregnancy;Speech disorder developmental,90293982,DS,,,,,,,,,90293982,1,Product used for unknown indication
9031911,90319112,2,F,20080918,20151117,20130125,20151129,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17316886,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151129,,CN,US,FR,SUSTIVA,Cholestasis;Gestational diabetes;Live birth;Maternal exposure during pregnancy,90319112,OT,,,90319112,1,20060615,,,,90319112,1,HIV infection
9060495,90604952,2,F,,20151028,20130212,20151112,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17351255,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151112,,CN,FR,FR,SUSTIVA,Bronchopulmonary dysplasia;Congenital anomaly of adrenal gland;Dysmorphism;Foetal exposure during pregnancy;Hydrocephalus,90604952,OT,,,,,,,,,90604952,1,Product used for unknown indication
9139008,91390082,2,F,,20151120,20130305,20151201,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17431057,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151201,,MD,PT,PT,EFAVIRENZ,Foetal exposure during pregnancy;Foetal malformation,91390082,OT,,,91390082,1,201202,,,,91390082,1,Product used for unknown indication
9139068,91390682,2,F,,20151116,20130305,20151124,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-17423922,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,,,20151124,,MD,PT,PT,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,91390682,OT,,,91390682,1,201202,,,,91390682,1,HIV infection
9167066,91670662,2,F,20121128,20151030,20130318,20151113,EXP,,BR-009507513-1302BRA013086,MERCK,,,,,F,Y,2.88,KG,20151113,,CN,US,BR,EFAVIRENZ,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,91670662,OT,,,91670662,1,20120521,20120611,,,91670662,1,Product used for unknown indication
9344804,93448043,3,F,20110705,20151022,20130612,20151106,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-18994129,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,,,20151106,,MD,PT,PT,EFAVIRENZ,Dizziness;Inappropriate schedule of drug administration;Maternal exposure during pregnancy;Premature delivery;Twin pregnancy;Viral load increased,93448043,OT,,,93448043,1,2011,,,,93448043,1,HIV infection
9344937,93449372,2,F,201111,20151118,20130612,20151129,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-18999789,BRISTOL MYERS SQUIBB,,9,MON,,M,Y,,,20151129,,MD,PT,PT,EFAVIRENZ,Abasia;Congenital hydrocephalus;Foetal exposure during pregnancy;Premature baby,93449372,DS,,,93449372,1,,2011,,,93449372,1,Product used for unknown indication
9462572,94625722,2,F,,20151209,20130816,20151210,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19180678,BRISTOL MYERS SQUIBB,,26,YR,,F,Y,,,20151210,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Anaemia macrocytic;Hypertension;Maternal exposure during pregnancy;Renal tubular acidosis,94625722,OT,,,,,,,,,94625722,1,HIV infection
9462593,94625932,2,F,,20151210,20130816,20151214,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19180645,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151214,,OT,ZA,ZA,EFAVIRENZ,Abortion induced;Maternal exposure during pregnancy,94625932,OT,,,,,,,,,94625932,1,HIV infection
9499125,94991252,2,F,,20151210,20130904,20151214,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340579,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151214,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth;Twin pregnancy,94991252,OT,,,,,,,,,94991252,1,HIV infection
9499126,94991262,2,F,,20151214,20130904,20151217,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340546,BRISTOL MYERS SQUIBB,,1,DY,,,Y,2.29,KG,20151217,,CN,US,ZA,EFAVIRENZ,Death neonatal;Foetal exposure during pregnancy;Low birth weight baby,94991262,DE,,,,,,,,,94991262,1,Product used for unknown indication
9499127,94991272,2,F,,20151030,20130904,20151114,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340462,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151114,,CN,US,ZA,EFAVIRENZ,Foetal death;Maternal exposure during pregnancy;Twin pregnancy,94991272,DE,,,,,,,,,94991272,1,HIV infection
9499128,94991282,2,F,,20151209,20130904,20151210,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340553,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151210,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,94991282,OT,,,,,,,,,94991282,1,HIV infection
9499130,94991302,2,F,,20130820,20130904,20151225,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19340504,BRISTOL MYERS SQUIBB,,1,DY,,,Y,1.33,KG,20151225,,CN,US,ZA,EFAVIRENZ,Death neonatal;Foetal exposure during pregnancy;Premature baby,94991302,OT,,,,,,,,,94991302,1,Product used for unknown indication
9529933,95299332,2,F,201111,20151118,20130917,20151129,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-19223171,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,,,20151129,,MD,PT,PT,EFAVIRENZ,Foetal exposure during pregnancy;Premature baby,95299332,OT,,,95299332,1,2011,201111,,,95299332,1,Product used for unknown indication
9607275,96072752,2,F,,20151210,20131009,20151214,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19532936,BRISTOL MYERS SQUIBB,"BARNARDT P, ET AL.. MANAGING AIDS-RELATED KAPOSI^S SARCOMA AND PREGNANCY. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE. 2013?14(2):87-8",24,YR,,F,Y,1.38,KG,20151214,,OT,ZA,ZA,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,96072752,OT,,,96072752,1,2012,,,,96072752,1,HIV infection
9705354,97053542,2,F,,20151208,20131122,20151208,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-19809417,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20151208,,CN,US,IT,EFAVIRENZ,Foetal exposure during pregnancy;Talipes,97053542,CA,,,,,,,,,97053542,1,Product used for unknown indication
9705451,97054512,2,F,,20151208,20131122,20151208,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-19838564,BRISTOL MYERS SQUIBB,,1,DY,,M,Y,,,20151208,,CN,IT,IT,EFAVIRENZ,Cryptorchism;Foetal exposure during pregnancy,97054512,OT,,,,,,,,,97054512,1,Product used for unknown indication
9744066,97440662,2,F,,20151123,20131210,20151208,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-19897651,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151208,,CN,US,ZA,EFAVIRENZ,Erythema annulare;Maternal exposure during pregnancy;Photosensitivity reaction,97440662,HO,,,,,,,,,97440662,1,HIV infection
9756654,97566542,2,F,,20151124,20131213,20151208,EXP,,ET-BRISTOL-MYERS SQUIBB COMPANY-19886787,BRISTOL MYERS SQUIBB,,,,,,Y,,,20151208,,OT,ET,ET,EFAVIRENZ,Encephalocele;Foetal exposure during pregnancy,97566542,CA,,,,,,,,,97566542,1,Product used for unknown indication
9808689,98086893,3,F,20130611,20151123,20140110,20151208,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-18766808,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20151208,,OT,GB,GB,EFAVIRENZ,Abnormal dreams;Drug level increased;Maternal exposure during pregnancy;Neurotoxicity;Normal newborn;Sleep disorder,98086893,OT,,,98086893,1,20121212,,,,98086893,1,Antiretroviral therapy
9821000,98210003,3,F,20121215,20151112,20140116,20151120,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-18849695,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20151120,,OT,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,98210003,OT,,,98210003,1,20121130,20121130,,,98210003,1,Antiretroviral therapy
9897411,98974113,3,F,20140116,20151210,20140214,20151217,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-20196218,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20151217,,OT,ZA,ZA,EFAVIRENZ,Live birth;Stillbirth;Twin pregnancy,98974113,OT,,,98974113,1,20100303,,,,98974113,1,Prophylaxis against HIV infection
9964461,99644612,2,F,,20151210,20140305,20151217,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-20339826,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20151217,,OT,FR,SN,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,99644612,OT,,,,,,,,,99644612,1,HIV infection
9981432,99814323,3,F,20130709,20151217,20140307,20151218,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-20386363,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20151218,,OT,BW,BW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,99814323,OT,,,99814323,1,20110818,20130313,,,99814323,1,HIV infection
